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Cha pter 1
Introduction
…Severe acute malnutrition a" ects 20 million children under 5 years of age each year and 
contributes to 1 million deaths per year…
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INTRODUCTION
Approximately 5000 children, aged 0 to 18 years, with a variety of medical and surgical condi-
tions are admitted to the 8 Dutch Pediatric Intensive Care Units (PICU’s) each year. A distinct 
subgroup of these children has critical illness, de! ned as any condition in which a patient 
requires mechanical aid or pharmacological agents to support failing vital organ functions. 
A variety of metabolic disturbances characterize the condition of critical illness, including 
hyperglycemia, dyslipidemia and increased protein turnover. This hypercatabolic state is char-
acterized by excessive breakdown of proteins to mobilize amino acids for tissue healing and 
synthesis of acute phase proteins and glucose in the liver. It may lead to profound breakdown 
of lean body mass and consequently put children at risk for protein-energy malnutrition.1 Mal-
nourished children have a higher risk of complications, such as hospital acquired infections due 
to poor immune defense, poor wound healing, decreased muscle function (heart, skeletal and 
respiratory muscle), impaired gut function and longer dependency on mechanical ventilation. 
All this results in longer length of hospital stay and increased mortality.2 Poor nutritional status 
has also been associated with adverse consequences on growth and development in children 
after discharge. Furthermore, the occurrence of “stress hyperglycemia” has been identi! ed as 
an independent risk factor for adverse outcome in critically ill children with various diagnoses.3 
The landmark study of the Leuven group in 20014 reported reduced mortality in adult 
surgical intensive care patients treated with strict insulin therapy aimed at normalizing 
blood glucose levels. The e#  cacy of glycemic control5 has been much debated since then 
and concerns were raised about extrapolating this therapy to children. Only one randomized 
controlled trial of glycemic control in pediatric intensive care patients has been published 
so far, again by the Leuven group.6 The authors reported shorter duration of PICU stay and 
mortality with the use of strict glycemic control. This study was criticized,7 however, notably 
for the 25% incidence of hypoglycemic events in the intervention group. Hypoglycemia is a 
serious complication of insulin therapy. It is thought that neonates and young children do 
have an increased risk for developing hypoglycemia and are very vulnerable to complications 
caused by hypoglycemia, as their brains are still developing.3 
Despite increased awareness for adequate nutritional support during critical illness, even 
today, malnutrition in PICU patients commonly occurs. Twenty percent of children admitted 
to a PICU are acutely or chronically malnourished at the time of admission, and their nutri-
tional status deteriorates during hospitalization.8 Adequate feeding is essential for complete 
recovery and normal functioning of the growing child. Clinicians working in the pediatric 
intensive care unit are challenged to provide adequate nutrition for optimal tissue synthesis 
and immune function while avoiding complications of under- or overfeeding. Therefore, 
nutritional therapy should aim to:9 1) provide adequate amounts of energy, especially when 
energy stores are depleted; 2) manipulate insulin secretion via glucose; and 3) conserve or 
restore the body protein mass. 
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Chapter 1
The focus of this thesis is on energy requirements in critically ill children in the acute phase 
of disease in relation with the hyperglycemic response to stress. Furthermore we elaborate 
on the causes and consequences of hyperglycemia. 
ENERGY REQUIREMENTS 
Energy expenditure
Predicting resting energy expenditure
Generally used equations to estimate resting energy expenditure (REE) are based on charac-
teristics, such as weight, height and sex.10 However, these equations have been shown to be 
inaccurate in critical illness and may underestimate or overestimate the true energy require-
ments in the individual.8 Nutritional intake based on estimated requirements often result in 
inadequate prescriptions. The cumulative e" ect of inaccurate estimations and suboptimal 
delivery of nutrition may result in signi! cant caloric imbalances over time. 
Measuring energy expenditure
Measuring energy expenditure allows for a more accurate monitoring of the child’s varying 
needs in the course of critical illness. Two basic approaches have been developed; direct and 
indirect calorimetry. Direct calorimetry measures heat liberated from the body.11 It can be 
performed in specialized insulated chambers but is not applicable in a clinical setting. 
The doubly labeled water method is the golden standard method of indirectly estimating 
total daily energy expenditure (TDEE), which includes energy expended in physical activity.12 
It is suitable for free-living subjects and measures TDEE over a period of days, but it is costly 
and requires specialized laboratory equipment. As the results are not readily available, its use 
in clinical practice is of limited value and restricted to the research setting.13 
Indirect calorimetry, using a metabolic monitor, can be performed at the bedside to mea-
sure the volume of oxygen consumed (VO2) and the volume of carbon dioxide produced 
(VCO2). The principle to calculate energy expenditure from gas exchange is calculated ac-
cording to the modi! ed Weir formula14 : Energy Expenditure (kJ/day) = 4184 (5.5 VO2 + 1.76 
VCO2); VO2 and VCO2 in l/min. The second parameter obtained from indirect calorimetry, the 
respiratory quotient (RQ), de! ned by the VCO2 to VO2 ratio, is partially determined by the 
substrate use in the child (carbohydrate: 1.00, protein: 0.83, and fat: 0.70). Underfeeding, 
which promotes use of endogenous fat stores, lowers the RQ, whereas overfeeding, which 
results in lipogenesis, raises the RQ. 
Although indirect calorimetry is a well-validated and accurate method for measuring 
energy expenditure in critically ill, mechanically ventilated children15, it is not infallible. It is 
less accurate if there is no steady hemodynamic, respiratory and/or metabolic state to ensure 
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that respiratory gas exchange is equivalent to tissue gas exchange, if there is an air leak of 
more than 10%, and if the level of inspired oxygen is high (FiO2 of >60%). As it takes 24 hours 
before most critically ill patient have been stabilized, it is di#  cult to accurately measure 
energy expenditure in the sickest children in the acute phase of intensive care admission. In 
addition, nursing care (e.g. endotracheal aspiration and daily toiletry), pain, anxiety, fever and 
medication (e.g. sedatives, analgesics, beta blockers) can also reduce the accuracy of indirect 
calorimetry when it is performed during a short period of time.16 Lastly, the initial purchase 
and the maintenance of metabolic carts are expensive and training is needed to perform 
the measurements and interpret the results. For all these reasons the method is not used 
routinely. Many health professionals therefore still rely on predictive equations and tables to 
assess the energy requirements for individual patients.17 
Energy intake
Several studies among critically ill children and adults have shown that nutritional needs 
are frequently not ful! lled by the actual nutritional intake.2, 18 This may be due to the lack of 
routine nutritional assessment, the poor estimation of energy and protein needs, and inad-
equate substrate delivery. A major problem in clinical practice is to de! ne general nutritional 
requirements for critically ill children, as demands range widely between individual patients.2 
Many PICUs use predictive equations with additional correction factors for type of illness (e.g. 
ARDS, sepsis, trauma or surgery), activity and intestinal absorption. However, these equa-
tions may incorrectly estimate individual energy needs. It has been suggested, therefore, 
that energy expenditure measurements are better than estimations.19 In the clinical setting, 
the measured energy expenditure re$ ects the resting energy expenditure and this should 
be considered the minimum value for energy intake. However, the optimal energy intakes 
during the acute and recovery phases of critical illness remain unclear.
Regarding substrate delivery, studies have shown that 75-90% of the prescribed caloric in-
take was actually delivered.2 Fluid volume restriction, procedural interruptions, interruption 
due to gastrointestinal intolerance and mechanical problems, such as gastric tube occlusion 
or displacement and absence of venous access for parenteral feeding were the main reasons 
for inadequate delivery.2
In conclusion, many factors can contribute to inadequate nutrition supply and under- or 
overfeeding of children admitted to the PICU. Standard nutritional assessment and standard 
evaluation of nutritional supply should be an integrated part of daily practice, for which a 
team consisting of dieticians, intensivists and specialized intensive care nurses can be made 
responsible.
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Chapter 1
HYPERGLYCEMIA 
Pathophysiological aspects 
Critically ill children, who are exposed to acute and chronic stress, often develop hyperglyce-
mia through multiple proposed mechanisms (Figure 1).20 
Many studies over the past 10 years in adults and children, challenge the assumption that 
hyperglycemia is a normal physiologic response to stress. The cause of hyperglycemia in 
critically ill children is multifactorial and presumed to be due to a combination of insulin re-
sistance, absolute insulin de! ciency, glycogenolysis and increased hepatic gluconeogenesis 
resulting from release of catecholamines, cortisol, glucagon, in$ ammatory mediators and 
cytokines. The relative contributions of these factors are unknown, but the e" ect of increased 
catecholamines, counter-regulatory hormones, and proin$ ammatory mediators is thought 
to impair insulin signaling in target cells, leading to peripheral insulin resistance and high 
blood glucose. 
!Immune function 
!Wound healing 
"Procoagulant state 
"Reactive O2 species 
!NO synthase activity,! NO 
!RBC function 
"Cell injury/death 
!Peripheral nerve function 
Dehydration 
Acid-base alterations 
Electrolyte abnormalities 
Exacerbated ischemia (CV/CNS) 
"Gluconeogenesis 
"Glycogenolysis 
"Stress hormones 
(catecholamines, glucocorticoids,              
growth hormone) 
"Cytokine/pro-inflammatory mediators 
"Transcription factors 
Exogenous glucocorticoids 
IV, Enteral/parenteral nutrition 
Inactivity 
CRITICAL ILLNES 
Glucose Control with Insulin in some populations 
!"#$%&'($)&*($+,$!"#$(-".()/"+($
"**,.&"+(0$1&+2$
Better 
outcome? 
HYPOGLYCEMIA 
Worse 
outcome? 
HYPERGLYCEMIA 
Figure 1 Summary of the presumed causes and consequences of hyperglycemia in critical illness.
Factors that predispose critically ill children to develop hyperglycemia.
CV, cardiovascular; CNS, central nervous system; NO, nitric oxide; IV, intravenous. Reproduced from Fahy et al. (5)
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Concurrently, the release of catecholamines, somatostatin, FFAs, and proin$ ammatory cyto-
kines, such as tumor necrosis factor alpha, directly and adversely e" ects pancreatic beta-cell 
function, such that insulin production is inhibited. This, will lead to relative hypoinsulinemia 
with high blood glucose levels. Moreover, in response to stress, glucagon synthesis is up-
regulated, likely because of stimulation of pancreatic cells by cortisol and epinephrine. Taken 
together, this leads to increased glucagon/insulin ratios and favours gluconeogenesis, result-
ing in central insulin resistance with increased hepatic glucose production. The combination 
of increased glucagon, suppression of insulin secretion, and insulin resistance results in 
hyperglycemia and inability of the organism to use substrate at the tissue level.21 Also exog-
enous factors, such as glucose or drug (e.g. glucocorticoids, catecholamines) administration 
contribute to the development of hyperglycemia during critical illness.22 
Clinical assessment of insulin sensitivity and β-cell function
Insulin sensitivity quanti! es the ability of insulin to lower blood glucose concentration by 
stimulating glucose uptake and suppressing its production. Thus insulin sensitivity has mul-
tiple aspects and, in principle, cannot be reduced to a single index. However, it has become 
customary to de! ne insulin sensitivity as the ability of insulin to stimulate glucose uptake 
and to consider the hyperinsulinemic euglycemic clamp as the gold standard method for its 
assessment.23 The clamping technique is a di#  cult method to apply in clinical practice, be-
cause of its complicated implementation. The hyperinsulinemic euglycemic clamp technique 
requires a steady IV infusion of insulin to be administered in one arm, while serum glucose 
level is “clamped” at a normal fasting concentration by administering a variable glucose infu-
sion in the other arm. Numerous blood samples are taken for monitoring glucose so that a 
steady “fasting” level can be maintained. The degree of insulin resistance should be inversely 
proportional to the glucose uptake by target tissues during the procedure. In other words, 
the less glucose is taken up by tissues during the procedure, the more insulin resistant a 
patient is.24 
The assessment of β-cell function is di#  cult because of the complexity of the β-cell re-
sponse to secretory stimuli. A gold standard for β-cell function assessment does not exist. 
The available methods are based on measurements of insulin concentration or on modeling 
analysis of C-peptide to calculate pre-hepatic insulin secretion in relation with blood glucose 
levels. The latter method or measuring both, could be more accurate because insulin un-
dergoes some ! rst-pass hepatic extraction and peripheral insulin levels may not re$ ect true 
insulin secretion.23 
Insulin sensitivity and β-cell function may be analyzed indirectly with the use of “minimal” 
models which require IV or oral administration of glucose. Examples are the frequently sam-
pled IV glucose tolerance test (FSIGT), and the oral glucose tolerance test (OGTT).23 Though 
simpler than the glucose clamp, these methods still remain quite complicated and laborious. 
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Chapter 1
The search for easy-to-use and inexpensive quantitative tools has led to the development 
of homeostatic assessments of insulin sensitivity. These tests are based on paired fasting 
glucose and insulin levels, and use mathematical calculations to assess insulin sensitivity and 
β-cell function. Examples are the fasting insulin level, glucose/insulin and insulin/glucose 
ratio, homeostatic model assessment (HOMA), and quantitative insulin sensitivity check 
index (QUICKI). The HOMA model has been most widely employed in clinical research and 
practice to assess insulin sensitivity. The original HOMA model is described by the follow-
ing equation: HOMA-IR=(FPIxFPG)/22.5, where IR is insulin resistance, FPI is fasting plasma 
insulin concentration (mU/L) and FPG is fasting plasma glucose (mmol/L). The formula for 
the estimation of β-cell function is: HOMA-B=(20*FPI)/(FPG-3.5).23 The updated HOMA 
model (i.e., the computer model) is available from www.OCDEM.ox.ac.uk25 and can be used 
to determine insulin sensitivity (HOMA-%S) and β-cell function (HOMA-%B) from paired 
fasting plasma glucose and insulin or C-peptide concentrations. Although the described 
tests were originally developed for application in diabetes mellitus and metabolic diseases, 
some of the techniques have also been used to evaluate insulin response to hyperglycemia 
in critically ill patients. The hyperinsulinemic euglycemic clamp technique revealed severe 
insulin resistance in critically ill medical patients on the day after ICU admission and this 
was associated with severity of illness, BMI and measured energy expenditure by indirect 
calorimetry.26 HOMA in non-fasting critically ill adults with acute renal failure, showed an 
association between mortality and insulin resistance.27 HOMA was also used to di" erentiate 
between patients with over insulin resistance (hyperglycemia), non-overt insulin resistance 
(normal glucose but elevated HOMA) and those who were insulin sensitive.28 
There are only few reports on the evaluation of insulin sensitivity or β-cell function in criti-
cally ill children. C-peptide/glucose ratios were elevated in children with respiratory failure 
only, suggesting insulin resistance, whereas decreased ratios were seen in children with re-
spiratory and cardiovascular failure, indicative for β-cell dysfunction.29 β-cell dysfunction was 
also suggested in children with meningococcal septic shock, as they showed lower insulin/
glucose ratios than children with sepsis only.30 
Relation with outcome
Table 1 provides details of the main studies that have evaluated the association between 
glycemic level and outcome such as length of stay, duration of mechanical ventilation, 
neurological outcome and mortality. All studies but one report an association between 
hyperglycemia and adverse outcome. The overall conclusion may be that hyperglycemia in 
critically ill children is associated with increased morbidity and mortality. However, some im-
portant limitations of these studies should be pointed out. Most importantly, all except one 
were retrospectively designed and could not demonstrate causality between the glucose 
levels and outcome measures; they demonstrated associations only. Furthermore, various 
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hyperglycemic thresholds were reported. A glucose level of 8.3 mmol/L (150 mg/dL) had the 
strongest association between hyperglycemia and increased morbidity and mortality.3
The reasons why hyperglycemia may be injurious in critically ill children are unclear. 
Under physiological circumstances, glucose uptake in the liver is directly proportional to 
blood glucose concentration, while peripheral uptake is insulin dependent. In physiological 
conditions, hyperglycemia down regulates insulin-independent glucose transporters (GLUT-
1, GLUT-2 and GLUT-3), thus protecting cells against glucose overload. However, in critical 
illness this mechanism fails, resulting in glucose overload in organ systems that express these 
transporters (e.g. central and peripheral nervous system, erythrocytes, hepatic, immune and 
endothelial cells, renal tubules and gastrointestinal mucosa). Glucose overload causes free-
radical formation, promotes injury to hepatic mitochondria and other cellular structures, 
leads to apoptosis and cell death in certain organs, and can impair the innate and humoral 
immune response to infection. In contrast, skeletal muscle and the myocardium, which nor-
mally take up glucose predominantly via the insulin-dependent GLUT-4 transporter, may be 
relatively protected against toxic e" ects of circulating glucose.22, 31
GLYCEMIC CONTROL 
Insulin action
Insulin is the most potent anabolic hormone in the body. It has profound e" ects on both 
carbohydrate and lipid metabolism, and signi! cantly in$ uences protein and mineral me-
tabolism. Insulin treatment may give protective e" ects by inhibiting some of the pathologic 
processes caused by high blood glucose levels. Furthermore it exerts anabolic e" ects on lipid 
and protein metabolism, on modulation of counter-regulatory hormones and catecholamines 
commonly increased during stress, and it has direct anti-in$ ammatory properties. It has been 
suggested that hepatic insulin resistance remains refractory to intensive insulin therapy. In 
critical illness, the expression of PhosphoEnolPyruvate Carboxy Kinase (PEPCK), which is the 
rate-limiting enzyme of gluconeogenesis, is increased due to elevated levels of cortisol and 
catecholamines. Under normal conditions, insulin is a potent inhibitor of PEPCK. However, in 
critically ill patients both the expressions of PEPCK and hepatic glucokinase, which controls 
glucose uptake and glycogen synthesis, remain unaltered by insulin therapy. As a result, 
insulin lowers glucose predominantly through increased skeletal muscle glucose uptake by 
increasing the expressions of GLUT-4 and hexokinase-II.3 In Figure 2 the mechanism of stress-
induced hyperglycemia and in$ uence of insulin therapy is shown.32 
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What is the evidence?
Glycemic control in critically ill adults
In 2001 van den Berghe et al. described the use of insulin to treat hyperglycemia and normal-
ize blood glucose level (4.4-6.1 mmol/L) in adult patients admitted to the surgical intensive 
care unit.4 This trial, known as the Leuven study, showed that strict insulin therapy reduced 
overall in-hospital mortality, and also reduced bacteremia, acute renal failure, the need 
for red-cell transfusions and critical-illness polyneuropathy. In 2006 van den Berghe et al. 
reported a second large randomized controlled trial of glycemic control, this time in medical 
adult patients.33 Mortality had gone down in a subgroup of patients who stayed in ICU longer 
than 3 days and overall morbidity had improved with the use of strict glycemic control. Since 
then, only a few studies have been able to reproduce the ! ndings of the Leuven studies. 
Alarmingly, two studies planned as large randomized controlled trials evaluating the e" ect 
of glycemic control in adults (Glucocontrol and VISEP, e#  cacy of Volume substitution and 
Insulin therapy in severe SEPsis) were stopped prematurely mainly because of concerns 
about increased incidence of hypoglycemia.34-35 Another large trial in adult critical care, the 
NICE-SUGAR (Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm 
Regulation) trial did not show additional survival bene! t by controlling blood glucose at the 
4.4-6.1 mmol/L range compared to 8.0-10.0 mmol/L.36 
Despite the seemingly contradictory outcomes, professional organizations such as the 
American Association of Clinical Endocrinologists, the American Diabetes Association, Sur-
viving Sepsis Campaign and other authorities suggested that stress hyperglycemia should 
be considered in any critically ill patient with a blood glucose level in excess of 6.1 mmol/L. 
They recommended intensive insulin therapy for the management of hyperglycemia in adult 
critically ill patients.37 
Figure 2 Mechanism of stress-induced hyperglycemia. Changes occurring during stress (dark solid lines) cause insulin resistance (X) in the liver 
(stimulating glycogenolysis) and in peripheral tissues (reducing glucose uptake and stimulating gluconeogenesis). Insulin therapy (dashed 
lines) reverses peripheral but not hepatic insulin resistance. Reproduced from Branco et al. (32)
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Glycemic control in critically ill children
Two large randomized controlled trials of glycemic control in critically ill children have been 
published so far.6, 38 The ! rst trial, by the Leuven group, included 317 infants <1 year and 383 
children ≥1 year, mainly admitted after cardiothoracic surgery. They reported decrease of 
mortality; 3% for those treated with intensive insulin therapy versus 6% for controls.6 The 
second trial included 239 severely burned children and showed that intensive insulin therapy 
improved post-burn mortality, as indicated by decreased incidence of infections and sepsis.38 
However, in both studies severe hypoglycemic events occurred in a quarter of the children in 
the intervention group.7 A follow-up study has been initiated by the Leuven group to study 
the long-term consequences of hypoglycemia and of hyperglycemia on neurocognitive 
development. 
In summary, nutritional support of critically ill children is of major importance. Indirect 
calorimetry can be used to measure resting energy expenditure and to tailor individual 
nutritional support for critically ill children with various clinical conditions. Hyperglycemia 
frequently occurs and is associated with adverse outcome. Glycemic control for critically 
ill children is controversial; there is no evidence for aiming at very strictly regulated blood 
glucose levels. 
Research on pathogenesis of hyperglycemia in critically ill children can guide the devel-
opment of preventive and therapeutic strategies. The HOMA model can be used to assess 
insulin sensitivity and pancreatic β-cell function associated with hyperglycemia. 
AIM OF THE THESIS
The studies presented in this thesis focused on energy requirements in critically ill children in 
the acute phase of disease in relation with the hyperglycemic response to stress.
The overall aims of this thesis are:
- To determine the actual energy needs of critically ill, mechanically ventilated children. 
- To study the value of prediction equations for energy expenditure in relation to energy 
expenditure measurements.
- To explore the mechanisms that lead to hyperglycemia in critically ill children.
- To evaluate the use of a glucose control protocol for prevention and treatment of hypergly-
cemia with insulin in critically ill children.
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OUTLINE OF THE THESIS
Chapter 1 provides a general introduction and the aims of the studies. Current methods to 
determine energy requirements are presented, as well as notions about assessment of insulin 
sensitivity in critically ill children.
PART I
Energy requirements 
The daily energy expenditure of mechanically ventilated children is measured by indirect 
calorimetry. Results are compared with prediction equations in chapter 2 and with ac-
tual caloric intake in chapter 3 to identify under-and overfeeding. In chapter 4 we evaluate 
whether “new” equations derived from actual energy expenditure measurements of venti-
lated critically ill children correctly predict energy expenditure in a larger group of patients 
and whether they were adequately fed. 
PART II
Hyperglycemia 
Two studies on pathophysiological aspects of hyperglycemia in homogenous groups of criti-
cally ill children are discussed in chapters 5 and 6. Chapter 5 concerns a homogenous group 
of children with meningococcal sepsis and septic shock; we studied the occurrence of hyper-
glycemia in relation with the insulin response and exogenous factors, such as glucose intake 
and drug use. Chapter 6 concerns children undergoing cardiac surgery for congenital heart 
disease; we evaluated peri-operative blood glucose levels and related these to endogenous 
stress hormone production, in$ ammatory mediators and exogenous factors such as caloric 
intake and glucocorticoid use. 
PART III
Glycemic control 
Chapter 7 concerns a heterogeneous group of critically ill children with hyperglycemia just 
before start of insulin therapy. As it would be useful to predict which children could bene! t 
from insulin therapy, the relationship between the endogenous insulin response to hypergly-
cemia and clinical outcome is explored. 
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The implementation of a stepwise nurse-driven glucose control protocol for the treatment of 
hyperglycemia in critically ill children is evaluated in chapter 8. The results of a randomized 
controlled trial on intensive insulin therapy in critically ill children with high incidence of 
hypoglycemic events is discussed in chapter 9. 
A synthesis and general discussion of the results are given in chapter 10. Summary and 
conclusions are presented in chapter 11.
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REQUIREMENTS 
I can accept failure, but I can’t accept not trying (Michael Jordan)

Cha pter 2
Comparison of measured and predicted 
energy expenditure in mechanically 
ventilated children
Jennifer J. Verhoeven, Jan A. Hazelzet, Edwin van der Voort, Koen F.M. Joosten
Intensive Care Medicine 1998; 24: 464-468
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ABSTRACT
Objective
To determine the energy requirements in mechanically ventilated pediatric patients using 
indirect calorimetry and to compare the results with the predicted metabolic rate.
Design
In 50 mechanically ventilated children with a moderate severity of illness, energy expenditure 
was measured by indirect calorimetry. Daily caloric intake was recorded for all patients. Total 
urinary nitrogen excretion was determined in 31 patients. 
Results 
Although there was a close correlation between the measured total energy expenditure 
(mTEE) and the predicted basal metabolic rate (pBMR)(r=0.93; p<0.001), Bland-Altman analy-
sis showed lack of agreement between individual mTEE and pBMR values. The ratio of caloric 
intake /mTEE was signi! cantly higher in the patients with a positive nitrogen balance (1.4 ± 
0.07) compared with those with a negative nitrogen balance (0.8 ± 0.1; p<0.001).
Conclusions
Standard prediction equations are not appropriate to calculate the energy needs of critically 
ill, mechanically ventilated children. Individual measurements of energy expenditure and 
respiratory quotient by means of indirect calorimetry in combination with nitrogen balance 
are necessary for matching adequate nutritional support.
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INTRODUCTION
Nutritional support is an essential management aspect of pediatric intensive care patients. 
Energy requirements of critically ill children were determined by calculation of basal meta-
bolic rate with adjustment for degree of stress (1, 2). Daily energy expenditure determination 
in the critical care setting can be performed by indirect calorimetry (3). Indirect calorimetry 
is the method by which the metabolic rate is calculated from measurements of oxygen con-
sumption and carbon dioxide production. Use of indirect calorimetry enables the clinician to 
assess more accurately the patient’s caloric energy needs and the patient’s ability to utilize 
nutrient substrates (4). In this way appropriate feeding regimens for critically ill children can 
be designed. 
Studies of nonventilated children have shown a wide variation of measured resting energy 
expenditure. It was recommended in these studies that measurement of resting energy 
expenditure (mREE) should be performed in individual patients instead of using a prediction 
equation for ensuring adequate nutrition (5, 6). In only six studies with small numbers of 
mechanically ventilated children were results of energy expenditure using indirect calo-
rimetry presented (Table 1) (2, 7-11). In ! ve of these six studies resting energy expenditure 
was measured, and in one study prolonged measurements of energy expenditure were per-
formed. These studies all showed a wide variation in individual actual energy requirements in 
di" erent diseases and a wide range in the ratio of measured total energy expenditure (mTEE) 
or mREE to predicted basal metabolic rate (pBMR). 
Table 1 Study population characteristics
[Reference] Age group n Diagnosis MEE/pBMR MEE (range)
[7] 5-17 years 9 Head injury 1.19 ± 0.07(a) -
[8] 5 days-46 months 20 Wide range 1.02 ± 0.07 (b) 100-343(b)
[2] 2-18 years 18 13 trauma; 
5 other
1.48 ± 0.09(a) 130-336(a)
[9] 2 days-120 months 12 Wide range - 125-236(a)
[10] 2 months-12 years 26 Open heart surgery 0.96 ± 0.03(a) 126-289(a)
[11] 3 months-10 years 18 Wide range 0.97 ± ?(a) -
Present study 2 days-13 years 50 Wide range 1.04 ± 0.03(b) 85-270(b)
MEE, Measured Energy Expenditure; pBMR, predicted Basal Metabolic Rate; mTEE, measured Total Energy Expenditure; mREE, measured Resting 
Energy Expenditure
(a) mREE (kJ/kg per day)
(b) mTEE (kJ/kg per day)
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The purpose of this study was to perform measurements of energy expenditure, which 
represent total daily energy expenditure in mechanically ventilated children, in order to get a 
better insight into actual energy requirements and to compare these measurements with the 
pBMR, energy intake, and nitrogen balance.
MATERIALS AND METHODS
Patient selection
Patients were eligible for the study when they met the following criteria:
1 Mechanical ventilation with a Servo Ventilator 300 (Siemens-Elema, Solna, Sweden) either 
with pressure regulated volume control mode or with volume support mode. 
2 A fractional inspired oxygen (FiO2) of less than 0.60.
3 A tube leakage of less than 10% (considered not to in$ uence the measurement sig-
ni! cantly (12)). Tube leakage was determined by comparison of inspired and expired 
tidal volumes measured by the ventilator, assuming that there were no other leaks in the 
patient-ventilator circuit.
4 A haemodynamic stable condition indicated by a normal, stable bloodpressure according 
to age within 2 SD (13), and normal renal function expressed by a normal serum creati-
nine concentration (14).
Severity of illness on the day of measurement was assessed by the Pediatric Risk of Mortal-
ity score (PRISM) (15) and Therapeutic Intervention Scoring System (TISS) (16).
The local Ethical Committee approved the study and informed consent was obtained from 
the parents.
Energy expenditure
Oxygen consumption (VO2), carbon dioxide production (VCO2) and respiratory quotient (RQ) 
were measured with a previously validated metabolic monitor (Deltatrac I MBM-100 and Del-
tatrac II MBM-200, Datex Division Instrumentarium, Finland) (17). All gas measurements were 
standardized for temperature, barometric pressure, and humidity (STPD). The Deltatrac is an 
open system indirect calorimetry device. The di" erence between the inspired and expired 
oxygen fractions is measured with a fast-response, paramagnetic di" erential oxygen sensor 
(OM-101, Datex Instrumentation). The expired CO2 fraction is measured with an infrared CO2 
sensor. Before each test, the calorimeter was calibrated with a reference gas mixture (95% O2, 
5% CO2). The accuracy of the Deltatrac was assessed with a butane burner. The mean error of 
VO2 and VCO2 obtained in repeated tests was 2.7 ± 0.5 and 3.7 ± 0.6% respectively. The mean 
RQ was 0.62 ± 0.01 (RQ of butane 0.615), with a mean error of 2.2 ± 0.4%. Studies were carried 
out for a period of at least 4 h with a maximum of 24 h. The mean coe#  cient of variation for 
measured energy expenditure was 4.6 ± 0.4%.
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Measurement results of at least 4 h were considered to represent the total daily energy 
expenditure (18, 19). Mean mTEE was calculated using the modi! ed Weir formula [20]: mTEE = 
4184(5.5 VO2 + 1.76 VCO2); mTEE in kJ/day; VO2 in l/min; VCO2 in l/min. The respiratory quotient 
was calculated by dividing VCO2 /VO2. The nonprotein RQ was calculated with the formula: 
(VCO2 - 4.84N)/(VO2 - 6.04N). N is urinary urea nitrogen excretion in g/min. pBMR was calcu-
lated from each patient’s weight, age and sex using the appropriate Scho! eld equations (21).
Caloric intake
The patients were fed enterally and/or parenterally. Enteral feeding was given continuously 
via a nasoduodenal drip with standard soja-based formula (Nutrilon soja for children £ 6 
months, Nutrilon soja plus for children 6-12 months, 75% Nutrison soja and 25% water and 
4% Fantomalt added for children 1-4 years, 90% Nutrison soja and 10% water and 4% Fanto-
malt added for children 4-10 years, and Nutrison soja for children > 10 years of age Nutricia, 
Zoetermeer, The Netherlands). Parenteral feeding was given either by peripheral infusion or 
by a central venous line (Intralipid 20%, Pharmacia Upjohn Holland and Aminovenös N-paed 
10%, Fresenius, The Netherlands). Fluid and electrolyte intakes were adjusted to individual re-
quirements. Daily caloric intake (subdivided into carbohydrate, protein and fat) was recorded 
for all patients. Caloric intake was corrected for extra protein calories from plasma infusions 
and/or albumin infusions on the day of measurement.
Urinary nitrogen excretion
In 31 patients, urine was collected on the day of measurement and analyzed for urinary urea 
nitrogen. In the remaining 19 patients, urine was not collected because of logistical prob-
lems. In 18/31 patients a urinary bladder catheter was in place and urine was collected over 
a 24-h period. In 13/31 patients, however, a pediatric urine collector was used and urine was 
collected over a shorter period but over 1of at least 6 h. This can be used to estimate a 24 hour 
period, but the inconsistency has to be taken into account when interpreting the results. 
Total urinary nitrogen excretion (TUN) was de! ned as 1.25 x urinary urea nitrogen, in order 
to adjust for the 20% of urinary nitrogen loss as ammonia, creatinine, and uric and amino 
acids (22). No correction was made for nitrogen losses through stools, skin, wound, nasogas-
tric suction, or blood sampling. Nitrogen balance was calculated with the following formula:
Nitrogen balance (mg/kg per day) = (protein intake/6.25) - (urinary urea nitrogen x 1.25).
Statistical analysis
Statistical analyses were performed with a software program (SPSS 7.0 for Windows 95, SPSS 
Software, Chicago, IL, USA). Results are expressed as mean ± SEM, unless otherwise indicated. 
For comparisons between groups the independent samples t-test was used. A p-value of 
0.05 or less was de! ned as statistically signi! cant. Pearson’s correlation coe#  cient (r) and 
a Bland-Altman plot were used to evaluate the relationship between mTEE and pBMR (23). 
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RESULTS
From among the 80 patients who were admitted consecutively from September 1995 to May 
1996 to our pediatric intensive care unit (PICU) 30 patients were excluded because they did 
not ful! ll the inclusion criteria. The study group consisted of 50 patients, 28 boys and 22 
girls, with a wide range of clinical characteristics (Table 2). The median age was 7 months (2 
days-13 years). Median PRISM score was 6 (0-13) and median TISS score was 17 (10-32) (Table 
3). All patients were sedated with midazolam and/or morphine and 4 patients with phar-
macological muscle paralysis. Five patients received inotropic drugs. There were no known 
pathological gastrointestinal absorption disturbances. The mean day of measurement after 
intubation was 5 ± 4 days. Ventilatory characteristics were as follows: mean FiO2 was 0.35 ± 
0.018 and mean tube leakage was 6 ± 1%; 24 patients were on pressure regulated volume 
control, 25 on volume support, and 1 was on continuous positive airway pressure. The results 
of the energy expenditure measurements are shown in Table 3. The correlation coe#  cient 
between mTEE and pBMR was r= 0.93 (p<0.001). A Bland-Altman plot for mTEE and pBMR 
shows a wide scatter around the mean (di" erence from the mean: -2120 to + 1970 kJ/day) 
(Fig 1)
Thirty-! ve patients received enteral nutrition (EN), 7 received only glucose infusion, 6 re-
ceived total parenteral nutrition (TPN) and 2 received a mixture of EN and TPN. Mean caloric 
intake was 243 ± 17 kJ/kg per day.
TUN was determined in 31 patients (Table 3). Mean TUN was 249 ± 22 mg/kg per day. The 
nitrogen balance was positive in 19 patients and negative in 12 patients. The ratio of caloric 
intake/mTEE was signi! cantly higher in the patients with a positive nitrogen balance (1.4 ± 
0.1 mg/kg per day) compared with those with a negative nitrogen balance (0.8 ± 0.1 mg/
Table 2 Clinical Diagnosis of study patients
Diagnosis Number of patients
Congenital heartdefect 15
Sepsis 9
Pneumonia 6
(RS) Bronchiolitis 5
Resection subglottic stenosis 4
Upper airway obstruction 3
Near drowning 2
Leigh’s Syndrome 1
Pediatric AIDS 1
Cardiomyopathy 1
Status asthmaticus 1
Post pylorotomy 1
Status epilepticus 1
Total 50
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kg per day; p<0.001) (Table 4). The actual caloric intake in patients with a positive nitrogen 
balance was 318 ± 21 versus 163 ± 29 kJ/kg per day for patients with a negative nitrogen 
balance (p<0.001). There was no signi! cant di" erence in nonprotein RQ between patients 
with a positive or negative nitrogen balance. In 6 patients the nonprotein RQ was > 1.0. The 
carbohydrate intake in 4 of them was 9-10 mg/kg per min, and in the other 2 patients, 4.2 and 
7.5 mg/kg per min, respectively.
Table 3 Patient characteristics and measurements results
Patients (n=50) Mean ± SEM Range 
Age 25 ± 6 months 2 days – 13 years
PRISM 6 ± 1 0-13
TISS 18 ± 1 10–32
Intake (kJ/kg per day) 243 ± 17 22–520
mTEE (kJ/day) 1987 ± 238 640-8678
mTEE (kJ/kg per day) 212 ± 5 85-270
pBMR (kJ/day) 2029 ± 212 590-6903
pBMR (kJ/kg per day) 213 ± 6 98-298
RQ 0.89 ± 0.01 0.77-1.02
TUN (n=31) (mg/kg per day) 249 ± 22 68-493
N-balance (n=31) (mg/kg per day) -4 ± 38 -471-335
PRISM, Pediatric RISk of Mortality score; TISS, Therapeutic Intervention Scoring System; mTEE, measured Total Energy Expenditure; pBMR, 
predicted Basal Metabolic Rate; RQ, Respiratory Quotient; TUN, Total Urinary Nitrogen excretion; N-balance, Nitrogen balance 
(pBMR + mTEE)/2 
 
pBMR – mTEE  
 
Figure 1. Bland-Altman plot for mTEE and pBMR
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DISCUSSION
We determined the metabolic and nutritional state of a heterogeneous group of mechani-
cally ventilated PICU patients with di" erent clinical diagnoses. Because of methodological 
problems (tube leakage, FiO2 above 0.60, unstable haemodynamics), we were only able to 
perform energy expenditure measurements on 50 of the 80 mechanically ventilated patients 
admitted to our PICU in the study period.
As a consequence of these limitations only patients with a moderate severity of illness in 
the beginning of disease or patients recovering from a severe illness could be included for 
indirect calorimetric studies, as is indicated by the low PRISM and TISS scores of our patient 
population. 
Total energy expenditure consists mainly of basal metabolic rate, growth, heat loss, and 
mechanical work. Growth can account for a substantial proportion of the energy expenditure 
in children (30- 35%), especially in the ! rst year of life (24). However, in critically ill, mechani-
cally ventilated children, counter-regulatory hormones could diminish and even stop growth, 
and mechanical ventilation will reduce the work of breathing (8). As a result the total energy, 
which is needed, will be lower and resemble basal metabolic rate. So far, there have been only 
six previous studies on mechanically ventilated children in which TEE or REE was measured 
by means of indirect calorimetry (2,7-11). In ! ve of these studies, there was a correlation 
between mTEE or mREE and pBMR. These correlations are misleading because of the wide 
variation in individual measurements. In our study, we also found a wide range of individual 
measurements. From the wide scatter of the Bland-Altman plot, it becomes obvious that the 
use of predicted energy expenditure is inappropriate for clinical purposes. Our study showed 
that the mean coe#  cient of variation for measured energy expenditure was 4.6 ± 0.4% 
compared with a coe#  cient of variation of 19.4% for prediction of mREE for an individual as 
stated by Scho! eld. This also advocates the use of measured energy expenditure instead of 
using prediction equations.
Prolonged measurements of energy expenditure, like we did in our study, give a better 
re$ ection of total daily energy expenditure. The calorie intake should be based on these 
measurements rather than on the basal or resting energy expenditure. These prolonged 
measurements are only possible in clinically stable, sedated patients. To determine resting 
energy expenditure a shorter period can be used (20-30 min with a steady state of 5 min 
Table 4 Nitrogen balance in relation to ratio of intake/mTDEE and nonprotein RQ
N-balance > 0 N-balance < 0 P-value
Patients 19 12
Intake/mTEE 1.4 ± 0.1 0.8 ± 0.1 <0.001
Nonprotein RQ 0.90 ± 0.02 0.87 ± 0.02 0.3
N-balance, Nitrogen balance; mTEE, measured Total Energy Expenditure; RQ, Respiratory Quotient
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during which average VO2 and VCO2 change by less than 10% and average RQ changes by 
less than 5%)(25).
In order to provide an appropriate number of calories, caloric intake should be individual-
ized using mTEE and RQ. In our study, we showed that feeding according to the mTEE could 
be a guideline because the ratio of caloric intake/mTEE was signi! cantly higher in patients 
with a positive nitrogen balance (1.4 ± 0.07) compared to those with a negative nitrogen 
balance (0.8 ± 0.1) (p<0.001). Feeding higher than mTEE is necessary for growth and tissue 
repair. In our patients with a positive nitrogen balance, the caloric intake exceeded the mTEE 
by 40%. However, in the case of enteral feeding, not all of the administered calories will be 
absorbed; the loss of energy in stools can account for 10-20% of the total caloric intake (26).
The RQ is the ratio of VCO2 to VO2 and re$ ects the percent substrate utilization of fat and 
carbohydrate in the body. By excluding protein, the nonprotein RQ provides a range of 
substrate utilization from 0.70 (100% fat utilization) to 1.0 (100% glucose utilization). Alcohol 
or ketone metabolism may reduce the nonprotein RQ below this range to 0.67. Overfeed-
ing with lipogenesis may increase it above this range to 1.3. In our study, 4 patients with 
a carbohydrate intake of 9-10 mg/kg per min showed an RQ > 1.0, suggesting excessive 
carbohydrate intake resulting in lipogenesis. A lower carbohydrate intake, however, can also 
lead to an RQ > 1.0, as was shown in 2 of our patients with a carbohydrate intake of 4.2 and 
7.5 mg/kg/min, respectively. There seems to be a maximum carbohydrate oxidation rate and 
thus a maximal capacity to use carbohydrate as a source of calories in the stressed patient. 
Beyond this oxidation maximum carbohydrate administration will lead to hyperglycemia, ex-
cess of CO2 (RQ > 1.0) and hepatic steatosis (27,28). An excessive amount of carbohydrate will 
not always lead to an RQ > 1.0, because in the hypermetabolic patient there is still ongoing 
oxidation of fat for energy, resulting in an RQ < 1.0 (29). This was the case in 2 of our patients 
with a carbohydrate intake of 9.8 and 11.4 mg/kg per min and an RQ which was < 1.0 (0.78 
and 0.95, respectively). Thus, the RQ can be used to detect overfeeding, but one should be 
cautious in using it as such.
In summary, this study shows that in critically ill, mechanically ventilated pediatric patients, 
although mTEE seemed to resemble pBMR, there was a wide range in the ratio of mTEE to 
pBMR and lack of agreement. Therefore, it seems not to be appropriate to use a standard 
prediction equation but to perform individual measurements of energy expenditure and RQ 
with indirect calorimetry in combination with nitrogen balance for matching adequate nutri-
tional support. Outcome-based studies could give more insight into how optimal nutritional 
support could be given to mechanically ventilated children in the intensive care setting. 
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ABSTRACT
Objective
To determine the value of indirect calorimetry and nitrogen balance (N-balance) in order to 
evaluate the current feeding protocols of mechanically ventilated children.
Study design
A cross-sectional prospective study. In 36 mechanically ventilated children energy expendi-
ture was measured by indirect calorimetry and total urinary nitrogen excretion (TUN) was 
determined. Substrate utilization and respiratory quotient (RQ) were calculated from the 
measured values of oxygen consumption (VO2), carbondioxide production (VCO2) and TUN. 
The RQ was compared with RQ of the macronutrients administered (RQmacr) according to 
the modi! ed criteria of Lusk.
Results
The total measured energy expenditure (TMEE) showed a wide variation (range 155 to 272 
kJ/kg/day). The N-balance was positive in 20 and negative in 16 patients. The ratio of caloric 
intake/TMEE was signi! cantly higher in patients with a positive N-balance (1.5 ± 0.06) as 
compared with those with a negative N-balance (0.8 ± 0.1; p<0.001). There was a signi! cant 
relation between the di" erence of RQ minus RQmacr versus the ratio caloric intake/TMEE 
(r=0.72, p<0.001). Carbohydrate and fat utilization were not signi! cant di" erent in patients 
with a positive or negative N-balance. Protein utilization was signi! cantly higher in those 
patients with a negative N-balance.
Conclusions
Measurement of TMEE with indirect calorimetry results in accurate determination of energy 
needs in critically ill mechanically ventilated children. Feeding according to or in excess the 
TMEE is correlated with a positive N-balance. A combination of the RQ and the RQmacr can 
be helpful in di" erentiating under- or overfeeding. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
45
Ch
ap
te
r 3
Energy expenditure and substrate utilization
INTRODUCTION
Protein-energy malnutrition is an important consequence of pediatric critical illness and 
is associated with increased physiologic instability and increased quantity of care (1,2). In 
critically ill patients there is a substantial interpatient variability in energy expenditure. The 
supply of calories based on prediction equations can be misleading and result in under- and 
overfeeding (3,4). Underfeeding will alter the immune function, the cardiorespiratory system 
and the gastro-intestinal tract (1). Overfeeding can a" ect respiratory and hepatic function 
and increases the risk of mortality (4).
Indirect calorimetry makes it possible to accurately determine energy expenditure and 
respiratory quotient. This can be used to monitor the adequacy and appropriateness of cur-
rent nutritional support. Furthermore when urinary nitrogen values are measured it allows 
the determination of substrate utilization. 
Until now only a small number of studies on mechanically ventilated children were presented 
with results of energy expenditure and substrate utilization using indirect calorimetry (5-11).
The purpose of this study is to determine the value of indirect calorimetry combined 
with nitrogen balance in order to evaluate the current feeding protocols of mechanically 
ventilated children and to obtain guidelines for improvement for individual patient groups 
or disease states.
MATERIALS AND METHODS
Patient Selection
Patients were consecutively included in this study after admission to level III Pediatric Inten-
sive Care Unit, when they ful! lled the following criteria:
- mechanical ventilation with a Servo Ventilator 300 (Siemens-Elema, Solna, Sweden) either 
with pressure regulated volume control or volume support mode. 
- FiO2 of less than 0.60.
- tube leakage of less than 10% (considered not to in$ uence the measurement signi! cantly 
(12)). Tube leakage was determined by comparison of inspired and expired tidal volumes 
measured by the ventilator assuming that there were no other leaks in the patient-
ventilator circuit.
- haemodynamically stable condition as indicated by a normal, stable blood pressure within 
2 SD of the age-related mean normal value (13) and a normal renal function expressed by 
a normal serum creatinine concentration (14).
Severity of illness on the day of measurement was assessed by the Pediatric Risk of Mortality 
score (PRISM) (15).
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The study was approved by the local Ethical Committee and informed consent was obtained 
from the parents or caregivers before entering into the study.
Energy Expenditure
Oxygen consumption (VO2), carbon dioxide production (VCO2)) and respiratory quotient (RQ), 
standardized for temperature, barometric pressure and humidity (STPD) were measured with a 
previously validated metabolic monitor (Deltatrac I MBM-100 and Deltatrac II MBM-200, Datex 
Division Instrumentarium Corp. Finland) (16). The Deltatrac is an open system indirect calorim-
etry device. The di" erence between the inspired and expired oxygen fractions is measured with 
a fast-response, paramagnetic di" erential oxygen sensor (OM-101, Datex Instrumentation). The 
expired CO2 fraction is measured with an infrared CO2 sensor. The accuracy of the Deltatrac was 
assessed with a butane burning set. Butane used for experiments was weighed before and after 
each experiment on a precise scale. The value obtained by the metabolic monitor for the total 
CO2 was compared to the predicted value of CO2 based on the weight of butane. The accuracy 
of the Deltatrac was assessed with a butane burning set every 3 months. Before each study, the 
calorimeter was calibrated with a reference gas mixture (95% O2, 5% CO2). The coe#  cient of 
variation of O2 consumption, CO2 production, and RQ did not exceed ± 4%. Studies were carried 
out during di" erent measurement periods from 4-24 hours. A measurement period more than 
4 hours resembled a 24 hour measurement with a coe#  cient of variation within 10% (17). Total 
measured energy expenditure (TMEE) was calculated using the modi! ed Weir formula (18): 
TMEE = 4184(5.5 VO2 + 1.76 VCO2); TMEE in kJ/day; VO2 in L/min; VCO2 in L/min).
Caloric intake
The patients were enterally and/or parenterally fed according to the current feeding protocol. 
The ! rst 12-24 hours only a glucose infusion is given. After 24 hours nasoduodenal feeding is 
started. The amount of feeding is 25-50% of the needs for healthy children and is increased 
to 100% in 2-4 days. Parenteral feeding is given if enteral feeding is not possible to give and 
increased in 2-4 days. Fluid and electrolyte intakes are adjusted to individual requirements. 
The caloric intake at the day of measurement was recorded. The amount of caloric intake 
was corrected for extra protein calories of plasma infusions and/or albumin infusions on 
the day of measurement. Retrospectively the results of energy expenditure measurements 
were combined with the amount of calories given. Enteral feeding was given continuously 
with a nasoduodenal drip with standard soja-based formula (Nutrilon soja for children < 6 
months, Nutrilon soja plus for children 6-12 months, 75% Nutrison soja and 25% water and 
4% Fantomalt added for children 1-4 years, 90% Nutrison soja and 10% water and 4% Fanto-
malt added for children 4-10 years and Nutrison soja for children > 10 years of age Nutricia, 
Zoetermeer, The Netherlands). Parenteral feeding was given either by peripheral infusion or 
by a central venous line (Intralipid 20%, Pharmacia Upjohn Holland and Aminovenös N-paed 
10%, Fresenius the Netherlands).
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A RQ of the macronutrients administered (RQmacr) was obtained from the modi! ed Lusk 
table after determining the carbohydrate to fat ratio for the total nonprotein calories of 
the infused regimen (20). The RQ was compared with the RQmacr. The RQ was assumed to 
approximate the RQmacr if RQ = RQmacr ± 0.05 (21). No correction was made for loss of 
carbohydrates and fat when enteral nutrition was given. This has to be taken into account 
when interpreting the results.
Urinary nitrogen excretion
Urine was collected on the day of measurement and analyzed for urinary urea nitrogen. In 
23 patients a urinary bladder catheter was in place and urine was collected over a 24-hour 
period. In 13 patients a pediatric urine collector was used and urine was collected over a 
shorter period of at least 6 hours which value can be used to estimate a 24 hour period. 
This inconsistency has to be taken into account when interpreting the results. Total urinary 
nitrogen excretion (TUN) was de! ned as 1.25 x urinary urea nitrogen, in order to adjust for 
the 20% of urinary nitrogen loss as ammonia, creatinine, and uric and amino acids (22). No 
correction was made for nitrogen losses through stools, skin, wound, nasogastric suction, or 
blood sampling. Nitrogen balance (N-balance) was calculated with the following formula:
N-balance (mg/kg/day) = (protein intake/6.25) - (urinary urea nitrogen x 1.25).
Substrate utilization
Net substrate utilization was calculated from the measured values of VO2, VCO2 and nitrogen 
excretion according to previously published methods (23). The following formulas were used: 
protein utilization (g/min) = 6.25 x urinary urea nitrogen (N); fat utilization (g/min) = 1.67(VO2 
- VCO2) - 1.92 N; fat synthesis (g/min) = 1.67(VCO2 - VO2) + 1.92 N; glucose utilization (g/min) 
in case of net fat utilization = 4.55VCO2 - 3.21VO2 - 2.87 N; glucose utilization in case of net 
fat synthesis = 1.34(VCO2 - 4.88 N), where VO2 is oxygen consumption in litres per minute (L/
min), VCO2 is carbon dioxide production in L/min and N is urinary urea nitrogen excretion in 
g/min. The RQ was calculated by the formula: VCO2/VO2
Statistical Analysis
Statistical analysis was performed with a statistical analysis software program (SPSS 7.0 for 
Windows 95, SPSS Software, Chicago, IL). Results are expressed as mean ± SEM, unless other-
wise indicated. For comparisons between groups the independent-samples t-test was used. 
Pearson’s correlation coe#  cient (r) was used to evaluate the relationship between RQ and the 
ratio caloric intake/TMEE, between RQ-RQmacr and the ratio caloric intake/TMEE, between 
TMEE and N-balance and between PRISM and TMEE.
A p-value of 0.05 or less was de! ned as statistically signi! cant.
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RESULTS
A total of 36 patients, 21 boys and 15 girls, with a wide range of clinical diagnoses ful! lled the 
entry criteria (Table 1). Their median age was 10 months (1 week -13 years). Median PRISM 
score was 7 (0-17). All patients were sedated with midazolam (0.05 - 0.3 mg/kg/hr) and/or 
morphine and muscle paralysis was present in 6 patients. Seven patients received inotropic 
drugs. There were no known gastro-intestinal absorption disturbances. The median day of 
Table 1 Clinical Characteristics of Study Patients
Diagnosis Age Sex Intake VO2 VCO2 TMEE RQ TUN
Congenital heartdefect 0.25 M 177 6.8 6.2 202 0.92 137
Congenital heartdefect 0.25 M 332 6.9 5.7 201 0.82 76
Congenital heartdefect 0.5 M 404 7.9 6.6 230 0.84 248
RS bronchiolitis 0.75 M 247 8.1 6.9 237 0.85 68
Congenital heartdefect 1.0 F 385 7.6 7.7 231 1.02 150
Congenital heartdefect 1.0 F 353 7.7 6.8 228 0.88 184
Congenital heartdefect 1.25 F 260 7.7 7.2 232 0.93 344
RS bronchiolitis 1.5 M 203 6.5 5.6 193 0.86 147
Sepsis 1.75 M 272 8.2 6.3 237 0.77 196
Congenital heartdefect 2.0 F 412 8.5 7.6 252 0.90 126
Congenital heartdefect 2.5 F 222 7.2 6.4 214 0.89 130
Congenital heartdefect 3.0 F 472 8.8 8.6 266 0.98 244
Meningitis 3.0 M 235 6.6 5.5 192 0.84 144
RS bronchiolitis 5.5 M 193 7.9 7.0 233 0.89 202
Congenital heartdefect 7.0 M 283 7.1 6.0 208 0.85 229
RS bronchiolitis 8.0 M 450 8.7 8.9 266 1.02 334
RS bronchiolitis 9.5 M 237 6.0 5.9 183 0.98 219
Status asthmaticus 10.0 M 298 7.6 7.0 228 0.92 232
Subglottic stenosis 10.0 M 368 7.0 6.7 212 0.95 255
Sepsis 11.0 M 242 6.4 5.4 188 0.85 493
Subglottic stenosis 11.0 M 465 9.2 7.4 252 0.81 116
Subglottic stenosis 13.0 F 387 9.6 8.7 273 0.91 486
Pneumonia 14.5 M 227 9.0 8.2 267 0.92 443
Cardiomyopathy 18.0 F 68 7.6 5.9 218 0.77 198
Sepsis 18.0 M 220 8.9 7.2 253 0.81 323
Pneumonia 19.0 F 65 6.3 5.7 189 0.90 471
Sepsis 22.0 M 118 6.8 5.2 197 0.76 201
Subglottic stenosis 28.0 F 166 6.1 5.3 180 0.86 96
Upper airway obstruction 32.0 M 413 8.2 6.4 236 0.78 298
Upper airway obstruction 33.0 M 61 7.1 5.9 209 0.83 387
Sepsis 36.0 F 289 8.2 7.8 246 0.96 421
Subglottic stenosis 38.5 F 278 5.5 5.2 166 0.95 300
Pneumonia 46.0 F 90 5.7 4.5 165 0.79 160
Sepsis 53.0 F 209 8.3 6.4 233 0.77 310
Sepsis 54.0 F 262 6.1 5.6 183 0.92 429
Sepsis 162.0 M 22 5.4 4.2 156 0.78 346
Age, months; Intake, kJ/kg/day; VO2, ml/kg/min; VCO2, ml/kg/min; TMEE, kJ/kg/day; TUN, mg/kg/day
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measurement after intubation was 3 days (range 0-15 days). Ventilatory characteristics were: 
mean FiO2 0.32 ± 0.02, mean tubeleakage 7% ± 1%; 18 patients were on pressure regulated 
volume control, 17 on volume support and 1 patient on continuous positive airway pressure.
Twenty-eight patients received enteral nutrition, 3 patients received only glucose infusion, 2 
patients received total parenteral nutrition and 3 patients received a mixture of enteral and 
parenteral nutrition.
The TMEE per kg body weight showed a wide variation with a minimum value of 155 kJ/
kg/day and a maximum of 272 kJ/kg/day. There was no correlation between the PRISM score 
and the TMEE (r=0.12, p=0.48).
The median TUN was 230 mg/kg/day (range 68 to 493 mg/kg/day). The N-balance was 
positive in 20 patients and negative in 16 patients (Table 2). 
There was a signi! cant relationship between the ratio caloric intake/TMEE and nitrogen 
balance (r=0.69, p<0.0001). There was no signi! cant di" erence in TMEE in patients with a 
positive or with a negative N-balance (211 ± 8 vs 223 ± 7 kJ/kg/day, p=0.23). There was a sig-
ni! cant di" erence between patients with a positive or negative N-balance for caloric intake 
(329 ± 21 vs 174 ± 22 kJ/kg/day), for the ratio caloric intake/TMEE (1.5 ± 0.1 vs 0.8 ± 0.1) and 
for the energy balance (106 ± 16 vs -37 ± 19 kJ/kg/day)(Table 2). 
There was no signi! cant di" erence in RQ between patients with a positive or negative 
N-balance (0.89 ± 0.02 vs 0.85 ± 0.02, p=0.19). In 2 patients with a positive N-balance the RQ 
was >1.0.
In 47% of the patients RQ approximated RQmacr, in 22% the RQ was above the RQmacr and 
in 31% the RQ was below the RQmacr. The ratio caloric intake/TMEE correlated signi! cantly 
with RQ (r=0.44, p=0.007). Caloric intake/TMEE correlated slightly better with the di" erence 
of RQ-RQmacr (r=0.72, p<0.001).
Table 2 Substrate intake and utilization versus N-balance
N-balance 
> 0
N-balance
 < 0
P-value
Caloric intake (kJ/kg/day) 329 ± 21 174 ± 22 <0.001
TMEE (kJ/kg/day) 223 ± 7 211 ± 8 0.23
Energy balance (kJ/kg/day) 106 ± 16 -37 ± 19 <0.001
Caloric intake/TMEE 1.5 ± 0.06 1.8 ±0.1 <0.001
CHO intake (mg/kg/min) 6.8 ± 0.5 4.8 ± 0.6 0.02
CHO utilization (mg/kg/min)
CHO balance (mg/kg/min)
6.0 ± 0.6
0.8 ± 0.6
4.4 ± 0.6
0.4 ± 0.3
0.08
0.60
Protein intake (g/kg/day) 2.2 ± 0.2 0.9 ± 0.2 <0.001
Protein utilization (g/kg/day)
Protein balance (g/kg/day)
1.2 ± 0.1
1.0 ± 0.1
1.9 ± 0.2
-1.0 ± 0.3
<0.001
<0.001
Fat intake (g/kg/day) 3.4 ± 0.2 1.1 ± 0.3 <0.001
Fat utilization(g/kg/day)
Fat balance (g/kg/day)
2.1 ± 0.3
1.3 ± 0.4
2.1 ± 0.4
-1.0 ± 0.5
1.0
0.001
RQ 0.89 ±0.02 0.85 ± 0.02 0.12
TMEE, total measured energy expenditure; CHO, carbohydrate; RQ, respiratory quotient 
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There was a signi! cant di" erence in protein, fat and carbohydrate intake in patients with a 
positive and negative N-balance. Carbohydrate and fat utilization were not signi! cant di" er-
ent in patients with a positive or negative N-balance but protein utilization was signi! cantly 
higher in those with a negative N-balance. Protein and fat balance were signi! cantly di" erent 
between patients with a positive or negative N-balance (Table 2).
DISCUSSION
An accurate way to determine energy requirements is to measure energy expenditure by 
indirect calorimetry, which we performed in a group of 36 patients with a moderate severity 
of illness (indicated by low PRISM scores). We con! rmed the ! nding of most studies on criti-
cal ill mechanically ventilated children that the measured energy expenditure shows a wide 
variation between individual patients. Due to this substantial interpatient variability there is 
a risk of under- and overfeeding in the individual patient. Providing an appropriate amount 
of calories in di" erent disease states without over- or underfeeding is crucial for optimal 
patient care. No validated observations in ventilated children were done so far.
In order to provide an appropriate amount of calories, caloric intake should have to be indi-
vidualized. In our study we showed that feeding according to or in excess of the TMEE could 
be a guideline because the ratio of caloric intake/TMEE was signi! cantly higher in patients 
with a positive nitrogen balance (1.5 ± 0.06) as compared to those with a negative nitrogen 
balance (0.8 ± 0.1) (p < 0.001). The energy for growth, which is not included in the TMEE, 
should be taken into account when calculating the amount of feeding required. For healthy 
children in the ! rst year of life 30-35% extra energy is needed but in the stressed patient this 
energy is less because growth will be diminished or even stopped (24).
The RQ re$ ects the percentage of fat and carbohydrate utilization. The apparent rates of 
substrates should be interpreted as net rates of “utilization”. The apparent rate of carbohydrate 
oxidation is the sum of the rates of utilization for oxidation and for lipogenesis minus the rate 
at which carbohydrate is formed from amino acids. The apparent rate of fat oxidation is the 
di" erence between the rates of oxidation and synthesis from carbohydrate (25). This has to 
be taken into account when interpreting the RQ values. In the stressed patient however the 
RQ may plateau at levels <1.0 despite high levels of carbohydrate infusion because there 
is continued net utilization of fat for energy. In our study in 3 patients with a carbohydrate 
intake > 9 mg/kg/min a RQ of 0.98, 0.90 and 0.78 was measured. It is presumed that the 
glucose intake which is above glucose utilization result in conversion of glucose to glycogen 
and conversion of glucose in fat (26,27).
Hyperventilation, metabolic acidosis (with bu" ering of acid generating carbon dioxide), 
and overfeeding (leading to lipogenesis) may all increase RQ above RQmacr. Hypoventilation 
or underfeeding with mild starvation ketosis may decrease RQ below RQmacr. Comparison 
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of the RQ with the RQmacr can probably be helpful in the determination of under- and over-
feeding (20,21). In our study in only 47% of the patients RQ approximated RQmacr, in 22% RQ 
was above the RQmacr suggesting overfeeding and in 31% RQ was below RQmacr suggest-
ing underfeeding or catabolism. Furthermore there was a signi! cant relation between the 
di" erence of RQ-RQmacr and the ratio caloric intake/TMEE (r=0.72, p<0.001). This means in 
case of a caloric intake which is lower than the TMEE a RQ lower than the RQmacr will suggest 
lipolysis and in case of a higher caloric intake than the TMEE a RQ higher than the RQmacr 
will suggest lipogenesis and overfeeding. The di" erence of RQ and RQmacr depends upon 
the accuracy with which both variables can be measured, for the RQ an accurate calorimeter 
is necessary in particular with increased FiO2 above 0.60 (16).
In acute illness endogenous fat is the main fuel for energy. In 2 studies of mechanically 
ventilated children receiving only glucose infusion indirect calorimetry showed that relative 
energy contribution of fat was 53% and 78% respectively (fat utilization rate 2.7 and 4.8 g/kg/
day) (7,9). In another study of mechanically ventilated head injured children, also receiving 
only glucose infusion, a fat utilization rate of 2.3 g/kg/day was measured. 
In our study a fat utilization of 2.1 g/kg/day was measured both in patients with a negative 
and positive N-balance, the relative energy contribution of fat was 38% and 36% respectively. 
In our study there was a lower energy contribution of fat because not only glucose but also fat 
was given. The fat intake was signi! cantly higher in patients with a positive N-balance com-
pared with a negative N-balance (3.4 ± 0.2 vs 1.1 ± 0.3 g/kg/day) and these data suggests that 
in the patients with the negative N-balance endogenous fat was utilized and in patients with 
the positive N-balance fat storage would occur. It can be concluded that energy-substrate 
utilization patterns may di" er markedly which depends on substrate intake.
In acute illness the accelerated net breakdown of body protein can be decreased by 
the use of a balanced glucose-lipid regimen as opposed to a glucose regimen. However it 
is extremely di#  cult to maintain or replenish body protein during catabolism (29,30,31). 
Furthermore there is an inability of many patients to e#  ciently utilize exogenous nutrients 
during severe catabolic illness which can lead to azotemia (29). 
In our study the protein intake of patients with a positive N-balance (2.2 ± 0.2 g/kg/day) 
was signi! cant higher (p<0.001) than in patients with a negative N-balance (0.9 ± 0.2 g/kg/
day) but protein utilization was signi! cant lower in the ! rst group (1.3 ± 0.1 vs 2.2 ± 0.2 g/kg/
day, p<0.001). The lower protein utilization of the ! rst group can be explained by the higher 
protein intake of these patients and/or by the nitrogen sparing e" ect of a higher fat intake 
(glucose utilization were not signi! cantly di" erent in these two groups) (32). The median 
nitrogen excretion data of our patient group, 230 mg/kg/day (range 68 to 493 mg/kg/day), 
suggest that a provision of 1.4 g/kg/day of protein (0.4 to 3.1 g/kg/day) should be su#  cient 
to approach nitrogen equilibrium. Previous studies have recommended a protein intake of 
1.5 to 2.5 g/kg/day (33,34).
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Conclusion
Measurement of the TMEE with indirect calorimetry will give an insight in the accurate en-
ergy needs of critically ill mechanically ventilated children. Feeding according to the TMEE is 
correlated with a positive nitrogen balance. A combination of RQ and RQmacr can be helpful 
in di" erentiating under- or overfeeding. Energy-substrate utilization patterns may di" er 
markedly.
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ABSTRACT
Introduction
Accurate assessment of energy expenditure provides important information for optimal 
nutritional support. The purpose of this study was: a) to measure energy expenditure in 
ventilated critically ill children and compare it with predicted energy expenditure, and b) 
to compare the respiratory quotient (RQ) with the ratio energy intake/measured energy 
expenditure and carbohydrate intake. 
Methods
In 94 mechanically ventilated children, resting energy expenditure was measured by indirect 
calorimetry (MREE). The predicted resting energy expenditure (PREE) was calculated with 
currently recommended equations for healthy children and for critically ill children. Modi! ed 
bland-Altman analysis and metabolic index [100*(MREE-PREE)/PREE] served to determine 
accuracy of prediction equations.
Results
None of the prediction equations reliably estimated measured energy expenditure in me-
chanically ventilated children. Scho! eld’s equation based on weight and height showed the 
highest accuracy: it predicted energy expenditure within 10% of the MREE in 40% of the 
children. RQ was correlated with the ratio energy intake/measured energy expenditure and 
carbohydrate intake. 
Conclusions
Prediction equations for energy requirements are not suitable for ventilated, critically ill 
children. Indirect calorimetry should be used to measure energy expenditure and RQ to ac-
curately assess energy needs of the individual child and to guide nutritional therapy. 
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INTRODUCTION
Knowledge of energy requirements for critically ill children is essential for the provision of 
adequate nutrition to prevent the detrimental consequences of over- and underfeeding. 
Inadequate feeding can increase morbidity and mortality rates [1-2]. Adequate nutritional 
support can signi! cantly improve physiological stability and outcome [2]. Furthermore, the 
goal of nutrition in critically ill children is not only to restore a normal functioning level but 
also to meet the requirements for growth and development. 
Nutritional requirements for critically ill children vary widely between individuals. There-
fore, measurement of energy expenditure is necessary to tailor optimal nutritional support. 
Indirect calorimetry is the method of choice to determine energy requirements. However, 
portable metabolic carts are not always routinely available, so most clinicians estimate en-
ergy expenditure using prediction equations [3]. Standard prediction equations are derived 
from indirect calorimetry measurements in healthy children. The relative di#  culty of indirect 
calorimetry and the poor precision of standard predictive methods have challenged re-
searchers to develop new equations derived from actual energy expenditure measurements 
of ventilated, critically ill children [4]. However, so far all developed predictive methods have 
failed to predict energy requirements with acceptable precision for clinical use in ventilated, 
critically ill children [5-11]. Details of the main studies comparing prediction equations with 
energy expenditure measurements by indirect calorimetry over the past 10 years are shown 
in Table 1. 
Table 1 Study population characteristics: comparison of measured and predicted energy expenditure in ventilated children with various diagnoses
Author (Year) Mean age year 
(range or ± SD)
Nr Prediction Equation MREE/ PREE Mean Bias 
(kcal/day)
Bias (range or ± 
SD) (kcal/day)
White [4] 
2000
4.5 ± 4.5 100 White I
White II
- -39
-37 
-292 to 324
-342 to 398
Briassoulis [8] 
2000
7 (0.1-18) 37 Scho! eld
(W/H)
<0.9: 57% 
0.9-1.1: 22% 
>1.1: 21%
- -
Coss-Bu [11] 
2001
5.5 (0.4-17) 33 Talbot 1.2 ± 0.7
(mean ± SD)
- -
Hardy [7] 
2002
4.5 (0-22) 52 Scho! eld (W) 1.3 0.9-1.1: 36% -1 -382 to 390
Taylor [10] 
2003
8.8 (0.8-16) 57 Scho! eld (W/H) <0.9: 51% 
0.9-1.1: 37% 
>1.1: 12%
-92 -484 to 300
Vazquez [9] 
2004
4.2 ± 3.7 43 Scho! eld (W/H) 0.89 - -
Oosterveld[21]
2006
4 (0-18) 46 Scho! eld (W/H) 1.0 95% 
CI (98-103)
- -
Framson [6] 
2007
5.2 (0-17) 44 Scho! eld (W/H) <0.9: 22% 
0.9-1.1:59% 
>1.1: 19%
- -
MREE, measured resting energy expenditure; PREE, predicted resting energy expenditure
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The study had a twofold aim: a) to compare measured energy expenditure in mechanically 
ventilated children with current available prediction equations for use in clinical practice, and 
b) to correlate the ratio actual caloric intake/measured energy expenditure and carbohydrate 
intake with the respiratory quotient.
MATERIALS AND METHODS
Patients
Children up to the age of 18 years admitted to our level III multidisciplinary pediatric/surgical 
ICU were eligible for the study when they met the following criteria: Mechanical ventilation 
with a Servo ventilator 300 (Siemens-Elema, Solna, Sweden); Inspired oxygen fraction (FiO2) 
less than 60%, tube leakage <10% (considered not to signi! cantly a" ect the measurements; 
determined by comparing inspired and expired tidal volumes measured by the ventilator 
assuming an absence of air leaks in the patient-ventilator circuit)[12]; Hemodynamic stable 
condition (blood pressure and heart rate within 2 SD of age-related values)[13]. An exclusion 
criterion for this study was inclusion into a nutritional intervention study. 
The institutional review board of the Erasmus MC approved the study protocol, and written 
(parental) informed consent was obtained before children entered the study. Clinical data 
collected included age, gender, weight, height, primary diagnosis, surgical status, days on 
mechanical ventilation, length of ICU-stay, route of nutritional support, and energy intake. 
Severity of illness on admission was assessed by the pediatric risk of mortality score (PRISM)
[14]. 
Measured Resting Energy expenditure (MREE) and respiratory quotient (RQ) 
Indirect calorimetry measurements were started as soon as technically possible after admis-
sion. Oxygen consumption (VO2), carbon dioxide production (VCO2), and RQ standardized for 
temperature, barometric pressure, and humidity were measured using the Deltatrac I MBM-
100 and Deltatrac II MBM-200 (Datex Division Instrumentarium, Helsinki, Finland) metabolic 
monitor. Measured resting energy expenditure (MREE) was calculated with the modi! ed 
Weir formula [15]. The properties of the Deltatrac metabolic monitor have been described 
previously [5]. Before each study the calorimeter was calibrated with a reference gas mixture 
(95% O2, 5% CO2, Datex Division Instrumentarium Corp.) The RQ was calculated from the 
measured oxygen consumption and carbon dioxide levels. Measurements lasted at least 2 
hours. 
Predicted Resting Energy Expenditure (PREE)
The PREE was calculated with the current equations for healthy children: the Scho! eld equa-
tions based on age and weight (W), the Scho! eld equations based on age, weight and height 
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(W/H) [16], and the WHO equations based on weight [17]. In addition, it was calculated with 
two prediction equations for ventilated critically ill children above 2 months of age; the White 
equations [4]. Details are provided in Table 2. Results are expressed in kilocalories per day. 
The PREE was compared with the MREE by means of the metabolic index [18]: [100*(MREE - 
PREE)/PREE]. The metabolic index represents the relation between MREE and PREE, expressed 
as a percentage. A negative value (<0) means the PREE overestimated the measured energy 
expenditure; a positive value (>0) re$ ects underestimation [18]. The proportion of each PREE 
falling within 10% of MREE was also used to evaluate prediction accuracy. Based on clini-
cal experience and implicit standards in prior studies we judged that a prediction method 
capable of predicting within 10% of MREE in the majority of patients would be clinical useful. 
Other authors use the ratio of MREE/PREE for de! ning a hypo- or hypermetabolic response: 
whenever MREE is >110% of PREE of healthy children (for this purpose we used the Scho! eld 
(W/H) equation), children are de! ned as hypermetabolic: when <90%, they are de! ned as 
hypometabolic [19].
Table 2 Standard equations used to predict resting energy expenditure in children (kcal/day).
Equation 0-3 year 3-10 year 10-18 year
Scho! eld (W/H) 0.2 x W + 1516.7 x L - 681,8 (M)
16.3 x W + 1022.7 x L – 413.3 (F)
19.6 x W + 130.2 x L + 414,7 (M)
17,0 x W + 161.7 x L + 371.0 (F)
16.2 x W + 137.1 x L + 515.3 (M)
8.4 x W + 465.4 x L + 200.0 (F)
Scho! eld (W) (59.5 x W)–30.3 (M)
(58.3xW)-31.1 (F)
(22.7xW)+504 (M)
(20.3xW)+486 (F)
(17.5xW)+658 (M)
(13.4xW)+692 (F)
WHO (60.9xW)-54 (M)
(61xW)-51 (F)
(22.7xW)+495 (M)
(22.5xW)+499 (F)
(17.5xW)+651 (M)
(12.2xW)+746 (F)
White I
(for children >2 
months)
[(20 x age) + (31 x W) + (151 x waz score) + (279 x body temperature) + (122 x days ICU) – 9200 + 0 (head injury) 
or + 105 (post surgical procedure) or -512 (respiratory illness) or + 98 (other) or – 227 (sepsis)] /4184
Age in months; body temperature in °C; days ICU, the number of days since ICU admission, if >4 then multiply 
by 4
White II
(for children >2 
months)
[(17 x age) + (48 x weight) + (292 x body temperature) – 9677]/4184
Age in months, body temperature in °C
Scho! eld (W/H) or (W), Scho! eld prediction equation based on weight and height or weight; WHO, World Health Organization; Kcal, 
kilocalories; W, weight in kg; L, length in meters; M, male; F ,female; waz score, weight for age Z score; ICU, intensive care unit
Energy intake
Children were enterally and/or parenterally fed on the guidance of the current feeding proto-
col as described previously [20] and the judgement of the physician clinically responsible for 
the individual child, independent of the study. Enteral feeding was started as soon as possible 
in all patients, either continuously or intermittently through a nasogastric tube (drip or bolus) 
or nasoduodenal tube (drip). It consisted of human milk or standard formula according to 
parents’ preference. Parenteral feeding was given either by peripheral infusion or by a central 
venous line. Fluid and electrolyte intakes were adjusted to individual requirements. 
Actual total daily energy, carbohydrate and fat intake were derived from patient records on 
the day of calorimetry.
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Statistical analysis
Statistical analyses were performed using SPSS 16.0 for Windows, SPSS software (Chicago, 
III., USA). Results are expressed as median and range. Spearman’s correlation, the metabolic 
index and modi! ed Bland and Altman comparison served to evaluate the relation between 
MREE and prediction equations. The mean percentual di" erence between MREE and PREE 
represents the performance bias. Two-tailed P-values <0.05 were considered signi! cant. 
RESULTS
Clinical Characteristics
The group consisted of 94 children, 51 boys, admitted to the PICU of the Erasmus MC - So-
phia Children’s Hospital. Key clinical characteristics are shown in Table 3. Median age was 
0.46 (0.01-15.2) years, including 63% of the children < 1 year of age. Twenty-two per cent 
of the children was classi! ed as malnourished (SD-score for WFH<-2.0). The median day 
of measurement was 2 days (0-69 days) after PICU admission and 2 days (0-15 days) after 
intubation. All children were on mechanical ventilation and sedated with midazolam and/or 
morphine. Nine children were treated with neuromuscular blocking agents and 19 children 
received inotropic drugs. Ventilatory characteristics were as follows: median tube leakage 
was 4% (0-17), 60 children were on PRVC, 32 on volume support, and 2 on other ventilatory 
support. There were no known gastrointestinal absorption disturbances. Forty-two children 
were on full enteral nutrition, 17 on total parenteral nutrition, 28 on a mixture of enteral and 
parenteral nutrition, and 7 children received only glucose infusion. 
Table 3 Patient characteristics 
 Variable Number Median (range)
Gender (M/F) 51/43
Age (years) 0.46 (0.01-15.2)
Weight (kg) 5.8 (2.3-60.0)
WFH SD score -0.24 (-4.39-3.14)
PRISM 9 (0-33)
Diagnostic groups:
Congenital anomalies 
Post-operative monitoring
Sepsis or meningitis
Respiratory illness
Cardiac illness 
Other
 10
 14
 16
 28
 17
 9
M, male; F, female; WFH SD score, weight for height SD score, PRISM, pediatric risk of mortality.
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Comparison of Predicted and Measured Resting Energy Expenditure 
For the total population, median MREE was 50 kcal/kg (20-67 kcal/kg), and median RQ was 
0.89 (0.67-1.07). The results of predictive energy expenditure calculations in relation with 
MREE are shown in Table 4. The correlation coe#  cients between MREE and predictive equa-
tions varied between 0.51 and 0.97. The median metabolic index for the di" erent equations 
ranged from -0.2% to -23%. The Scho! eld equation (W/H) showed the highest accuracy; it 
predicted energy expenditure within 10% of the MREE in 40% of the children. Thirty-one 
percent of the children were classi! ed as hypermetabolic and 29% as hypometabolic. Bland-
Altman comparison of MREE and PREE by Scho! eld (W/H) showed a mean percentual bias of 
-1.0% and a precision (±1 SD of bias) of 20.7% (Figure 1). The ratio of MREE divided by PREE 
(using Scho! eld (W/H) did not di" er between the diagnostic groups nor between surgical 
and non-surgical children. The metabolic index correlated positively with the Z-score for 
weight for height (r=0.49, p<0.001).
Table 4 Comparison of measured energy expenditure (MREE) and predicted energy expenditure (PREE) in ventilated critically ill children
Prediction 
Equation
PREE
Median (range)
Correlation
PREE and MREE
(p-value)
[(MREE-PREE)/ PREE]*100%
Median (range)
% of children within 
10% of MREE
Scho! eld (W/H) 312
(96-1731)
0.96 (<0.001) -0.2
(-45 to 76)
40
Scho! eld (W) 312
(104-1720)
0.97 (<0.001) -0.9
(-42 to 42)
36
WHO 301
(84-3112)
0.97 (<0.001) 2.5
(-46 to 57)
33
White I 
(infants<2 mo excluded)
477
(28-8629)
0.51 (<0.001) -19
(-93 to 705)
16
White II (simpli! ed) 
(infants <2 mo excluded)
392
(233-1776)
0.93 (<0.001) -23
(-73 to 42)
19
RQ measurements
For the total population, median RQ was 0.89 (0.67-1.07). RQ was >1.0 in seven children. 
These seven children had a signi! cantly higher carbohydrate intake than those with a RQ 
≤1.0 (9.1 vs 5.1 mg/kg/min, p<0.001). The RQ was also positively correlated with the ratio 
energy intake/MEE (r=0.45, p<0.001) and carbohydrate intake (r=0.51, p<0.001) (Figure 2). 
DISCUSSION
This study shows that all predictive methods fail to reliably estimate measured energy 
expenditure in mechanically ventilated children. Although all prediction equations were sig-
ni! cantly correlated with measured energy expenditure, the metabolic indices showed wide 
ranges and lack of agreement. This is in accordance with previous studies [5-11]. Scho! eld’s 
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Figure 1. Modi! ed Bland-Altman plot of comparison between measured energy expenditure (MREE) using indirect calorimetry and predicted 
energy expenditure (PREE) using the Scho! eld (W/H) equation. The Y-axis, shows the percentual di" erence between MREE and PREE. A lack 
of agreement exists between individual predicted energy expenditure and measured energy expenditure values as indicated by the wide 2SD 
range (-39.4% to 40.4%). The mean values of PREE and MREE are presented in kcal/day. 
Figure 2. Relation between glucose intake and RQ.
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equation (W/H) showed the highest accuracy, as it predicted energy expenditure within 10% 
of the MREE in 40% of the children. Like in previous studies, Scho! eld’s equation (W) was 
second best, with 35% of the predictions within 10% of the MREE [6-7]. The two equations 
developed by White et al. for critically ill mechanically ventilated children yielded the lowest 
accuracies [4]. The accuracy of the ! rst White (I) equation, derived from 6 patient variables 
(age, weight, weight for age Z-score, body temperature, number of days after PICU admission 
and primary reason for admission) was only 16%; that of the simpli! ed version (White II) was 
19%. PREE according to the White equations overestimated MREE in most children, which 
was in accordance with a previous report [6]. 
There may be several reasons for the inaccuracy of the White equations. One concerns the 
primary reason for admission: White et al. found the highest MREE in postoperative children, 
and the lowest MREE in children with respiratory illness. In the present study, however, and 
in accordance with others, there was no signi! cant di" erence in MREE between di" erent 
diagnostic groups with di" erent severity of illness (expressed by PRISM score) or between 
surgical and medical patients [4,6,8,19,21-23]. Only after severe traumatic brain injury and 
severe burn injury a hypermetabolic response is reported in the majority of children [22, 
24-25]. Second, White used clinical estimations of weight [4], which have been shown to be 
very unreliable [2]. Some have argued to use ideal body weight for predictive equations [26]. 
Vazquez-Martinez et al. showed that use of the ideal weight resulted in a higher PREE, but not 
in improvement of the accuracy of the prediction equations tested [9]. Moreover, actual mea-
sured body weight does not always re$ ect true body mass either, since measured weights are 
often skewed by edema and rapid loss of lean body mass in the beginning of disease. 
However, like White et al. reported, there is a rationale for the use of the Z-score for weight 
for age in prediction equations for PREE, as it was positively correlated with MREE [4, 8, 27]. 
MREE will be decreased in children with a low Z-score, because of decreased muscle cell 
mass. Third, the use of number of days after intensive care admission in the White equation 
is another questionable parameter as serial measurements of energy expenditure during 
PICU admission showed no change in energy expenditure over time [6, 8, 21, 28], this will 
be discussed below. And ! nally fourth, in both the original White and the simpli! ed White 
equation the addition of the temperature variable is presumed to increase accuracy. White et 
al. showed that body temperature was signi! cantly correlated with MREE [4]. Previous studies 
have shown a 6-12% increase in MREE per degree of increase in body temperature in indi-
vidual critically ill infants and children [10, 29-30]. However, taking temperature into account 
will not increase accuracy of a general prediction equation, because the increase in energy 
expenditure caused by increase in temperature occurs relative to a patient’s “baseline” MREE. 
Overall, in our study 29% of the children were de! ned as hypometabolic, 40% as normo-
metabolic and 31% as hypermetabolic based on MREE in comparison with PREE according to 
Scho! eld (W/H). This distribution is consistent with previous studies in critically ill children 
[6, 8-9]. Hypermetabolism in critically ill children is not as frequent as in adults, probably 
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owing to re-channeling of energy normally used for growth toward energy needs caused 
by the acute disease state. There are several other reasons for the prevailing hypo- or nor-
mometabolic response in critically ill children. Mechanical ventilation decreases the work of 
breathing, sedation and muscle relaxants decrease physical activity, and continuous feeding 
as well as treatment in a temperature controlled environment also reduce energy expen-
diture. Furthermore, it is often assumed that critically ill children resemble adults in their 
metabolic response to critical illness, showing phases of hypometabolism (Ebb phase) and 
hypermetabolism (Flow phase). However, serial measurements of energy expenditure during 
PICU admission showed no change in energy expenditure over time [6, 8, 21, 28]. It is possible 
that energy expenditure measurements were performed too late to recognize the relative 
short Ebb phase in critically ill children. Only two studies have evaluated energy expenditure 
in the ! rst hours after elective surgery. Although a temporary increase in MREE was reported 
in the ! rst 2-4 hours after surgery, there was no preceding hypometabolic (Ebb) phase in both 
studies [9, 31]. The lack of intraindividual variation in MREE facilitates monitoring of energy 
expenditure. 
From a clinical viewpoint a single measurement of energy expenditure by indirect calo-
rimetry early during admission may serve to assess the energy needs of the individual child 
and guide nutritional therapy. An optimal feeding regimen would be de! ned as a feeding 
protocol enabling the early restoration of nutritional losses and aiming at achieving normal 
growth rates. Therefore, caloric amounts should equal the measured energy expenditure in 
the acute metabolic stress period [32], thereafter energy intake should be increased to ac-
count for tissue repair and growth. In the majority of critically ill children, the acute metabolic 
stress period typically lasts no more than 1 or 2 days. It is not clear, however, how soon energy 
intake can be increased without the risk of overfeeding [33]. An energy intake of 1.4-1.5 times 
MREE was suggested to be optimal [28, 34], whereas others considered an energy intake of 
1.1 times MREE as overfeeding [35]. Also RQ has been proposed to identify carbohydrate 
overfeeding (RQ>1.0) and to exclude underfeeding (RQ>0.85). Consistently, we showed that 
carbohydrate intake in children with a RQ>1.0 was signi! cantly higher than in those with a 
RQ≤1.0. On the other hand, a high amount of carbohydrates will not always result in a RQ>1.0 
(Figure 2), because in the critically ill child there can be ongoing oxidation of fat for energy, 
resulting in an RQ <1.0. 
The question remains whether a prediction equation might be the best alternative to assess 
energy needs when indirect calorimetry is not possible. If we would have used Scho! eld’s 
equation (W/H) in the acute phase of illness, energy intake of 30% of the children would 
have been too low. As pointed out above, energy intake should be increased in 1 or 2 days 
to account for growth and tissue repair. Increases should be tailored to prevent excessive 
carbohydrate, protein and fat intakes. Carbohydrate intake can be monitored by serial RQ 
measurements and blood glucose levels to prevent hyperglycemia. Protein and fat intakes 
can be monitored by determination of the blood content of urea and trigycerides [36]. The 
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optimal energy intake after the initial phase of acute illness might be as high as the recom-
mended intake for healthy children [20]. 
Conclusion
We demonstrated that equations for predicting energy requirements are not suitable for ven-
tilated, critically ill children. These children were frequently hypo- or normometabolic during 
the ! rst days of PICU admission. Our ! ndings support the use of indirect calorimetry in the 
individual patient for measurement of energy expenditure early after admission followed by 
serial RQ measurements. This will lead to greater accuracy and can help avoid under- and 
overfeeding.
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PA RT II
HYPER GLYCEMIA
A pessimist sees the di#  culty in every opportunity; an optimist sees the 
opportunity in every di#  culty (Winston Churchill)
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ABSTRACT
Introduction
Children with meningococcal disease show considerable morbidity. Better understanding of 
pathophysiological mechanisms will improve outcome. The objective of this study was to 
investigate the occurrence of hyperglycemia and insulin response in critically ill children with 
meningococcal disease. Setting: Intensive Care Unit in academic children’s hospital.
Methods
Seventy-eight children with meningococcal disease were included. The group was classi! ed 
into shock non-survivors, shock survivors and sepsis survivors. The course of laboratory pa-
rameters during 48 hours was assessed. Insulin sensitivity and β-cell function on admission 
were investigated by relating blood glucose levels to insulin levels and C-peptide levels and 
by homeostasis model assessment (HOMA). 
Results
On admission, hyperglycemia (glucose >8.3 mmol/l (>150 mg/dl)) was present in 33% of the 
children. Shock and sepsis survivors had higher blood glucose levels compared with shock 
non-survivors. Blood glucose level on admission correlated positively with plasma insulin, C-
peptide, cortisol, age and glucose intake. Multiple regression analysis revealed that both age 
and plasma insulin on admission were signi! cantly related to blood glucose. On admission 
62% of the hyperglycemic children had overt insulin resistance (glucose >8.3 mmol/l and 
HOMA-%S <50%); 17% had decreased β-cell function (glucose >8.3 mmol/l and HOMA-%B 
<50%) and 21% had both insulin resistance and decreased β-cell function. Hyperglycemia 
was present in 11% and 8% of the children at 24 and 48 hours after admission, respectively.
Conclusions
Children with meningococcal disease often show hyperglycemia on admission. Both insulin 
resistance and decreased β-cell function play a role in the occurrence of hyperglycemia. 
Normalization of blood glucose levels occurs within 48 hours, typically with normal glucose 
intake and without insulin treatment.
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INTRODUCTION
Critical illness is associated with many endocrine and metabolic changes, including changes in 
the glucose homeostasis [1-7]. Both hypoglycemia and hyperglycemia may lead to adverse out-
come as expressed in length of pediatric intensive care unit (PICU) stay and mortality rates [6-16]. 
A follow-up study in patients who survived meningococcal septic shock in childhood 
showed that severe mental retardation was associated with hypoglycemia during admission 
[17]. Children who died from meningococcal septic shock appeared to have signi! cantly low-
er levels of blood glucose on admission to the PICU than those who survived, in whom levels 
were moderately increased [4-5]. The most severely ill children had signs of (relative) adrenal 
insu#  ciency on admission. De! ciency of substrate, reduced activity of adrenal enzymes due 
to endotoxins, cytokines or medication and shock with disseminated intravascular throm-
bosis can cause necrosis of the adrenal glands resulting in (relative) adrenal insu#  ciency in 
children with meningococcal disease [5]. 
Many children with meningococcal septic shock su" er from hyperglycemia [12, 18-19]. The 
pathophysiological mechanism leading to hyperglycemia in critically ill children with menin-
gococcal disease may be di" erent from adults. Recently, it was shown that the acute phase 
of sepsis in children is quite di" erent from adults [18]. It was suggested that hyperglycemia 
associated with β-cell dysfunction rather than insulin resistance may be the normal patho-
physiological response in children with meningococcal septic shock. It was also suggested 
that treatment of hyperglycemia with exogenous insulin may not be supportive and may 
even be potentially detrimental in critically ill children [18]. 
Better insight into pathophysiological mechanisms leading to hyperglycemia is crucial to 
improve treatment strategies. The gold standard for quantifying insulin sensitivity in vivo 
is the hyperinsulinemic euglycemic clamp technique [20]. This is a complex and invasive 
technique, and therefore not easily applied in studies with critically ill children. The search for 
uncomplicated and inexpensive quantitative tools to evaluate insulin sensitivity has led to 
the development of other assessments. The fasting glucose-to-insulin ratio and homeostasis 
model assessment (HOMA) of insulin resistance have been proven to be useful estimates of 
insulin sensitivity, also in critical illness [21-24]. There is a good correlation between estimates 
of insulin resistance derived from HOMA (HOMA-%S) and from the hyperinsulinemic eugly-
cemic clamp [24]. The assessment of β-cell function is di#  cult because the β-cell response 
to the secretory stimuli is complex. There is no gold standard for β-cell function. The HOMA 
method for assessing β-cell function (HOMA-%B) is based on measurements of fasting insulin 
or C-peptide concentration to calculate pre-hepatic insulin secretion in relation with blood 
glucose levels [24]. The objective of the present study was to investigate the occurrence of 
hyperglycemia in relation with the insulin response and exogenous factors, such as glucose 
intake and drug use, in a homogenous group of critically ill children with meningococcal 
sepsis and/or meningococcal septic shock. 
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MATERIALS AND METHODS 
Patients 
The study population consisted of previously healthy children admitted to the PICU of the 
Erasmus MC-Sophia Children’s Hospital between October 1997 and May 2004, su" ering 
from meningococcal sepsis, i.e. sepsis with petechiae/purpura. Sepsis was de! ned as body 
temperature of less than 36.0ºC or more than 38.5ºC with tachycardia and tachypnea [5]. 
Children were determined to have septic shock if they had persistent hypotension or evi-
dence of poor end-organ perfusion, de! ned as at least two of the following: a) unexplained 
metabolic acidosis (pH <7.3 or base excess <-5 mmol/l or plasma lactate levels >2.0 mmol/l); 
b) arterial hypoxia (PO2 <75 mm Hg, a PO2/FiO2 ratio <250 or transcutaneous oxygen satura-
tion <96%) in patients without overt cardiopulmonary disease; c) acute renal failure (diuresis 
<0.5 ml/kg/h for at least one hour despite acute volume loading or evidence of adequate 
intravascular volume without pre-existing renal disease); or d) sudden deterioration of the 
baseline mental status [5].
Children were not eligible for the study if they had pre-existing diabetes mellitus or had 
received radiation or chemotherapy within the previous 6 months. Thirty-! ve of the included 
78 children participated in a randomized, double-blinded, placebo-controlled study. They 
received either placebo or activated protein C concentrate (APC) starting after admission, 
every 6 hours for the ! rst days of admission, and next every 12 hours to a maximum of 7 days 
[19]. APC is assumed not to in$ uence the endocrine and metabolic assays [5]. The Erasmus 
MC Medical Ethics Review Board approved the study and written informed consent was 
obtained from the parents or legal representatives.
Clinical parameters 
Disease severity was assessed by the pediatric risk of mortality (PRISM II) score on day of 
admission [25]. Glucocorticoid administration, inotropic medication, and use of mechanical 
ventilation were recorded. Equivalent doses of prednisolone, expressed per body weight 
(mg/kg) were calculated, using the glucocorticoid equivalents of 20/5/0.75 mg for hydrocor-
tisone, prednisolone and dexamethasone, respectively. Inotropic support was quanti! ed by 
the vasopressor score developed by Hatherill et al. [26] 
Nutrition
The children were fed enterally and/or parenterally according to a standard feeding proto-
col as previously described [27]. If enteral feeding could not be started on the second day, 
parenteral feeding was started. On admission at the PICU glucose was administered at a rate 
of 2-6 mg/kg/min, depending on weight. The initial dose of proteins was 1.0 g/kg/day and 
that of lipids 1.0 g/kg/day. If clinically possible, nutrition was adjusted to the normal needs 
according to dietary reference intakes for healthy children on days 3 and 4. 
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Collection of blood and assays 
Arterial blood samples for the determination of blood glucose levels and plasma levels of in-
sulin, C-peptide, cortisol, cytokines, C-reactive protein (CRP), lactate and free fatty acids (FFA) 
were collected on admission and at 24 and 48 hours thereafter. Assays were used according 
to manufacturer’s instructions. Arterial glucose and lactate were determined on blood gas 
analyzer (ABL 625, Radiometer, Copenhagen, Denmark). Hypoglycemia was de! ned as a 
blood glucose level ≤2.2 mmol/l (≤40 mg/dl), and hyperglycemia as a blood glucose level 
>8.3 mmol/l (>150 mg/dl)[28]. The reference level for lactate was <2.0 mmol/l. Serum insulin 
was measured by a two-site chemiluminescent immunometric assay (Immulite 2000, DPC, 
Los Angeles, USA) with minimum detection level of 35 pmol/l and maximum fasting reference 
value of 180 pmol/l. Serum C-peptide was measured by a chemiluminescent immunometric 
method (Immulite 2000, Siemens, Los Angeles, CA). For children under the age of 13 years the 
reference interval ranged between 0.2 and 2.6 nmol/l (0.6 – 7.8 ng/ml) and for children older 
than 13 years between 0.4 and 2.6 nmol/l (1.3 – 7.9 ng/ml) [29]. Serum cortisol concentra-
tions were determined with a competitive luminescence immunoassay (Immulite 2000, DPC, 
Los Angeles, CA). The detection limits of this assay are: 3-1380 nmol/l. Adrenal insu#  ciency 
in case of catecholamine-resistant septic shock is assumed at a random total cortisol level 
<496 nmol/l (<18 mcg/dl) [30]. FFA was determined by enzymatic method (Nefac-kit, Eako, 
Instruchemie BV). CRP was determined by immunoturbidimetric assay (normal <2 mg/l), and 
examined on a 912 analyzer (Roche Molecular Biochemicals, Mannheim, Germany). Cytokine 
levels were analyzed with an enzyme-linked immunosorbent assay (Sanquin, Amsterdam, 
The Netherlands). The detection limit of interleukin-6 (IL-6) (lowest positive standard) was: 10 
pg/ml. The detection limit of tumor necrosis factor-a (TNF-α) was: 5 pg/ml [31].
Outcome measurements
The total sample was divided into three groups: shock non-survivors, shock survivors and 
sepsis survivors, as we have previously reported striking di" erences in endocrinological 
and metabolic responses between survivors and non-survivors [5]. The courses of the main 
endocrinological, metabolic and immunological laboratory parameters during the ! rst 48 
hours of PICU stay were assessed.
The insulin response to hyperglycemia was assessed by investigating insulin response to 
glucose, and by HOMA modeling [24]. The updated HOMA2 computer model was used to 
determine insulin sensitivity (%S) and β-cell function (%B) from paired plasma glucose and 
insulin and C-peptide concentrations on admission. Children were considered to be fasting 
until admission with subsequently only a continuous glucose infusion without enteral intake 
for more than 6 hours. Determinations of insulin sensitivity and β-cell function were made 
on admission only.
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Statistical analysis
Analysis was performed with the SPSS statistical software package for Windows (version 16.0; 
SPSS inc., Chicago, USA). Results are expressed as medians and interquartile range, unless 
speci! ed otherwise. Between-group comparisons were made using the Mann-Whitney U test 
for continuous data. Chi-square test was used for comparison of nominal data. Spearman’s 
correlation coe#  cient was used to evaluate the relationship between di" erent parameters. 
Multiple linear regression analysis was applied to evaluate the relationship between admis-
sion hyperglycemia and various variables. Data were log-transformed for multiple linear 
regression analysis when necessary. P-values less than 0.05 are considered as statistically 
signi! cant.
RESULTS 
Patient characteristics (Table 1)
Seventy-eight children (32 female) admitted to our PICU with meningococcal disease were 
included. Their median age was 3.5 years (1.6-9.4 years). Blood cultures revealed Neisseria 
meningitidis in 65 children, 13 children were diagnosed as having meningococcal disease 
based on their typical clinical picture. Sixty-seven children were classi! ed as having menin-
gococcal septic shock and 11 as meningococcal sepsis. Nine children with shock died within 
24 hours after PICU admission, 1 child with shock died within 48 hours.
The total sample was classi! ed into three groups: shock non-survivors (n=10), shock 
survivors (n=57) and sepsis survivors (n=11). All children with sepsis survived. Shock non-
survivors were signi! cantly younger than shock survivors and sepsis survivors (p<0.01). 
Shock survivors stayed a median 4.1 days (2.7-8.9 days) in the PICU; sepsis survivors a median 
of 1.1 days (1.0-1.9 days) (p<0.001).
Clinical parameters (Table 1)
Median PRISM score was 20 (14-29). PRISM scores and IL-6 levels for shock non-survivors 
were signi! cantly higher than those for both groups of survivors (p<0.001), and those for 
shock survivors were signi! cantly higher than those for sepsis survivors (p<0.001). APC 
administration did not in$ uence cortisol levels nor coagulation pro! le (data not shown). Con-
comitant therapy included antibiotics and administration of $ uids in all children. Forty-nine 
children were mechanically ventilated and 69 children received inotropic support. Thirty-! ve 
children were intubated with a single dose of etomidate. Indications for steroid use were 
catecholamine-resistant septic shock, with or without hypoglycemia, and meningitis. Nine 
children received glucocorticoids (hydrocortisone or dexamethasone) just before admis-
sion to the PICU; 8 of them had catecholamine-resistant septic shock and one had sepsis 
with meningitis. During admission, another 6 children with septic shock received steroids 
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(hydrocortisone), because of catecholamine resistant septic shock . One child experienced 
severe hyperglycemia (glucose >20 mmol/l (>360mg/dl)) after PICU admission, was treated 
with insulin and excluded from further analysis after admission. The other children did not 
receive insulin treatment.
Nutrition; glucose intake (Table 1)
On admission, median glucose intake was 2.8 mg/kg/min (1.0-5.0 mg/kg/min), which was 
not signi! cantly di" erent between shock non-survivors, shock survivors and sepsis survivors. 
Twenty-four hours after admission, median glucose intake in shock survivors was 5.2 mg/kg/
min (4.3-6.4 mg/kg/min); 48 hours after admission it was 4.4 mg/kg/min (3.7-6.3 mg/kg/min). 
Most sepsis survivors were on a partial oral diet at 24 hours after admission, which made it 
di#  cult to calculate the exact glucose intake.
Blood analysis 
Time course (Table 2)
On admission, 26 of the children (33%) were hyperglycemic; 1 shock non-survivor, 19 shock 
survivors and 6 sepsis survivors. One child (a shock survivor) was hypoglycemic. In general, 
shock survivors and sepsis survivors had signi! cantly higher blood glucose levels on admis-
sion compared to shock non-survivors. Hyperglycemia was present in 5 shock survivors and 1 
shock non-survivor after 24 hours (11%) and in 3 shock survivors after 48 hours (8%). Cortisol 
and cytokine levels decreased to normal levels within 24 hours. 
Table 1. Patients’ characteristics on admission.
Shock non-survivors Shock survivors Sepsis survivors
Number 10 57 11
Sex (F/M) 2F/8M 24F/33M 6F/5M
Age (years) 1.1 (0.6-2.2) *bc 4.1 (1.8-9.3)*a 6.1 (2.8-11.4)*a
PRISM 31 (25-35)**bc 21 (16-28)**ac 9 (8-11)**ab
Inotropic medication (n,%)
Vasopressor score
10 (100%)
3 (3-3)
57 (100%)
2 (1-3)
2 (18%)
0 (0-1)
Mechanical ventilation (n,%) 10 (100%) 37 (65%) 2 (18%)
Steroid treatment (n,%)
Prednisolone equivalents (mg/kg)
2 (20%) 
0.9 (0.2-1.6)
6 (11%)
2.4 (0.6-4.5)
1 (9%)
1.0
Glucose intake (mg/kg/min) 3.3 (0-5.8) 3.9 (1.4-5.0) 1.1 (0.6-3.1)
Data expressed as median (25-75 percentile). 
F = female, M = male, PRISM = pediatric risk of mortality score, vasopressor score developed by Hatherill et al.[26] 
* p <0.05, **p <0.001
a = compared to shock non-survivors, b = compared to shock survivors, c = compared to sepsis survivors
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Insulinemic response
Association between glucose and insulin
In ! gure 1 the association between glucose and insulin levels is shown for the three groups. 
Hyperglycemic children had signi! cant higher insulin levels (214 pmol/l (128-375 pmol/l)) and 
C-peptide levels (1.9 nmol/l (0.8-3.7 nmol/l)) than normoglycemic children (insulin 57 pmol/l 
(18-101pmol/l)), C-peptide 0.7 nmol/l (0.3-1.6 nmol/l), p<0.001 and p=0.02, respectively).
In$ uence of glucose infusion on insulinemic response
Because blood glucose levels and endogenous insulin production are related to exogenous 
glucose administration, we assessed intravenous glucose infusion rates at the times when 
blood glucose and insulin levels were drawn (! gure 2). All children received parenteral 
glucose infusions without enteral intake on admission. Glucose intake rates were not signi! -
Table 2. Glucose, insulin, C-peptide, cortisol, FFA, lactate, CRP and cytokines on admission (T0 ), at 24 (T24) and at 48 hours (T48). 
Shock non-
survivors
Shock
Survivors
Sepsis
Survivors
T0 
(n=10)
T0 
(n=57)
T24# 
(n=48)
T48# 
(n=36)
T0 
(n=11)
T24 
(n=6)
Glucose 4.9*bc
(2.7-7.0)
7.2*ac
(5.3-9.0)
6.7
(5.9-7.8)
5.9
(5.3-6.6)
8.8*ab
(7.5-10.5)
6.6
(4.7-7.1)
Insulin <35*bc
(<35-57)
101*a
(35-197)
111
(71-169)
89
(61-157)
104*a
(52-226)
136
(51-236)
C-peptide - 1.1
(0.6-2.7)
2.0
(1.0-3.0)
1.5
(1.0-1.9)
1.0
(0.5-1.8)
1.7 
(1.0-2.6)
Cortisol
(no 
glucocorticoids)
615*bc
(510-930)
954*a
(713-1241)
603
(430-1409)
554
(501-927)
1140*a
(1066-1409)
447
(263-657)
FFA 0.3
(0.2-0.5)
0.8
(0.5-1.1)
0.6
(0.4-0.8)
0.3
(0.3-0.6)
0.6 
(0.5-0.7)
0.5
(0.4-0.7)
Lactate 6.8**bc
(5.1-8.0)
3.7**ac
(2.6-5.4)
2.0
(1.5-2.8)
1.6
(1.2-2.3)
2.1**ab
(1.6-2.7)
0.8
(0.7-0.9)
CRP 34 *b**c
(23-41)
89*a
(59-131)
229
(181-274)
223
(159-301)
75**a
(36-191)
236 
(195-273)
IL-6 120x104**bc
(70-160x104)
3.5x104**ac
(1-16x104)
0.02x104*c
(0.01-0.2x104)
0.01x104
(0.003-
0.03x104)
0.04x104**ab
(82-1x104)
17*b
(<10-0.02x104)
TNF-α 42**b
(20-127)
6**a
(<5-10.5)
4
(1-12)
- - 3
(1-10)
Children who received steroids before or on admission were excluded for determination of median cortisol levels 
Data expressed as median (25-75 percentile) Glucose (mmol/l), Insulin (pmol/l), C-peptide (nmol/l), Cortisol (nmol/l), FFA, Free Fatty Acids 
(mmol/l), Lactate (mmol/l), IL-6 (pg/ml), TNF-α (pg/ml) CRP = C-reactive protein (mg/l)
MSS=meningococcal septic shock, MS=meningococcal sepsis
* p< 0.05, **p<0.001 
a = compared to shock non-survivors, b = compared to shock survivors, c = compared to sepsis survivors
# one patient with insulin therapy excluded
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cantly di" erent between children with normo- and hyperglycemia (2.4 mg/kg/min (0.8-5.0 
mg/kg/min) versus 4.0 mg/kg/min (1.5-6.1 mg/kg/min), respectively, p=0.14) and neither 
between shock non-survivors, shock survivors and sepsis survivors (Table 1). 
Homeostasis model assessment
To determine the occurrence of insulin resistance and decreased β-cell function in hyper-
glycemic children, HOMA-%S and HOMA-%B were calculated. Paired insulin and glucose 
levels were used to calculate HOMA-%S. Paired C-peptide (n=35) or insulin levels (n=43) and 
glucose levels were used to calculate HOMA-%B. In ! gure 3 the association between glucose 
and HOMA is shown for the three groups. Figure 3a shows the association between glucose 
levels and insulin sensitivity (HOMA-%S); ! gure 3b shows the association between glucose 
levels and β-cell function (HOMA-%B). The scatter plots are divided into 4 zones by the X-
axis reference line representing the maximum reference level for normoglycemia (glucose 
of 8.3 mmol/l, 150 mg/dl) and a Y-axis reference line at 50% of normal insulin sensitivity 
(! gure 3a) or at 50% of normal β-cell function (! gure 3b). Zone D represents children with 
hyperglycemia and insulin resistance; zone H represents children with hyperglycemia and 
β-cell dysfunction. Sixty-two percent of hyperglycemic children was insulin resistant, 17% 
had β-cell dysfunction and 21% had both insulin resistance and β-cell dysfunction. Figure 3a 
(zone C) shows that insulin resistance also occurred in the children with blood glucose levels 
below 8.3 mmol/l (<150 mg/dl), but less frequently than in the hyperglycemic children. The 
Figure 1. Relation between plasma insulin levels and blood glucose levels on admission in shock non-survivors, shock survivors and sepsis 
survivors (r=0.67, p<0.001). 
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4 children in zone B (! gure 3a) all had a decreased β-cell function as they were also located 
in zone H (! gure 3b).
In! uence of exogenous factors on glucose homeostasis
In$ uence of glucocorticoids 
Nine children were treated with glucocorticoids just before admission. They tended to have 
higher blood glucose (8.4 mmol/l, 5.4-12.4 mmol/l, 153 mg/dl, 98-225 mg/dl) and cortisol 
levels (1308 nmol/l, 615-2094 nmol/l) on admission than the other children (glucose 7.2 
mmol/l, 5.3-8.9 mmol/l, 131 mg/dl, 96-162 mg/dl and cortisol 955 nmol/l, 666-1201 nmol/l), 
but these di" erences were not signi! cant (p=0.18 and p=0.22, respectively). After admission, 
an additional 6 children were treated with hydrocortisone (prednisolon equivalent dose of 
1.6 mg/kg (0.5-3.1 mg/kg)) within 24 hours. At 24 hours after admission cortisol levels (1824 
nmol/l (270-8490 nmol/l)) in the children with glucocorticoid treatment were signi! cantly 
Figure 2  
 
 
 
*
Figure 2 . Mean glucose intake rates and insulin levels on admission in shock non-survivors, shock survivors and sepsis survivors. Bars represent 
mean insulin levels and dots represent glucose intake rates. Insulin levels in shock survivors and sepsis survivors were signi! cantly higher than 
in shock non-survivors (* p<0.05). There were no di" erences in glucose intake between the patient categories. 
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Figure 3a
Figure 3b
Figure 3. Relation between HOMA and blood glucose levels on admission in shock non-survivors, shock survivors and sepsis survivors.
a) HOMA-%S, homeostatic model assessment of insulin sensitivity
The vertical, X-axis reference line represents the limit for normoglycemia (8.3 mmol/l, 150 mg/dl)
The horizontal, Y-axis reference line represents 50% of maximum insulin sensitivity.
b) HOMA-%B, homeostatic model assessment of ß-cell function
The vertical, X-axis reference line represents the limit for normoglycemia (8.3 mmol/l, 150 mg/dl)
The horizontal, Y-axis reference line represents 50% of maximum ß-cell function.
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higher than in those without glucocorticoid treatment (560 nmol/l (41-8069 nmol/l), p<0.01); 
blood glucose levels did not di" er. 
In$ uence of etomidate 
Thirty-! ve of the children were intubated and had received a single dose of etomidate. As 
we have previously shown that use of etomidate negatively in$ uenced blood glucose levels, 
we assessed the in$ uence of etomidate. The children who had received etomidate showed 
signi! cantly lower glucose and cortisol levels (6.2 mmol/l (4.7-8.5 mmol/l) and 713 nmol/l 
(555-958 nmol/l), respectively) on admission than the other children (7.7 mmol/l (5.6-10.0 
mmol/l) and 1133 nmol/l (953-1342 nmol/l), respectively, p<0.01). At 24 hours after admis-
sion, blood glucose levels in etomidate treated children were signi! cantly higher than in the 
others (7.2 mmol/l vs 6.6 mmol/l, p=0.03), presumably because of a rebound e" ect. Multiple 
regression analysis showed that the insulin and age e" ect on blood glucose levels as de-
scribed in section 3.4.4 was not in$ uenced by etomidate administration.
Correlations 
Blood glucose levels correlated positively with plasma insulin levels (Figure 1; r=0.67, p<0.001), 
C-peptide levels (r=0.46, p<0.01), cortisol levels (r=0.27, p,0.05), age (r=0.43, p<0.001). Mul-
tiple regression analysis revealed that both age and plasma insulin level on admission were 
factors positively related to blood glucose level (p=0.035 and p<0.001, respectively). These 
two variables together explained 41% of the variance in blood glucose level on admission. 
The other variables (glucose intake, cortisol level, (nor)-adrenaline therapy and steroid use) 
were not signi! cantly related to blood glucose level on admission. 
The two outcome parameters, HOMA-%S and insulin to glucose ratio were signi! cantly cor-
related (r=0.87, p<0.001). C-peptide levels were strongly correlated with insulin levels; r=0.82, 
p<0.001). 
In hyperglycemic children, lactate was inversely correlated with HOMA-%S (r=-0.65, p=0.001). 
DISCUSSION
Thirty-three percent of all children in the present study were hyperglycemic on admission 
and one child was hypoglycemic. Blood glucose levels in shock and sepsis survivors were 
higher than in shock non-survivors. Hyperglycemic children had signi! cant higher insulin 
and C-peptide levels than normoglycemic children. Homeostatic model assessment showed 
a predominance of insulin resistance in hyperglycemic children, although β-cell insu#  ciency 
or a combination of insulin resistance and β-cell insu#  ciency were also seen. Multiple regres-
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sion analysis revealed that both age and plasma insulin level on admission were signi! cantly 
related to blood glucose level. 
Hyperglycemia is a common ! nding in critically ill children and our results are in line with 
previous studies [8, 11, 14]. Whereas others have reported an association between hypergly-
cemia and mortality [8-14], in the present study shock non-survivors had the lowest blood 
glucose levels. This study concerns children with meningococcal sepsis and septic shock, 
whereas the other studies included children with mixed diagnoses. Only Branco et al. stud-
ied children with septic shock (various causes), and showed that a peak glucose level >9.8 
mmol/l (>177 mg/dl) was independently associated with an increased risk of death (relative 
risk: 2.59) [12]. 
In our study, insulin levels on admission were the lowest in children who did not survive 
and were closely related to the low blood glucose levels. The association between a lower 
blood glucose level on admission and mortality in the present study might be explained by 
the speci! c features of meningococcal disease like the high risk for relative adrenal insuf-
! ciency [5]. This could also explain the positive correlation between blood glucose levels 
and age, as the youngest children showed the highest mortality rate in combination with the 
lowest blood glucose levels on admission. Previously we have shown that the concomitant 
use of therapeutic drugs such as etomidate which was used in almost half of the studied 
children, in$ uenced blood glucose levels as well [5]. In accordance with previous ! ndings, 
children intubated with etomidate showed lower glucose and cortisol levels on admission 
than those without etomidate. Hyperglycemia was associated with elevated insulin levels in 
half of the children. HOMA showed that insulin resistance as well as β-cell dysfunction result-
ing in a hypoinsulinemic response resulted in hyperglycemia. Insulin resistance, caused by 
high levels of counter-regulatory hormones and cytokines, oxidative stress and therapeutic 
interventions (such as glucocorticoid and catecholamine administration), is the main patho-
physiological mechanism of hyperglycemia in critically ill patients [32]. 
Concerning therapeutic interventions glucocorticoid and catecholamine use in insulin 
resistant hyperglycemic children was more frequent than in those without insulin resistance. 
However the numbers were too small to detect signi! cant di" erences. Serum lactate was 
negatively correlated to HOMA-%S in hyperglycemic children, which might indicate the 
negative in$ uence of a compromised circulation on β-cell function. Cortisol level on ad-
mission was positively correlated with plasma glucose level in children without previous 
glucocorticoid treatment, indicating that endogenous cortisol release is a causative factor 
for hyperglycemia. Sepsis guidelines recommend glucocorticoids for the treatment of vaso-
pressor-dependent septic shock [15]. Glucocorticoids stimulate hepatic glucose production 
mainly by mobilizing substrate for hepatic gluconeogenesis and activation of key hepatic 
gluconeogenic enzymes. Furthermore, glucocorticoid excess reduces glucose uptake and 
utilization by peripheral tissues, due in part to direct inhibition of glucose transport into the 
cells [33]. Hyperglycemic episodes were more common in adult septic shock patients who 
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received hydrocortisone in bolus therapy as compared to those who received continuous 
infusion with equivalent dose [34]. This important side e" ect of glucocorticoid treatment has 
not yet been addressed in studies in critically ill children
Another important causative factor of hyperglycemia might be the amount of glucose 
intake. In the present study children were considered as fasting on admission, because they 
only received a continuous glucose infusion without enteral intake. Glucose intake did not 
di" er between normo-and hyperglycemic children. In critically ill adults an association was 
shown between hyperglycemia and a high glucose infusion rate (> 5 mg/kg/min) [35]. On the 
other hand, low-caloric parenteral nutrition in adult surgical trauma patients resulted in less 
hyperglycemic events and lower insulin requirements [36]. Maximum glucose oxidation rates 
in severely burned children approximate 5 mg/kg/min [37]. Exogenous glucose in excess of 
this amount enters nonoxidative pathways and is unlikely to improve energy balance and 
lipogenesis and may result in hyperglycemia [38-39]. 
Two studies have suggested that a hypoinsulinemic response in critically ill children might 
result in hyperglycemia [18,40]. First, Van Waardenburg et al. studied 16 children with me-
ningococcal disease on the third day of admission (10 shock survivors and 6 sepsis survivors) 
[18]. While most children were normoglycemic, shock survivors had lower insulin levels (50 
pmol/l) and insulin to glucose ratios (8 pmol insulin per mmol glucose) than sepsis survivors 
(130 pmol/l and 24 pmol insulin per mmol glucose, respectively), suggesting normal or en-
hanced insulin sensitivity in shock survivors. Second, Preissig and Rigby [40] showed relatively 
low C-peptide levels (1.5 nmol/l, 4.4 ng/ml) within 48 hours after admission in hyperglycemic 
critically ill children with respiratory and cardiovascular failure. Accordingly, the present 
study also showed relatively low C-peptide levels for shock survivors and sepsis survivors 
during admission (1.0 -1.7 nmol/l, 3.0-5.1 ng/ml). Homeostatic model assessment of β-cell 
function based on paired C-peptide, insulin and glucose levels showed β-cell dysfunction of 
the pancreas in 38% of hyperglycemic children, both shock and sepsis survivors. The cause 
of pancreatic dysfunction could be multifactorial, including elevations in pro-in$ ammatory 
cytokines, catecholamines and glucocorticoids. It was hypothesized that β-cells become 
dysfunctional if physiological changes occur acutely. When the same changes occur more 
gradually this might allow β-cells to adapt and function at supraphysiological levels over 
time, resulting in insulin resistance. Also β-cell exhaustion is a known phenomenon charac-
terized by an ability to increase secretion up to a certain level and thereafter fail in response 
to further demand. 
Finally, proin$ ammatory cytokines are important mediators of the hyperglycemic stress 
response. We did not ! nd correlations between cytokines and insulin levels or HOMA-%S in 
hyperglycemic children, presumably because of the relatively small sample size.
Forty-eight hours after admission the percentage of children with hyperglycemia had 
decreased from 33 to 8% without insulin therapy. In contrast, in critically ill adult patients 
hyperglycemia may persist for days to weeks with or without insulin therapy [41]. This di" er-
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ence might be due to the rapid resolution of the acute stress response that is seen in severely 
ill children with meningococcal disease [5]. The present data also show that the elevated 
cortisol and cytokine levels on admission decrease to normal values within 24 hours. 
There are several limitiations to this study. The hyperinsulinemic euglycemic clamp 
technique is the “gold standard” for quantifying insulin sensitivity in vivo because it directly 
measures the e" ects of insulin to promote glucose utilization under steady state conditions. 
It is not easily implemented, however, in large studies with critically ill children. In the pres-
ent study, therefore, insulin sensitivity was indirectly assessed by investigating the insulin 
response to glucose, and by homeostatic model assessment. Diabetes studies and epide-
miological studies on glucose tolerance have frequently used HOMA and recent reports have 
shown its value for assessment of insulin sensitivity in critically ill [22-23]. 
Conclusions 
Hyperglycemia with blood glucose level >8.3 mmol/L (>150 mg/dL) on admission is 
frequently seen in children with meningococcal sepsis and septic shock, hypoglycemia is 
also seen but less frequently. Blood glucose levels in most children spontaneously normal-
ize within 48 hours, at normal glucose intake and without insulin treatment. Both insulin 
resistance as well as β-cell dysfunction may contribute to the occurrence of hyperglycemia in 
critically ill children with meningococcal sepsis and septic shock. 
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SUMMARY
The objective was to evaluate the time course of peri-operative blood glucose levels in chil-
dren undergoing cardiac surgery for congenital heart disease in relation with endogenous 
stress hormones, in$ ammatory mediators and exogenous factors such as caloric intake 
and glucocorticoid use. Forty-nine children undergoing cardiac surgery were prospectively 
included. Blood glucose levels, hormonal alterations and in$ ammatory responses were in-
vestigated before and at end of surgery and 12 and 24 hours thereafter. In general, blood 
glucose levels were highest at the end of surgery. Hyperglycemia, de! ned as glucose >8.3 
mmol/L (>150 mg/dL), was present in 52% of the children at end of surgery. Spontaneous 
normalisation of blood glucose occurred in 94% of children within 24 hours. During surgery 
glucocorticoids were administered to 65% of all children and this was the main factor as-
sociated with hyperglycemia at the end of surgery (determined by univariate analysis of 
variance). Hyperglycemia disappeared spontaneously, without insulin therapy, within 12 to 
24 hours in the majority of children. Postoperative morbidity was low in the study group, so 
the presumed positive e" ects of glucocorticoids seemed to outweigh the adverse e" ects of 
iatrogenic hyperglycemia. 
INTRODUCTION
Hyperglycemia is a regular phenomenon in critically ill children following surgical repair or 
palliation of congenital heart defects. Some recent studies showed an association between 
hyperglycemia and increased postoperative morbidity and mortality in these children 
[7,18,35]. 
In the adult literature there is a debate on the usefulness of intensive insulin therapy 
for glucose control to improve morbidity and mortality in cardiac surgical patients [8,13]. 
The only randomized controlled study in critically ill children showed improved short-term 
outcome after treatment with intensive insulin therapy targeting blood glucose levels to 
age-adjusted normal fasting concentrations [31], but there is debate on the harm of insulin 
induced hypoglycemic events [11].
For glucose control protocols to be most e#  cient, they should be based on pathophysi-
ological mechanisms [30]. While several studies have addressed this topic for critically ill 
adults [15-16, 26], such studies in critically ill children are lacking.
Hyperglycemia in critically ill children is caused by multiple factors, among which endogenous 
stress hormones [2], in$ ammatory mediators, oxidative stress and therapeutic interventions 
such as glucose and drug administration, are the main causative factors.
Children undergoing cardiopulmonary bypass surgery often receive perioperative gluco-
corticoids to attenuate the systematic in$ ammatory response, but so far no clinical bene! t 
has been shown [22]. However, hyperglycemia is a well-known side e" ect of glucocorticoid 
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use. We hypothesize that in some settings the adverse e" ects of steroid induced hyperglyce-
mia could outweigh the anticipated bene! ts.
The objective of the present study was to evaluate blood glucose levels in children under-
going open-heart surgery in relation with stress-induced endogenous hormonal production, 
in$ ammatory mediators and exogenous factors such as caloric intake and glucocorticoid use. 
MATERIAL AND METHODS
Patients
Eligible subjects were consecutive children with congenital heart disease who underwent 
open-heart surgery in the Erasmus MC in a two-year period. 
Children were not eligible for the study if they had endocrine or chromosomal abnormalities 
or had received radiation or chemotherapy within the previous 6 months. 
The Erasmus MC Medical Ethics Review Board approved the study (196.429/2000/222) and 
written informed consent was obtained from the parents or legal representatives of each 
child and of all children aged >12 years. 
Clinical parameters
Anthropometric measurements were taken the day before cardiac surgery. Children were 
fasted before and during surgery and received glucose intravenously (4-6 mg/kg/min) after 
surgery according to protocol. Enteral nutrition was initiated at the ! rst post-operative day 
if clinically possible.
Severity of illness was assessed by RACHS (Risk Adjustment for Congenital Heart Surgery) 
[10], PRISM-score (pediatric risk of mortality score) [19], PELOD-score (pediatric logistic organ 
dysfunction score) [14] and levels of established biomarkers, such as interleukin-6 (IL-6) and 
interleukin-10 (IL-10) and arterial lactate.
Congestive heart failure was de! ned by the criteria of Van der Kuip et al. adjusted for age 
[27]. The presence of cyanotic heart disease, duration of cardiopulmonary bypass (CPB) and 
aorta cross clamp time were recorded. 
Most children received mild hypothermia (median 31°C) and one (aged 16.6 years) re-
ceived deep hypothermia (22.5°C) during cardiac surgery. All children received standardized 
analgesia during and after surgery. Glucocorticoids were administered at the discretion of 
the attending anaesthesist. The decision to administer glucocorticoids was made before start 
of surgery and independent of the operative course. Standardized protocols were used for 
administration of inotropes and weaning from the ventilator. The weighted inotropic (WI) 
score based on maximum inotropic support during surgery and ICU (intensive care unit) stay 
was calculated [33]. Duration of mechanical ventilation, as well as wound infections, length 
of ICU and hospital stay and survival were recorded.
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Collection of blood and assays
Arterial blood samples were obtained at start of surgery after induction of anaesthesia, at 
the end of surgery after sternal closure, and at 12 and 24 hours thereafter. All laboratory 
parameters were determined immediately, except cytokines. Serum and plasma were stored 
at -80° C until assayed.
Glucose and lactate were determined on an ABL 725 blood gas analyser (Radiometer 
Copenhagen, Denmark) in a certi! ed clinical chemistry laboratory (ISO 17025 and 9001). 
Hypoglycemia was de! ned as a blood glucose level ≤2.2 mmol/L (≤40 mg/dL), and hypergly-
cemia as a blood glucose level >8.3 mmol/L (>150 mg/dL) (30). Normal value for lactate was 
<2.0 mmol/L.
Serum insulin concentrations were determined with an immunoradiometric assay on an 
Immulite 2000 (DPC) with a minimum detection level of 35 pmol/L [6]. In our laboratory the 
maximum fasting reference value for insulin is 180 pmol/L. The insulin/glucose ratio was 
calculated to assess insulin sensitivity. To date there are no strict reference values for the 
(non)-fasting glucose-to-insulin ratio. In our study the maximum reference value for insulin/
glucose ratio was de! ned as 18 pmol/mmol. This value was derived from current literature 
data, taking into account the di" erences between insulin assays and units of analysis [5,28,32]. 
Serum cortisol concentrations were determined with an Immulite 2000 competitive 
luminescence immunoassay (DPC, Los Angeles, CA) with detection limits of 3-1380 nmol/L. 
Normal level of cortisol during stress was de! ned as cortisol > 496 nmol/L [17]. Plasma ACTH 
(adrenocorticotrope hormone) concentrations were determined by an immunoradiometric 
assay (Bio International, Gif sur Yvette, France). The within- and between-assay variation coef-
! cients for the assays of cortisol and ACTH were less than 7%.
Plasma cytokine levels were analyzed with an enzyme-linked immunosorbent assay (San-
quin, Amsterdam, The Netherlands). The detection limit of IL-6 (lowest positive standard) was 
10 pg/ml ; that of IL-10 was 25 pg/ml.
Statistics
Data were analysed with SPSS 16.0. Results are expressed as median (interquartile range), 
unless speci! ed otherwise. Mann-Whitney U, Chi-square test and Fisher’s Exact Test were 
used for group comparison. Univariate Analysis of Variance was used to assess relationships 
between glucose, steroid use, disease severity as expressed by WI-score and cardiopulmo-
nary bypass time. Data were log-transformed when necessary. Two-tailed P-values <0.05 
were considered statistically signi! cant.
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RESULTS
Patient characteristics 
The study group consisted of 49 children (24 boys), aged 2 months to 18 years. They had 
surgery for left-right shunt patch closure of ventricular septal defect (n=13 (including six with 
combined closure of atrial septal defect and one with additional repair of tricuspid valve); 
closure of atrial septal defect, n=7; patch closure of aortopulmonary window together with 
reimplantation of anomalous left coronary artery from pulmonary artery, n=1); corrective 
surgery for Tetralogy of Fallot (n=9), univentricular heart (partial cavo-pulmonary connec-
tion, n=4; total cavo-pulmonary connection, n=2), left ventricular out$ ow tract obstruction 
(enucleation, n=4; pulmonary autograft, n=2; allograft aortic root replacement, n=2), right 
ventricular out$ ow tract obstruction (infundibulectomy, n=2; pulmonary allograft, n=1), 
mitral valve insu#  ciency (mitral valve annuloplasty, n=2).
Clinical parameters
All children underwent elective cardiac surgery upon cardiopulmonary bypass support (CPB) 
and 45 of them underwent cardioplegic arrest. All survived.
Thirty children were on inotropic support at the end of surgery; 16 of them received do-
pamine, 6 received dobutamine, 7 received both dopamine and dobutamine and 1 patient 
received noradrenalin.
Thirty-two (65%) children received one bolus of glucocorticoids during cardiac surgery. 
Twelve children received their bolus after induction before surgical incision, 8 at start of 
heparinisation before cardiopulmonary bypass and 12 at aortic cross clamping. All children 
but 2 received methylprednisolone (30 mg/kg); 1 received dexamethasone (1 mg/kg) and 
1 received hydrocortisone (2 mg/kg). For the purpose of this study we created two groups: 
those treated with glucocorticoids (n=32) and those without glucocorticoid treatment 
(n=17). No wound infections occurred. None of the patients received insulin during surgery 
or ICU stay.
Clinical parameters are depicted in Table 1.
Time courses of laboratory parameters 
Laboratory results at start of surgery, end of surgery and at 12 and 24 hours after end of 
surgery for the group as a whole, are shown in Table 2.
Glucose 
Table 2 shows blood glucose levels from start of surgery up to 24 hours after end of surgery. 
Hypoglycemia ≤2.2 mmol/L (≤40 mg/dL) did not occur. In general, blood glucose levels were 
highest at the end of surgery.
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At start of surgery, hyperglycemia >8.3 mmol/L (>150mg/dL) was present in 1 patient. At 
the end of surgery, hyperglycemia was present in 52% (25/48) of the children, decreasing 
to 11% (5/47) after 12 hours and 6 % (3/47) after 24 hours. Thus almost all children were 
normoglycemic after 24 hours. Hyperglycemia was not associated with ventilation days, nor 
with length of ICU and hospital stay.
Plasma insulin and insulin/glucose ratios 
Table 2 shows endogenous plasma insulin levels and the insulin/glucose ratios from start of 
surgery up to 24 hours after end of surgery.
Table 1 Clinical parameters
Variable Glucocorticoids 
(n=32)
No glucocorticoids
(n=17)
All patients
(n=49)
Demographic data
 Age (years) 1.4 (0.5-6.2) 3.2 (0.6-13.3) 1.7 (0.5-8.7)
 Sex (F/M) 15/17 10/7 25/24
 Weight (kg) 8.7 (6.6-18.2) 13.0 (6.3-42.0) 12.3 (6.6-24.4)
 Body mass index 14.8 (13.6-15.9) 15.1 (14.3-17.5) 14.9 (14.1-16.3)
Illness Severity 
 Congestive heart failure (%) 11/32 (34%) 3/17 (18%) 14/49 (29%)
 Cyanotic heart disease (%) 10/32 (31%)a 1/17 (6%) 11/49 (22%)
 RACHS 3 (2-3) 2 (1-3) 3 (2-3)
 PRISM-score 14 (11-17) 13 (11-17) 13 (11-17)
 PELOD-score 11(1-11) 6 (1-11) 11 (1-11)
 WI score 38 (22-54)a 3 (0-28) 30 (0-45)
Operative course
 CPB time (min) 78 (55-126) 64 (44-117) 73 (50-120)
 Aortic crossclamp time (min) 50 (37-90) 39 (25-83) 45 (34-86)
 Hypothermia (°C) 30.0 (28.7-31.7) 32.4 (29.8-34.1) 31.0 (28.8-33.0)
Postoperative course
 Glucose Intake (mg/kg/min) 3.5 (1.8-7.4) 3.3 (1.0-6.2) 3.4 (1.8-6.5)
 Ventilation duration (hours) 11 (7-25) 7 (6-11) 9 (6-17)
 Inotropes (%) 24/32 (75%) 6/17 (35%) 30/49 (61%)
 Length of ICU stay (days) 2 (2-2) 2 (2-2) 2 (2-2)
 Length of hospital stay (days) 7 (7-9) 7 (7-8) 7 (7-8)
Data are expressed as median (interquartile range) or numbers (percentage).
RACHS, risk adjustment for congenital heart surgery
PRISM-score, pediatric risk of mortality score
PELOD-score, paediatric logistic organ dysfunction score
WI score, weighted inotropic score based on maximum inotropic support during surgery and ICU stay
CPB, cardiopulmonary bypass
Glucose intake, started at ICU admission
adenotes signi! cant di" erence between patients treated with and without glucocorticoids, p<0.05.
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At start of surgery, plasma levels of insulin in all children were below the maximum fasting 
reference level. In all but one of the children (98%) the insulin/glucose ratios were below the 
maximum reference value.
At the end of surgery, plasma levels of insulin in 6% (3/48) of the children were above 
maximum reference level. The insulin/glucose ratio was increased >18 pmol/mmol in 9% 
(4/47) of the children. They had blood glucose levels varying between 7.4 and 10.8 mmol/L. 
In the remaining children with an insulin/glucose ratio ≤18 pmol/mmol, hyperglycemia was 
seen in 53% (23/43) of them. 
Twelve hours after surgery, none of the children had plasma insulin levels and insulin/
glucose ratio above maximum reference value. 
Twenty-four hours after surgery, the insulin levels and insulin/glucose ratios were highest. 
Plasma insulin levels in 9% (4/46) of the children were above maximum reference level. The 
insulin/glucose ratio was increased >18 pmol/mmol in 20% (9/46) of the children, but only 
three of them were hyperglycemic. In the remaining children with an insulin/glucose ratio 
<18 pmol/mmol, hyperglycemia did not occur.
In" uence of glucocorticoids 
Sixty-! ve percent (32/49) of the children were treated with glucocorticoids during surgery. 
Clinical parameters before surgery did not di" er between children with and without gluco-
corticoid treatment, except for the prevalence of cyanotic heart disease and the WI-score, 
which both were signi! cantly higher in children with steroid treatment (Table 1). Laboratory 
results at the various time points are shown in Table 2 and Figure 1.
Blood glucose levels at the start of surgery, before glucocorticoid treatment, did not di" er 
between the groups (Figure 1A). At the end of surgery blood glucose levels in children treated 
with glucocorticoids were signi! cantly higher than levels in those without glucocorticoid 
treatment. Hyperglycemia occurred signi! cantly more often (p=0.001) in the group with glu-
cocorticoid treatment. The e" ect of glucocorticoid treatment on blood glucose levels at the 
end of surgery was independent of other parameters such as glucose intake, the presence of 
cyanotic heart disease, WI-score and cardiopulmonary bypass time. At twelve and twenty-
four hours after surgery median blood glucose levels did not di" er between the groups.
Insulin levels and insulin/glucose ratios at all time points did not di" er between the groups 
(Figure 1B and C).
The maximum peak cortisol levels were found at the end of surgery, with signi! cantly 
higher cortisol levels and cortisol/ACTH ratios in children treated with glucocoricoids (Figure 
1D). At twelve and twenty-four hours after surgery, cortisol levels and cortisol/ACTH ratios of 
children with glucocorticoid treatment had spontaneously decreased to the levels in children 
without glucocorticoid treatment. In both groups, however, cortisol levels were still higher 
than levels at the start of surgery.
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Figure 1C
!
Figure 1D
Figure 1. Time course of blood glucose (A), insulin (B), insulin/glucose ratio (C) and cortisol (D) for patients with and without glucocorticoid 
treatment.
Time course of blood levels of glucose (A), insulin (B), insulin/glucose ratios (C) and cortisol (D) at start of surgery, end of surgery and 12 and 
24 hours after surgery for patients treated with glucocorticoids and without glucocorticoids. Box-whisker-plots: the boxes indicate 25 to 75 
percentile with the median and the attached whiskers the complete range (with exclusion of outliers (o) and extremes (*)).
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IL-6 at 12 and 24 hours after surgery was signi! cantly lower in the children treated with 
glucocorticoids. IL-10 at the end of surgery and at 12 hours after surgery was signi! cantly 
higher in children treated with glucocorticoids. There were no other di" erences in laboratory 
parameters between both groups.
DISCUSSION
Our study shows that treatment with glucocorticoids during surgery was the main factor 
associated with the occurrence of hyperglycemia at the end of cardiopulmonary bypass 
surgery for congenital heart defects. Hyperglycemia frequently occurred with the highest 
blood glucose levels at the end of surgery. Hyperglycemia disappeared spontaneously (with-
out insulin therapy) within 12 to 24 hours in the majority of the children without signi! cant 
postoperative morbidity. The occurrence of hyperglycemia was not associated with increased 
morbidity in terms of duration of ventilation, ICU stay or hospital stay. Moreover, overall 
morbidity in our population was low. Median duration of mechanical ventilation was 9 hours, 
while length of ICU and hospital stay were 2 and 7 days respectively. Wound infections, renal 
dialysis and extracorporeal life support (ECLS) did not occur and all patients survived.
Hyperglycemia in critically ill children is caused by multiple proposed mechanisms, includ-
ing counterregulatory hormone-mediated upregulation of gluconeogenesis and glycoge-
nolysis, and downregulation of glucose transporters with decreased peripheral utilization of 
glucose by tissues such as skeletal muscle and liver [29]. In the present study we evaluated 
how many hyperglycemic patients showed signs of insulin resistance, as this is described as 
the main causative factor in development of hyperglycemia in critically ill adults [23,26,36]. 
In only 4 children (9%) an increased insulin/glucose ratio (>18 pmol/mmol) was seen at the 
end of surgery. The other hyperglycemic children showed a normal or (relatively) decreased 
insulin/glucose ratio. Plasma insulin levels increased 24 hours after surgery, which might be 
due to the fact that most patients were detubated and already on enteral nutrition. The in-
crease in insulin levels can be interpreted as a recovery response to the administered enteral 
feeding.
The decreased insulin response after surgery might be due to the fact that critically ill chil-
dren seem to be more vulnerable than adults to develop beta-cell dysfunction. Preissig et al. 
hypothesized that beta-cells, known to be exquisitely sensitive to rapid physiological chang-
es, may become dysfunctional if these changes acutely occur above a certain threshold [20].
These changes may be induced by multiple factors like hypothermia, vasopressors, elevations 
of pro-in$ ammatory cytokines and use of glucocorticoids [1,9,12,20]. In the study by Preissig 
et al. in critically ill children with respiratory and cardiovascular failure [20], the vasopressor 
score was inversely correlated with c-peptide level, indicating beta-cell dysfunction due to 
the suppressing e" ect of exogeneous catecholamines. In our study the use of vasopressors 
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was low, with only one patient on noradrenalin. This might explain the relatively normal 
plasma insulin levels at the end of surgery. Another explanation for the less pronounced 
hypoinsulinemic response in our study might be the mild e" ect of cardiac surgery on the 
in$ ammatory response as shown by the low levels of Il-6 and mild increased IL-10 at the end 
of surgery in the patients without glucocorticoid treatment. Perioperative administration of 
glucocorticoids was associated with decreased IL-6 and increased IL-10 levels after CPB. This 
is in accordance with adult studies, which have shown that glucocorticoids may decrease the 
in$ ammatory response during the CPB procedure [3]. However, for pediatric patients with 
congenital heart disease undergoing cardiopulmonary bypass surgery, the clinical bene! t of 
this suppressed cytokine response remains unclear. 
There is debate about the positive e" ects of steroid use during cardiopulmonary bypass 
in pediatric patients and whether the potential positive e" ects of corticosteroid treatment 
during cardiopulmonary bypass surgery outweigh the potential adverse e" ects, such as 
hyperglycemia [4,22]. High blood glucose levels at the end of CPB surgery for congenital 
heart defects were also found in previous studies [1,7,21,24]. We found a spontaneous nor-
malisation of blood glucose levels within 24 hours postoperatively, which is in line with one 
other study [24], whereas in a few other studies a more gradual decrease in blood glucose 
levels over 3 days was shown [18,35]. This could be related to our relatively low postoperative 
morbidity as compared with other studies, with comparable pre-operative illness severity as 
expressed by RACHS. Other authors [21] reported increased length of ICU stay (median 3-6 
days), mechanical ventilation (4.4 days), dialysis (1.1-4%), ECLS (3-8%) and mortality (4-11%). 
Vlasselaers et al. reported their results from a prospective randomized controlled trial treat-
ing critically ill children (75% were patients after cardiac surgery for congenital heart defects). 
Intensive insulin therapy for hyperglycemia improved morbidity and reduced mortality [31], 
but there is debate on the harm of insulin induced hypoglycaemic events [11]. It is important 
to realize that not only hyperglycemia, but also hypoglycemia is associated with adverse 
outcome [7,25,34-35].
In general it can be stated that there are important di" erences in morbidity and mortal-
ity after pediatric cardiac surgery between centres. In our study none of the patients were 
treated with insulin for hyperglycemia and overall morbidity was low, so there is no need for 
the standard use intensive insulin therapy for tight glycemic control. 
A limitation of this study was that glucocorticoids were administered at the discretion 
of the attending anaesthesist. Although treatment was not randomized, glucocorticoids 
were administered before aortic clamping and thus independent of the operative course. 
Moreover, there were no di" erences in age, clinical course and duration of cardiopulmonary 
bypass time between patients with and without glucocorticoid treatment. Furthermore, al-
though patients with cyanotic heart disease were more likely to receive glucocorticoids and 
the median WI score was higher in the glucocorticoid treated patients, univariate analysis 
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of variance showed that preoperatively administered glucocorticoids were independently 
associated with increased blood glucose levels at the end of surgery. 
In summary, we showed that the development of hyperglycemia at the end of cardiac 
surgery for congenital heart disease was associated with glucocorticoid administration dur-
ing surgery. Postoperative hyperglycemia was frequent, but in almost all cases (94%) blood 
glucose levels spontaneously normalized within 24 hours, without the use of insulin admin-
istration and without signi! cant morbidity or mortality. Standard use of intensive insulin 
therapy for tight glycemic control is not needed in this patient group. In contrast with our 
hypothesis, we conclude that since postoperative morbidity was low in the study group, 
the presumed positive e" ects of glucocorticoids seemed to outweigh the adverse e" ects of 
iatrogenic hyperglycemia. 
Future research should focus on the value of corticosteroid therapy during pediatric cardiac 
surgery to weigh both the pros and cons of either hyperglycemia and corticosteroid therapy. 
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PA RT III
GLYCEMIC CONTROL
The fact that your patient gets well does not prove that your therapy was 
correct (vrij naar Samuel J. Meltier)

Cha pter 7
Insulin/Glucose ratio as a marker for 
insulin therapy in critically ill children
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ABSTRACT 
Objective
To investigate the endogenous insulin response in critically ill children with hyperglycemia 
and to explore the relationship between insulin response and clinical outcome. 
Research Methods & Procedures
Sixty-four consecutively admitted critically ill children with hyperglycemia, de! ned as blood 
glucose >8 mmol/L (>145 mg/dL), and treated with insulin according to a glucose control 
protocol were included. Demographic data and clinical and laboratory parameters were col-
lected. Insulin sensitivity was investigated by relating blood glucose levels to endogenous 
insulin levels just before start of insulin administration. Results are expressed as median 
(range).
Results
64 children (24 girls), age 7.0 yrs (0.3-16.9 yrs) with various diagnoses were included. A hy-
perinsulinemic response, indicated by elevated insulin/glucose ratios (>18 pmol/mmol), was 
seen in 55% of the children. Duration of insulin therapy, mechanical ventilation and PICU 
length of stay in children with a hyperinsulinemic response was longer than in children with 
a hypoinsulinemic response. 
Conclusion
Both a hyper- and a hypoinsulinemic response play a role in the occurrence of hyperglycemia 
in critically ill children. The insulin/glucose ratio in relation with the clinical picture might be 
used to judge about the usefulness of insulin therapy for the individual child.
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INTRODUCTION
Critical illness is associated with many endocrine, metabolic and immunologic changes 
[1]. One of these is hyperglycemia, caused by a complex interaction of endogenous and 
exogenous factors. Hepatic insulin resistance and the resulting excessive gluconeogenesis 
together with impaired glucose use in peripheral tissues are considered to be the driving 
forces behind stress hyperglycemia in critically ill adults [2-3]. Studies in critically ill children 
have reported an association between hyperglycemia and morbidity (e.g. longer length 
of stay in the intensive care unit (ICU), duration of ventilator use and adverse neurological 
outcome) [4-12].
The underlying mechanisms of hyperglycemia and risk factors in critically ill children have 
been little studied and in small groups of patients only [13-14]. Waardenburg et al. proposed 
that hyperglycemia associated with hypoinsulinemia rather than insulin resistance may be 
the common pathophysiological response at least in children with meningococcal septic 
shock [13]. Preissig and Rigby reported a di" erent aetiology of hyperglycemia in critically 
ill children dependent on the presence of respiratory and/or cardiovascular failure. Insulin 
resistance, as de! ned by elevated C-peptide/glucose ratio’s was the prominent cause of 
hyperglycemia in children with respiratory failure only, versus primary beta-cell dysfunction 
in children with both respiratory and cardiovascular failure [14].
Intensive insulin therapy in critically ill children (targeting blood glucose concentrations 
of 2.8-4.4 mmol/L (50-80 mg/dL) in infants and 3.9-5.5 mmol/L (70-100 mg/dL) in older chil-
dren) resulted in shorter ICU stay and fewer secondary infections [15]. We have successfully 
implemented a nurse-driven glucose control protocol for critically ill children of all ages with 
hyperglycemia, de! ned as blood glucose level >8 mmol/L (>145mg/dL) at any time during 
admission. This resulted in normoglycemia within 12 hours for 94% of the children involved 
without episodes of hypoglycemia ≤2.2 mmol/L [16].
Better insight into pathophysiological mechanisms leading to hyperglycemia might even 
improve treatment strategies like these. We studied the endogenous insulin response in 
relation with hormonal, metabolic and immunologic parameters in critically ill children with 
hyperglycemia just before start of insulin therapy, and hypothesized that both a hyper- and 
a hypoinsulinemic response play a role in the occurrence of hyperglycemia. The objective of 
this study was to explore the relationship between insulin response and clinical characteris-
tics and outcome of critically ill children. 
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MATERIALS AND METHODS
Setting
The Pediatric Intensive Care Unit of the university children’s hospital is a tertiary 34-bed 
multidisciplinary unit providing for high acute medical and surgical conditions in children 
aged up to 18 years.
Design
Prospective evaluation of critically ill children aged 2 weeks to 18 years consecutively admit-
ted to the PICU of the Erasmus MC-Sophia Children’s Hospital from January 2006 till July 2009 
and showing hyperglycemia (de! ned as blood glucose level exceeding the value of 8 mmol/L 
(>145 mg/dL)) meeting the criteria for insulin treatment [16]. Children with diabetes mellitus 
were excluded. The local Medical Ethics Review Board approved the study.
Clinical characteristics and outcome parameters 
Patients’ baseline characteristics and other clinical information were recorded. Anthropomet-
ric measurements were taken on the day of admission.
Disease severity was determined by the Pediatric Risk of Mortality score (PRISM II) and the 
Pediatric Logistic Organ Dysfunction (PELOD) scoring system [17-18]. 
Respiratory and inotropic support, use of glucocorticoids and antimicrobiological agents 
were recorded. Inotropic support was quanti! ed by the vasopressor score developed by 
Hatherill et al. [19]. We calculated equivalent doses of prednisolone, expressed per body 
weight (mg/kg), using the glucocorticoid equivalent potencies 20/5/0.75 for hydrocortisone, 
prednisolone and dexamethasone, respectively.
Children received standardized analgesia, sedation and nutritional support [20]. The glucose 
control protocol prescribes glucose intake rates dependent on bodyweight and insulin dose 
dependent on the actual blood glucose level. Actual glucose intake was calculated. All chil-
dren were on continuous enteral and/or parenteral feeding. 
Laboratory tests 
A standard care physician-initiated, nurse-driven glucose control protocol was used to 
screen and treat all hyperglycemic patients [16]. Blood glucose measurements were obtained 
as soon as possible after admission. In case of hyperglycemia >8 mmol/L (>145 mg/dL) 
measurements were repeated every hour and further according to the protocol. Blood was 
collected from an indwelling arterial or venous catheter or from capillary puncture. Arterial 
blood samples for the determination of glucose, insulin, cortisol, C-reactive protein (CRP), 
lactate, cholesterol, free fatty acids (FFA), triglycerides, creatinin, urea, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) and prothrombin time (PT) were taken at the 
start of insulin therapy. All laboratory parameters were determined immediately in a certi! ed 
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laboratory of clinical chemistry (ISO 17025 and 9001). Assays were performed according to 
manufacturer’s instructions. 
Blood glucose was measured on either a blood gas analyzer (ABL 625; Radiometer, Copen-
hagen, Denmark) or by a bedside capillary glucose measurement with a point of care system 
(HemoCue AB, Sweden). Blood glucose levels of <2.6 mmol/L (<47 mg/dL) or >15 mmol/L 
(>272 mg/dL) obtained by the latter method were considered to be unreliable. Measure-
ments were then repeated on the blood gas analyzer. Hypoglycemia was de! ned as a blood 
glucose level ≤2.2 mmol/L (≤40 mg/dL), and hyperglycemia as a blood glucose level >8.0 
mmol/L (>150 mg/dL) [16].
Serum insulin was measured by a two-site chemiluminescent immunometric assay (Im-
mulite 2000, DPC, Los Angeles, USA) with minimum detection level of 35 pmol/L. The maxi-
mum fasting reference value for insulin was set at 180 pmol/L. The insulin/glucose ratio was 
calculated to assess insulin sensitivity. The maximum reference value for insulin/glucose ratio 
was de! ned as 18 pmol/mmol. This value was derived from current literature data, taking 
into account the di" erences between insulin assays and units of analysis [13, 21-22]. Insulin 
sensitivity was also measured using the homeostasis model assessment method (HOMA). 
Scores ≥ 4 indicate decreased insulin sensitivity [23]. 
Serum cortisol concentrations were determined with a competitive luminescence im-
munoassay (Immulite 2000, DPC, Los Angeles, CA). The detection limits of this assay are: 
3-1380 nmol/L. Nonstressed reference values for cortisol were between 200 and 800 nmol/l. 
Although there are no strict de! nitions on adrenal insu#  ciency assessment in critically ill 
children, adrenal insu#  ciency in the case of catecholamine-resistant septic shock may be 
assumed at a random level < 496 nmol/L [24].
Arterial lactate was determined on blood gas analyzer (ABL 625, Radiometer, Copenhagen, 
Denmark). The reference level for lactate was <2.0 mmol/L. Serum CRP was determined 
by immunoturbidimetric assay (normal <2 mg/l), and examined on a 912 analyzer (Roche 
Molecular Biochemicals, Mannheim, Germany).
Plasma FFA concentrations were determined by enzymatic method (Nefac-kit, Wako, 
Instruchemie BV). Reference levels for FFA for children between 4 months- 10 years: 0.3-1.1 
mmol/L, children >10 years: 0.2-0.8 mmol/L. 
Statistics
Data were analysed with SPSS 16.0. Results are expressed as median (range), unless speci! ed 
otherwise. Data were log-transformed when necessary. Mann-Whitney U test was used for 
group comparison. Chi-square test was used for comparison of nominal data. In the between-
group comparison and analysis of correlations on duration of insulin therapy, ventilation 
days, PICU and hospital length of stay, children who died during insulin therapy, mechanical 
ventilation, PICU and/or hospital stay, respectively, were excluded from analysis. None of the 
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children died during glucocorticoid treatment. Two-tailed P-values <0.05 were considered 
statistically signi! cant. 
RESULTS 
Baseline characteristics
The study group consisted of 64 children (24 girls), median age 7.0 years (0.3 – 16.9) with 
various diagnoses. Fifty-one had respiratory or cardiovascular failure, for which they were 
mechanically ventilated or received inotropic support. None of all children had severe he-
patic failure. One child was admitted with acute renal insu#  ciency requiring dialysis therapy. 
Eleven children (17%) died during PICU admission. Five of them died during insulin therapy. 
Patients’ characteristics just before start of insulin therapy are shown in table 1.
Table 1 Patients’ characteristics at start of insulin treatment
Variable
Insulin/Glucose
<18
(n=29)
Insulin/Glucose
>18
(n=35)
P-value
Gender (M/F) 18/11 22/11
Age (years) 7.0 (0.3-16.4) 6.9 (0.2.-17.0) 0.55
Weight (kg) 20.0 (4.5-85.0) 24.0 (3.2-80.0) 0.63
Diagnostic category
Infectious
Cardiac Surgery
Trauma
Neurologic
Respiratory
Surgery
Other
9
5
5
6
1
3
0
14
4
4
3
5
3
2
NA
PRISM 14 (1-44) 12 (2-36) 0.50
PELOD 12 (0-61) 11 (0-50) 0.54
MV (%) 16 (55%) 31 (88%) 0.004**
Inotropics (%)
VAS score
12 (41%)
1 (0-3)
17 (49%)
1 (0-3)
0.62
NA
Antibiotics (%) 15 (52%) 23 (66%) 0.31
Nutrition (%)
Parenteral
Enteral
Parenteral/Enteral
23 (79%)
0 
6 (21%)
23 (66%)
4 (11%)
8 (23%)
NA
Glucocorticoids (%)
Prednisolone equivalents (mg/kg)
11 (38%)
0.6 (0.03-1.0)
11 (31%)
0.6 (0.2-8.0)
0.61
0.49
Data are expressed as median (range) or numbers.
PRISM, pediatric risk of mortality; PELOD, Pediatric Logistic Organ Dysfunction; MV, mechanical ventilation; VAS, vasopressor score developed by 
Hatherill et al. [19] 
* signi! cant (p<0.05) di" erence between children with hypo- and hyperinsulinemic response
** signi! cant (p<0.001) di" erence between children with hypo- and hyperinsulinemic response
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Insulinemic response
Blood samples were taken just before start of insulin treatment. The group median blood 
glucose level at start of therapy was 9.9 mmol/L (5.7-43.3) (180, 104-787 mg/dL). Median 
plasma insulin level was 235 pmol/L (<35-3803). Insulin levels were below detection level in 
3 patients. Median insulin/glucose ratio was 20 pmol/mmol (1-235). Median HOMA was 13 
(2-385). 
A hyperinsulinemic response as expressed by an elevated insulin/glucose ratio >18 pmol/
mmol was seen in 35 children (55%). The other 29 children (45%) with an insulin/glucose 
ratio <18 pmol/mmol were classi! ed as having a hypoinsulinemic response. Children with 
a hyperinsulinemic response had similar baseline clinical parameters as compared to those 
with a hypoinsulinemic response (Table 1). All children with a hyperinsulinemic response had 
a HOMA score ≥ 4.
Laboratory parameters (Table 2) did not di" er between children with a hyperinsulinemic 
response and those with a hypoinsulinemic response. Although free fatty acids were signi! -
cantly elevated in children with hypoinsulinemic response versus those with a hyperinsulin-
emic response, results were below maximum reference levels in both groups; 0.53 (0.23-1.29) 
versus 0.28 (0.09-0.83) mmol/L, respectively. 
Table 2 Laboratory parameters at start of insulin therapy
Variable
Insulin/Glucose
<18
(n=29)
Insulin/Glucose
>18
(n=35)
P-value
Glucose (mmol/L) 10.3 (5.7-43.3) 9.7 (7.1-21.7) 0.60
Insulin (pmol/L) 79 (<35-351) 364 (166-3803) <0.001**
Insulin/Glucose
HOMA
9 (1-16)
5 (2-80)
41 (19-24)
25 (9-385)
<0.001**
<0.001**
Cortisol (nmol/L) 560 (28-2715) 648 (40-4442) 0.74
CRP (mg/L) 30 (1-366) 67 (1-314) 0.12
FFA (mmol/L)
TG (mmol/L)
Cholesterol (mmol/L)
0.5 (0.2-1.3)
0.8 (0.2-9.7)
2.5 (0.7-6.2)
0.3 (0.09-0.83)
1.1 (0.3-6.6)
2.6 (0.7-4.8)
<0.001**
0.31
0.90
Lactate (mmol/L) 2.4 (0.7-8.3) 2.5 (0.9-11.7) 0.95
Ureum (mmol/L)
Creatinin (μmol/L)
5.2 (1.6-20.1)
41 (20-324)
5.2 (1.8-45.1)
56 (11-995)
0.48
0.11
PT (sec) 17 (12-39) 18 (13-52) 0.42
AST (IU/L)
ALT (IU/L)
96 (19-2145)
26 (12-372)
69 (18-1375)
47 (5-468)
0.84
0.75
Trombocyte (IEx109/L)
Leucocyte (IEx109/L)
169 (5-332)
9 (1-26)
183 (13-572)
10 (1-21)
0.35
0.84
Data are expressed as median (range) or numbers.
CRP, C-reactive protein; FFA, Free Fatty Acids; TG, triglycerides; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
* signi! cant (p<0.05) di" erence between children with hypo- and hyperinsulinemic response
** signi! cant (p<0.001) di" erence between children with hypo- and hyperinsulinemic response
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Clinical outcome parameters are shown in Table 3. The two groups signi! cantly di" ered on 
glucose intake (3.4 vs 4.2 mg/kg/min), duration of insulin therapy (10 vs 33 hours), mechani-
cal ventilation (2 vs 5 days) and PICU length of stay (5 vs 11 days). Non-ventilated children 
with an insulin/glucose ratio <18 pmol/mmol (n=10) were treated with insulin for 8 hours (0.2 
-124); the others for 32 hours (2-540, p<0.05). 
Table 3 Patients’ characteristics during PICU stay
Variable
Insulin/Glucose
<18
(n=29)
Insulin/Glucose
>18
(n=35)
P-value
Days from admission to 
hyperglycemia
0.5 (0.03-2.8) 0.6 (0.1-60.4) 0.13
Glucose control protocol 
characteristics:
Glucose intake (mg/kg/min) 3.4 (0.0-6.2) 4.2 (0.4-19.3) 0.03*
Time from start of insulin infusion 
to normoglycemia (hrs)
4 (0.2-17) 4 (0.8-759) 0.93
Max insulin dose, (mIU/kg/hrs) 50 (3-140) 70 (20-200) 0.20
Duration of insulin therapy (hrs) 10 (0.2-124) 33 (3-540) 0.005**
Glucocorticoids (days) 2 (0.04-11) 2 (0.04-8) 0.78
MV (days) 2 (0-18) 5 (0-35) 0.04*
PICU LOS (days)
Hospital LOS (days)
5 (1-22)
7 (1-96)
11 (2-106)
17 (1-155)
0.02*
0.28
PICU Survival (n) 23 (79%) 26 (74%) 0.53
Data are expressed as median (range) or numbers.
MV, mechanical ventilation; PICU LOS, pediatric intensive care unit length of stay
* signi! cant (p<0.05) di" erence between children with hypo- and hyperinsulinemic response
** signi! cant (p<0.001) di" erence between children with hypo- and hyperinsulinemic response
Correlations
Insulin/glucose ratio was signi! cantly correlated with HOMA (r=0.79, p<0.001). There were 
weak but statistically signi! cant correlations between insulin/glucose ratio and duration of 
insulin therapy (r=0.39, p<0.01), duration of mechanical ventilation (r=0.34, p<0.05), and 
PICU LOS (r=0.34, p<0.05). Duration of insulin therapy was also positively correlated with 
duration of steroid treatment (r=0.60, p<0.01), maximum insulin dose (r=0.54, p<0.01), PICU 
LOS (r=0.37, p<0.01), insulin level (r=0.35, p<0.01) and CRP level (r=0.32, p<0.05). 
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DISCUSSION
In this study, children with a hyperinsulinemic response were more often mechanically 
ventilated, had a signi! cant longer duration of insulin therapy, mechanical ventilation and 
PICU stay, than children with a hypoinsulinemic response. Duration of hospital stay, mortality 
and other clinical outcome parameters did not di" er between both groups. A recent study in 
critically ill adults found no di" erences in morbidity or mortality between patients with overt 
insulin resistance and patients who were insulin sensitive [3]. The authors suggested that 
severity of illness and the underlying in$ ammatory response, rather than hyperglycemia or 
insulin resistance, may be the main contributor to outcome of severely ill patients [3]. How-
ever, in our study we did ! nd di" erences in morbidity (duration of mechanical ventilation 
and PICU length of stay) between patients with a hyperinsulinemic response compared with 
those with a hypoinsulinemic response. Our ! nding that a hyperinsulinemic response was 
associated with respiratory failure, is in line with ! ndings from Preissig and Rigby [14]. These 
authors reported signs of insulin resistance, measured by C-peptide levels in children with 
respiratory failure. On the other hand, they also reported primary beta-cell dysfunction as 
the prominent cause of hyperglycemia in children with both respiratory and cardiovascular 
failure at the same time, whereas in the present study both a hyper-and a hypoinsulinemic 
response were seen in children with cardiovascular failure. They postulated that especially 
noradrenalin has a deleterious e" ect on beta-cell function. Lower vasopressor scores in our 
study population is a possible explanation of the ! nding of a decreased insulin response to 
hyperglycemia in only a minority of our patients. Preissig and Rigby unfortunately did not 
report these scores. 
Adult studies have yielded many factors that may in$ uence the insulin and glucose re-
sponse to critical illness. Hyperglycemia associated with elevated insulin levels may result 
from higher glucose intake, as well as the presence of excessive amounts of counterregula-
tory hormones (noradrenalin, adrenalin, glucagon, glucocorticoids, and growth hormone) 
and cytokines (tumor necrosis factor-α, interleukin-1 and interleukin-6) [2]. With regard to 
drug-induced hyperglycemia, both steroid therapy and vasopressors have a negative e" ect 
on insulin sensitivity [25]. 
Concerning glucose intake, we found higher glucose intake rates, without signi! cant dif-
ferences in bodyweight, in children with a hyperinsulinemic response compared to those 
with a hypoinsulinemic response. A study in critically ill adults reported a strong association 
between the amount of infused glucose and intensive care outcome in a situation without 
insulin treatment and without active glucose control. As, in our study, all children were 
treated with insulin for hyperglycemia, this unfavourable association does not apply to our 
population [26]. 
Concerning the use of vasopressors, we did not ! nd a correlation between the vasopressor 
score and beta-cell dysfunction as expressed by insulin/glucose ratio. Regarding glucocor-
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ticoid use, duration of glucocorticoid treatment was strongly correlated with duration of 
insulin therapy, which might re$ ect the depressing e" ect of glucocorticoids on insulin sen-
sitivity. This is supported by the correlations found between duration of insulin therapy and 
insulin level, insulin/glucose ratio and peak insulin dose. Also, the strong correlation between 
duration of glucocorticoid therapy and insulin therapy is in accordance with pharmacologi-
cal studies, which have reported decreased insulin sensitivity from 4 hours after the start of 
glucocorticoid infusion, which did not change for a further 2 months of glucocorticoid treat-
ment [27]. It would be interesting for future studies to determine blood levels of glucose, 
cortisol, C-peptide and insulin during glucocorticoid treatment.
A limitation of this study is the fact that insulin sensitivity was measured indirectly by 
insulin/glucose ratio and HOMA. The hyperinsulinemic euglycemic clamp technique is the 
“gold standard” for quantifying insulin sensitivity in vivo because it directly measures the 
e" ects of insulin to promote glucose utilization under steady state conditions. We resorted 
to the indirect methods, because the clamp technique is not easily implemented in large 
studies with critically ill children. As glucagon is the primary hormonal stimulator of hepatic 
gluconeogenesis during critical illness which is resistant to the inhibitory e" ect of physiologi-
cal concentrations of insulin [28], the ratio of insulin to glucagon may have additional value 
in future studies on hormonal response to hyperglycemia. 
From previous studies [14], as well as from this study, it has become obvious that many 
critically ill children are treated with exogenous insulin for a relatively short period of time. In 
this study it was a median duration of 23 hours (7-55). As the duration in the group of non-
ventilated children with an insulin/glucose ratio <18 pmol/mmol, was signi! cantly shorter 
than in the other children, it might be postulated that in these children the acute stress 
response is rather brief, so that consequently the hyperglycemic state lasts shortly. Therefore, 
the value of insulin therapy in these children could be questioned. Without insulin therapy, 
their hyperglycemia would probably also have normalized within a day without adverse ef-
fects on morbidity, as occurred in young children after surgery [29]. It would be worthwhile 
to investigate if the insulinemic response to hyperglycemia, determined by insulin/glucose 
ratio or HOMA in combination with type of organ dysfunction, could be used in clinical prac-
tice to determine the need of exogenous insulin treatment. 
Conclusions
Both a hyper- and a hypoinsulinemic response play a role in the occurrence of hyperglycemia 
in critically ill children. Children with a hyperinsulinemic response had a longer duration of 
insulin therapy, mechanical ventilation and PICU length of stay compared with those with a 
hypoinsulinemic response. Most of the children without respiratory failure showed relatively 
low insulin levels and insulin/glucose ratios, in combination with a short duration of insulin 
therapy. 
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Future research should focus on pathophysiological mechanisms of hyperglycemia in criti-
cally ill children. It would be challenging to develop predictor equations that could foretell in 
advance which hyperglycemic children would bene! t from insulin therapy and which would 
not. 
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ABSTRACT
Objective
To evaluate a stepwise nurse-driven glucose control protocol for the treatment of hypergly-
cemia in critically ill pediatric patients.
Setting
Academic pediatric intensive care unit.
Design
Prospective observational study.
Patients
50 consecutively admitted critically ill children with hyperglycemia above 8 mmol/L (145 mg/
dL) were included and treated according to the glucose control protocol.
Methods
Demographic data and clinical parameters were collected and di" erent steps in the protocol 
were evaluated. Data were expressed as medians with interquartile ranges.
Main Results
Fifty children (28 boys), age 3.5 yrs (1.2 -9.3 yrs) were treated in 18 months. 42 children had 
multiple organ failure. Eight children died. Insulin treatment was initiated 4 hours after the 
! rst episode of hyperglycemia was documented (median blood glucose 11.4 mmol/L (207 
mg/dL) (9.7-14.5 mmol/L, 176-264 mg/dL)). Blood glucose was <8 mmol/L (145 mg/dL) 
within 12 hours of initiating insulin therapy in 47/50 children (94%) (median 5 hrs). Duration 
of treatment was 34 hr (17-72 hrs) and the maximum insulin dose ranged between 20 and 
200 mIU/kg/hr (median 70 mIU/kg/hr). Episodes of severe hypoglycemia <2.2 mmol/L (47 
mg/dL) did not occur.
Conclusion
The use of a stepwise nurse-driven glucose control protocol resulted in normoglycemia within 
12 hours for 94% of the children involved. Episodes of severe hypoglycemia did not occur.
We conclude that the glucose control protocol is e" ective in treating hyperglycemia in criti-
cally ill children. Further studies are necessary to assess safety before the protocol could also 
be implemented in other PICU’s.
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INTRODUCTION
Hyperglycemia and insulin resistance are universal ! ndings in critically ill adult patients. In 
the acute stress state this metabolic response could be regarded as an adaptive response. 
Nevertheless, several studies in adults and children have observed associations of both initial 
hyperglycemia and prolonged hyperglycemia with adverse outcomes (1-12).
Since then, several studies on the management of hyperglycemia in critically ill adults by 
intensive insulin therapy have reported con$ icting results (13-15).
The Leuven investigators showed that intensive insulin therapy reduced mortality in 
surgical patients and in medical patients staying in the ICU for at least 3 days (13, 14). They 
also showed bene! cial e" ects on a variety of indicators of morbidity, such as a reduction in 
nosocomial infections, acute renal failure, critical illness polyneuropathy, and anemia, as well 
as shorter duration of mechanical ventilation and overall length of ICU stay. A multicenter, 
randomized trial showed no signi! cant bene! ts of intensive insulin therapy in the rate of 
death or the mean score for organ failure. Moreover, the use of intensive insulin therapy was 
associated with an increased risk for serious adverse events related to hypoglycemia (15). 
Studies in critically ill children which have shown an association between hyperglycemia 
and greater morbidity and mortality, were mostly retrospective and could not demonstrate 
causality between glucose levels and outcome measures (1-12). 
The overall hypothesis regarding treatment of hyperglycemia is that critically ill children 
will bene! t from maintaining normoglycemia with exogenous insulin, as in critically ill adults 
(13, 14). Two studies in a small group of children with severe burns reported bene! cial ef-
fects of insulin treatment on survival, infection rates and in$ ammatory response (16, 17). 
The insulin treatment protocol was not published. Such a protocol for critically ill children 
with hyperglycemia would obviously have to be both safe and e" ective. Factors like time to 
normoglycemia, target blood glucose level, occurrence of hypoglycemia, practical feasability 
and workload are some of the aspects to be taken into account.
So far no studies have published results of implementation of an insulin treatment proto-
col in critically ill children in relation with di" erent blood glucose levels. The present study 
documents experiences with the implementation of such a glucose control protocol in our 
pediatric intensive care unit (PICU). 
MATERIALS AND METHODS
Patients
All children with single or multiple organ failure consecutively admitted to the PICU of the 
Erasmus MC-Sophia Children’s Hospital from January 2006 to June 2007 with hyperglycemia 
(de! ned as blood glucose level exceeding the value of 8 mmol/L (145 mg/dL)) at any time 
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during admission meeting the criteria for insulin treatment, were prospectively evaluated 
(see below). This hospital is a tertiary care center embedded in the Erasmus University Medi-
cal Center, Rotterdam, the Netherlands. Children with diabetes mellitus were excluded. The 
Medical Ethics Committee of the Erasmus MC approved the study.
Insulin protocol (Figure 1)
On admission, children with bodyweight ≤30 kg received intravenous glucose at a rate of 4–6 
mg/kg/min; the rate for those with body weight >30 kg was 2-4 mg/kg/min. To achieve the 
target glucose infusion rates, 5% and 10% dextrose infusions were given. 
Children with sepsis, trauma, multi-organ failure and/or receiving mechanical ventilation 
were included in the protocol when two consecutive blood or capillary glucose values at a 
1-hr interval were >8 mmol/L (145 mg/dL). Children with single organ failure were included 
when blood glucose levels were >8 mmol/L (145 mg/dL) for more than 6 hours and decreased 
less than 50% during the following 6 hours. 
The glucose control protocol was initiated by the attending physician at a dose dependent 
on the actual blood glucose level. Thereafter, nursing sta"  was allowed to adjust the insulin 
rate according to the rate of increase or decrease of blood glucose level. Initially blood glucose 
level was measured every hour until it had reached the target range with values between 4 
and 8 mmol/L (72-145 mg/dL). After three consecutive measurements had shown glucose 
levels within the target range, glucose level was measured every 3 hours. Frequency of mea-
surements was intensi! ed again to once hourly for 3 hours when continuous enteral feeding 
was started and parenteral glucose administration had been reduced by more than 50%. 
When insulin dose exceeded 200 mIU/kg/hour the protocol required nurses to consult 
with the attending physician. Maximum insulin dose was 600 mIU/kg/hour. Stop criteria 
were de! ned as: a) blood glucose level <4 mmol/L (72 mg/dL); b) insulin rate <15 mIU/kg/
hr at any time or <30 mIU/kg/hr for more than 24 hours; c) start enteral bolus feeding and or 
interruption of continuous feeding or dextrose infusions; d) discharge from the PICU. When 
blood glucose decreased < 2.6 mmol/L (47 mg/dL), a bolus infusion of dextrose 10% of 5ml/
kg was administered intravenously.
Insulin infusion was restarted after discontinuation when blood glucose rose to 
>8 mmol/L (145 mg/dL), at the “insulin initial dose” level shown in ! gure 1.
Time to reach goal blood glucose level was de! ned as the time elapsed from start of insulin 
infusion until the ! rst measurement showing that blood glucose level had dropped to ≤8 
mmol/L (145 mg/dL). Hypoglycemia was de! ned as blood glucose level either <4 mmol/L (72 
mg/dL) with hypoglycemic symptoms or <2.6 mmol/L (47 mg/dL) regardless of symptoms. 
Severe hypoglycemia was de! ned as blood glucose <2.2 mmol/L (40 mg/dL) in accordance 
with most studies in literature. Neurological sequelae were monitored by clinical assessment. 
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Clinical parameters 
Disease severity was determined by the Pediatric Risk of Mortality score (PRISM II) during 
the ! rst 6 hours of admission. Respiratory and inotropic support, use of glucocorticoids and 
antibiotics were recorded. 
 
glucose intake: !30 kg: 4-6 mg/kg/min   &   >30 kg: 2-4 mg/kg/min 
glucose >8 (145)  multiple organ failure or 
sepsis/trauma/mechanical 
ventilation 
single organ failure 
(not sepsis/trauma) 
glucose >8 (145) after 1 hour 
glucose >8 (145) after 6 hours 
and no decrease >50% 
insulin initial dose (mIU/kg/hr):  
glucose        insulin  
>8-11 (145-200)  " 20      
>11-15 (200-272) " 30  
>15-20 (272-364)   " 40 
>20 (364)  " 50 
after insulin start or adjustment: 
check glucose hourly till 3x within target range 4-8 (72-145) 
then check glucose every 3 hours 
glucose <4 (72) glucose increase or 
!25% decrease 
glucose >25% 
decrease 
glucose >50% 
decrease 
STOP INSULIN 
 
glucose <2.6 (47) " 
bolus dextrose 10% 
5ml/kg in 10 minutes 
glucose         "   insulin  
4-6 (72-110)  " half  
>6-8 (110-145)  " sqa 
>8-11 (145-200)  " ! 10 
>11-15 (200-272) " ! 20 
>15-20 (272-364) " ! 30  
>20 (364)  " !! 40 
 
half insulin dose glucose        "  insulin  
4-8 (72-145)     ! half  
>8-11(145-200)" 2/3  
>11 (200)         " sqa  
check glucose every 30 minutes 
until glucose >4 (72) 
insulin >200 mIU/kg/hr " consult physician 
(maximum dose = 600 mIU/kg/hr) 
Stop criteria:
-blood glucose <4 mmol/L (72 mg/dL)
-insulin rate <15 mIU/kg/hr at any time or < 30 mIU/kg/hr during 24 hours
-start enteral bolus feeding
-interruption of continuous feeding or dextrose infusions
-discharge from PICU\
Figure 1 Glucose control protocol
Glucose = blood glucose level in mmol/L (mg/dL).
Insulin = insulin dose in mIU/kg/hr.
(!10 = increase current dose with 10 mIU/kg/hr, 2/3 = continue with 2/3 of current dose)
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Collection of blood samples and analysis 
Blood glucose measurements were obtained as soon as possible after admission. In case of 
hyperglycemia >8 mmol/L (145 mg/dL) measurements were repeated every hour and further 
according to the protocol. Blood was collected from an indwelling arterial or venous catheter 
or from capillary puncture. Blood glucose was measured on either a blood gas analyzer (ABL 
625; Radiometer, Copenhagen, Denmark) or by a bedside capillary glucose measurement 
with a point of care system (HemoCue AB, Sweden). Blood glucose levels of <2.6 mmol/L (47 
mg/dL) or >15 mmol/L (272 mg/dL) obtained by the latter method were recon! rmed with the 
blood gas analyzer. Hypoglycemia <2.6 mmol/L (47 mg/dL) was treated with dextrose bolus 
prior to recon! rmation. 
Statistics
Results are expressed as medians with interquartile range unless speci! ed otherwise. 
Statistical analysis was performed with a statistical analysis software program (SPSS 13.0 for 
WINDOWS, SPSS, Inc, Chicago, IL). Comparisons between children with one- or multi- organ 
failure were made with the Mann-Whitney U-test. A p-value < 0.05 was considered to be 
signi! cant.
RESULTS 
In an 18-month study period 50 children (28 boys), age 3.5 yrs (1.2-9.3 yrs) with various di-
agnoses received insulin treatment and were eligible for inclusion in the study (tables 1 and 
2). Forty-two children had multiple organ failure. Median PRISM score was 12 (8-22). Eight 
children died, of whom three died during insulin treatment.
Concomitant therapy on admission included inotropic agents in 26 children (12 children 
were treated with dobutamine, 12 with dobutamine and noradrenaline, one with noradrena-
line, and one with dopamine, dobutamine and noradrenaline). Forty children were mechani-
cally ventilated and received benzodiazepines and/or morphine for sedation. Twenty-one 
patients received steroids (di" erent doses and types) during insulin treatment. The duration 
of steroid treatment was positively correlated with the duration of insulin treatment (r=0.65, 
p=0.001).
Insulin protocol
Glucose intake in children ≤30 kg and >30 kg was 4.3 (2.4-5.7) and 2.6 (0.8-3.7) mg/kg/min, re-
spectively. Five patients received full continuous enteral feeding at start of insulin treatment, 
22 patients were fully parenterally fed and 23 patients received partial continuous enteral 
and partial parenteral feeding.
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Insulin treatment was initiated 3.8 hours (2.0-8.0 hrs) after the ! rst episode of hyperglyce-
mia occurred in children with multiple organ failure. Insulin treatment was initiated 7.5 hours 
(3.5-9.0 hrs) after the ! rst episode of hyperglycemia in children with single organ failure. 
Blood glucose level at initiation of therapy was 11.4 mmol/L (207 mg/dL) (9.7-14.5 mmol/L, 
176-264 mg/dL).
Table 1 Clinical diagnoses
Diagnosis Number of patients
Sepsis 13
Surgical 10
Status epilepticus 6
Pneumonia 5
Status asthmaticus 4
Trauma 3
Congenital heart defect 2
Guillain Barre 2
Acute renal failure 2
Acute renal/liver failure 1
Intracerebral hemorrhage 1
Coma 1
Table 2 Characteristics of all children and those with multiple or single organ failure
Multiple organ failure
N=42
Single organ failure
N=8
All children
N=50
Age (yrs) 2.8 (1.0-9.0)* 11.5 (6.3-14.9)* 3.5 (1.2-9.3)
Female (%) 45% 38% 44%
PRISM 14 (7-23) 11 (8-15) 12 (8-22)
Steroid use 15 (33%) 6 (75%) 21 (42%)
Glucose intake 
(mg/kg/min)
3.8 (2.2-5.3) 2.7 (0.7-5.3) 3.7 (2.0-5.3)
Time from 1st episode of 
hyperglycemia to start insulin 
infusion (hrs)
3.8 (2.0-8.0) 7.5 (3.5-9.0) 4 (2.0-8.1)
Time from start of insulin 
infusion to normoglycemia (hrs) 5.0 (2.8-8.0) 5.5 (3.3-6.2) 5 (3.0-7.3)
Glucose at start of insulin 
infusion
(mmol/L)
(mg/dL)
11.0 (9.5-13.8)
200 (173-251)
13.0 (11.7-15.3)
236 (213-278)
11.4 (9.7-14.5)
207 (176-264)
Max insulin dose (mIU/kg/hr) 70 (40-90) 70 (40-100) 70 (40-100)
Hypoglycemic events
<4 mmol/L (72 mg/dL)
<2.6 mmol/L (47 mg/dL)
<2.2 mmol/L (40 mg/dL) 
15 (33%)
 3 (7%) 
 0
0
0
0
15 (30%)
 3 (6%)
 0
Duration of therapy (hrs) 36 (16-78) 21 (18-45) 34 (17-72)
Data are expressed as medians with interquartile ranges
*p<0.05
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Within 12 hours after initiation of therapy blood glucose had dropped to ≤8 mmol/L (145 
mg/dL) in 47/50 children (94%). Median time needed to reach goal level was 5.0 hrs (3.0-7.3 
hrs). The maximum dose of insulin ranged from 20 to 200 mIU/kg/hr (median 70 mIU/kg/hr). 
Duration of treatment (the 3 children who died during treatment excluded) was 34 hrs 
(17-72 hrs). Thirteen children received insulin for more than 72 hrs. 
Rebound hyperglycemia >8mmol/L (145 mg/dL) during insulin therapy occurred in 25 
patients. Median blood glucose level during rebound was 8.9 mmol/L (162 mg/dL) (8.3-9.7 
mmol/L, 150-176 mg/dL) with a duration of 1 hour (1-3 hours). There was no relation between 
the occurrence of rebound hyperglycemia and either blood glucose level at start of treatment 
or the length of time to glucose control. Duration of insulin therapy (51 vs 19 hours, p<0.01) 
and maximum insulin dose during treatment (80 vs 44 mIU/kg/uur, p<0.05) in the rebound 
group were signi! cantly higher than in the patients without rebound hyperglycemia.
Hypoglycemia <4 mmol/L (72 mg/dL) was noted in 3.5% of all blood samples (in 15 chil-
dren). Hypoglycemia <2.6 mmol/L (47 mg/dL) was noted in 0.4% of all samples (in 3 children, 
all without clinical symptoms). Episodes of severe hypoglycemia <2.2 mmol/L (40 mg/dL) 
did not occur. The occurrence of hypoglycemia was associated with the following ! ndings: 
delayed glucose measurement (4 times, leading to hypoglycemia <2.6 mmol/L (47 mg/dL) 
in 3 cases), incorrect insulin adjustment (4 times), change of parenteral to enteral nutrition 
without insulin dose adjustment (3 times), and other reasons (4 times).
Various reasons to stop insulin treatment were (table 3): Blood glucose <4 mmol/L (72 
mg/dL) (11 times), insulin dose <15 mIU/kg/hr (15 times), insulin dose <30 mIU/kg/hr for 
more than 24 hours (5 times), start enteral bolus feeding (4 times), death during treatment (3 
times), or discharge (2 times). In 10 instances the reason had not been documented.
Table 3 Reasons to stop insulin treatment 
Reason Number of patients (percentage)
Hypoglycemia <4 mmol/L (72 mg/dL) 11 (22%)
Insulin dose <15 mIU/kg/hrs 15 (30%)
Insulin dose <30 mIU/kg/hr more than 24 hrs 5 (10%)
Start enteral bolus feeding 4 (8%)
Death during insulin therapy 3 (6%)
Discharge from PICU 2 (4%)
Unknown reasons 10 (20%)
Problems encountered with implementation of the protocol 
Several protocol violations were encountered. Glucose was not always administered accord-
ing to the protocol. At start of the insulin treatment, intake was too low in 17 children (34%) 
and too high in 10 children (20%). 
Insulin treatment was initiated in time in 9 children (21%) with multiple organ failure and in 
3 children (38%) with single organ failure. The insulin starting dose was correct in 39 children 
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(78%). Nine children (18%) started with an insulin dose that was too low (10 mIU/kg/hr (10-20 
mIU/kg/hr) below the recommended dose). Two children (4%) started with a dose that was 
too high (10 mIU/kg/hr above the recommended dose).
Glucose measurements were done more frequently than was necessary according to the 
protocol. The median number of glucose measurements per hour until normoglycemia was 
1.2 (1.0-1.6). It dropped to 0.5 (0.3-0.8) in the period after normoglycemia until discontinua-
tion of insulin treatment. In the period until normoglycemia, the number of adjustments of 
insulin dosage was 3 (1-7), i.e. 0.5 adjustments per hour (0.3-0.8).
In 42% (120/285) of occasions the adjustments were done incorrectly. 
Regarding those insulin adjustments that were done incorrectly, insulin infusion rate was 
too low in the majority (63%, 76/120) of the occasions. The median insulin infusion rate was 
10 mIU/kg/hr (10-20 mIU/kg/hr) below the recommended dose according to the protocol. 
Insulin infusion rate was too high in 37% (44/120) of the occasions, with a median insulin rate 
of 10 mIU/kg/hr (10-20 mIU/kg/hr) above the recommended dose according to the protocol.
DISCUSSION
This study showed that implementation of a stepwise nurse-driven protocol enabled 
achievement of normoglycemia within 12 hours after initiation of insulin therapy in 94% of 
the children. Severe hypoglycemia <2.2 mmol/L (40 mg/dL) did not occur. 
Studies in critically ill children have de! ned di" erent blood glucose thresholds for hy-
perglycemia (18). Levels >8.3 mmol/L (>150 mg/dl) seem to have the strongest association 
between hyperglycemia and increased morbidity and mortality (4, 8, 19). Based on these 
studies, we de! ned the threshold for hyperglycemia as blood glucose level >8 mmol/L (145 
mg/dL). Consequently, the target range for blood glucose level was established at 4 to 8 
mmol/L (72-145 mg/dL). This range di" ers from the range used in clinical trials in adults, from 
4 to 6.1 mmol/L (72-110 mg/dL). We opted for a slightly higher target range, because critically 
ill children are believed to be at a higher risk of developing hypoglycemia. The time elapsed 
until normoglycemia was reached was relatively short (5 hours), suggesting that the glucose 
control protocol was well designed. Still, as only 58% of the adjustments until normoglycemia 
were correct, an even faster time until normoglycemia could have been reached. 
Although severe hypoglycemia <2.2 mmol/L (40 mg/dL) did not occur, hypoglycemia <4 
mmol/L (72 mg/dL) was seen in 15 of the 50 children (30%). The most plausible explana-
tions for the occurrence of hypoglycemia were: delayed glucose measurements, incorrect 
insulin adjustments and change of parenteral to enteral nutrition without insulin dose 
adjustments. These ! ndings accentuated the importance of adherence to the protocol. Seri-
ous concerns have arisen about the consequences of hypoglycemia in critically ill adults on 
intensive insulin therapy (20, 21). While it is clear that severe and prolonged hypoglycemia 
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is harmful for individuals of any age, there has been no evaluation to date of the e" ect of 
brief hypoglycemia on PICU outcome. In adult studies the incidence of severe hypoglycemia 
was four to seven times greater in critically ill patients treated with intensive insulin therapy 
as compared to control groups (13-15, 22). Adult studies which evaluated the association 
between hypoglycemia and risk of death show con$ icting results (20, 23). Larger prospective 
studies are needed to evaluate outcome after hypoglycemia in the (P)ICU. 
The protocol intensi! ed nursing workload, notably during acute admissions. Frequencies 
of blood glucose determinations and adjustments of insulin infusion rates were highest dur-
ing the period from start of insulin treatment to normoglycemia occurred. Previous surveys 
among nurses revealed that the frequency of blood glucose sampling was considered as the 
most common reason for the increased workload (24).  
The nursing burden was not quanti! ed explicitly, which can be considered a limitation of 
this study. A second limitation of this study is that blood glucose measurements were done 
by either of two methods, and that the type of blood was capillary, arterial or venous. Values 
found could di" er as to the method and type of blood used. 
This study was not designed to show bene! cial e" ects on morbidity or mortality. It ap-
peared, however, that 37 of the 50 children were treated for less than three 3 days. The ques-
tion is, whether it will be possible to study the e" ects on morbidity and mortality in children 
whose insulin treatment is very short. Future studies should elucidate which children might 
bene! t from insulin treatment. Furthermore, a computer decision support system for glucose 
control could exhibit even more e#  cient glucose control with less occurrence of hypoglyce-
mia (25). 
Conclusions
In this study we showed that a stepwise, nurse-driven protocol enabled achievement of 
normoglycemia within 12 hours after initiation of insulin therapy in almost all of the patients. 
Although there were many protocol violations, these were mostly of minor importance and 
severe hypoglycemia <2.2 mmol/L (40 mg/dL) did not occur. We conclude that the glucose 
control protocol is e" ective in treating hyperglycemia in critically ill children. Further studies 
are necessary to assess safety before the protocol could also be implemented in other PICU’s. 
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To the Editor:
We were very excited to see the recent 
publication by Dr. Verhoeven et al describ-
ing another experience of active glycemic 
control in critically ill children (1). This 
study describes the implementation 
of a protocolized approach to control 
hyperglycemia in children with single or 
multiple organ failures admitted to their 
pediatric intensive care unit in Rotterdam, 
Netherlands. Patients with sepsis, trauma, 
multiple organ failure, and/or receiving 
mechanical ventilation were included 
in this study, and the glycemic control 
protocol was initiated when blood glucose 
(BG) was >145 mg/dL on two consecutive 
readings in 6 hrs (in those with single 
organ failure) or one reading (in those 
with >2 organ failures). Those with known 
diabetes mellitus were excluded and there 
were no apparent age restrictions. Goal BG 
levels were targeted at <145 mg/dL, using 
a nurse-driven, weight-based insulin infu-
sion algorithm, and all patients received 
routine glucose infusions. Although the 
authors report no occurrence of severe hy-
poglycemia (de! ned as BG <40 mg/dL), no 
data on how successful their approach was 
at maintaining their target glycemic goal 
is provided. Although the authors indicate 
“So far,no studies have published results 
of implementation of an insulin treatment 
protocol in critically ill children . . .,” theirs is 
in fact the third peer-reviewed description 
of an active approach to glycemic control in 
a pediatric intensive care unit. In November 
2008, our group published our experience, 
using a physician-initiated, nurse-driven 
approach to hyperglycemia detection 
and management (2). We showed that we 
could e" ectively maintain BG levels in our 
target range of 80 to 140 mg/dL with little 
to no increase in baseline hypoglycemic 
episodes. In addition, we have also shown 
and recently published that hyperglycemia 
prevalence and severity are correlated with 
certain illness-severity risk factors (3). In 
February 2009, Vlasselaers et al published 
a groundbreaking, randomized, controlled 
trial in pediatric critical care, where strict 
glycemic control (in age-adjusted fast-
ing ranges) was compared with more 
conservative control (180–214 mg/dL) 
(4). Although there wasoutcome bene! t 
(including decreased mortality) in the strict 
control arm, hypoglycemic rates of ~ 25% 
in that group raises concerns and likely ob-
viates this approach into standard practice. 
Reports describing successful protocols 
and suggesting that glycemic control can 
be accomplished safely and e" ectively is 
important as many pediatric intensivists 
cite fear of hypoglycemia as a primary 
concern when considering adopting such 
an approach. Likely, only after experience 
with such safe, e" ective approaches can 
convincing outcome studies be conducted 
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which will provide the evidence needed to 
truly support the routine practice of glyce-
mic control in pediatric critical care.
The authors have not disclosed any poten-
tial con$ icts of interest.
Mark R. Rigby, Catherine M. Preissig Emory 
University School of Medicine; Children’s 
Healthcare of Atlanta at Egleston, Atlanta, 
GA 
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The authors reply:
We would like to thank Catherine Preissig 
and Mark Rigby for their additional remarks 
in the January issue of PCCM about our 
recent publication on management of hy-
perglycemia in the pediatric intensive care 
by implementation of our glucose control 
protocol (1).
Today, our protocol is indeed the third 
peer-reviewed description of an active ap-
proach to glycemic control in the pediatric 
intensive care. Preissig et al (2) and Vlasse-
laers et al (3) have recently published their 
protocolized approach to control hypergly-
cemia in critically ill children. In addition, at 
this moment, there is a large multicenter 
study in England investigating if strict 
blood glucose control in pediatric intensive 
care units is bene! cial when compared 
to current standard practices (Control of 
Hyperglycemia in Pediatric intensive care, 
CHiP trial) (4).
There are some notable di" erences 
between the protocolized approaches to 
control hyperglycemia that need to be 
discussed. First, although our glucose con-
trol protocol is designed for all ages (same 
as the work of Vlasselaers et al and CHiP 
trial), Preissig et al only use their protocol 
for pediatric intensive care patients aged 
>6 months and weighing >5 kg. Second, 
di" erent target ranges for plasma glucose 
levels are being used: 4.4 –7.7 mmol/L 
(80–140 mg/dL) by Preissig et al, 2.8–4.4 
mmol/L (51–80 mg/dL) for infants aged 
0–1 yr and 3.9 –5.5 mmol/L (71–100 mg/dL) 
for children aged 1–16 yrs by Vlasselaers et 
al, 4–7 mmol/L (72–128 mg/dL) in the CHiP 
trial and 4–8 mmol/L (72–145 mg/dL) in 
our study. Third, in the study by Preissig et 
al and CHiP trial, no glucose intake ranges 
are recommended, whereas we advocate 
to start with a standard glucose regimen, 
in children ≤30 kg: 4–6 mg/kg/min and 
in children >30 kg: 2–4 mg/kg/min. In the 
study of Vlasselaers et al, median glucose 
intake on day 1 after admission was only 
3.5 mg/kg/min for infants <1 yr of age and 
2.8 mg/kg/min for children 1–16 yrs of age. 
Fourth, we start with an insulin infusion 
rate depending on the exact glucose level 
varying between 0.02 IU/kg/hr and 0.05 
IU/kg/hr, whereas the other protocols use 
one or two starting doses, which are con-
siderably higher than our insulin starting 
doses: 0.05 IU/kg/hr by Preissig et al, 0.1 IU/
kg/hr to 0.2 IU/kg/hr depending on initial 
blood glucose level by Vlasselaers et al and 
CHiP trial. It should be further investigated 
whether one or more of the above issues 
are associated with early achievement of 
normoglycemia, the prevalence of hypo-
glycemia (especially in infants), and most 
importantly bene! cial outcome. We agree 
with Preissig and Rigby that hypoglycemic 
rates of 25%, as described in the random-
ized control trial by Vlasselaers et al, with 
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the majority of hypoglycemias in infants <1 
yr (70 infants and 17 children), raises con-
cerns. With our approach, no hypoglycemia 
≤2.2 mmol/L (≤40 mg/dL) occurred, and 
Preissig et al also showed that, with their 
approach, the occurrence rate of hypogly-
cemia was very low (4%). At this moment, 
we have treated 323 children with our 
glucose control protocol, and an ad hoc 
analysis of 7195 blood glucose samples 
showed hypoglycemia of ≤2.2 mmol/L 
(≤40 mg/dL) in only 0.3% of the samples, 
corresponding with 4% of the patients. 
Furthermore, mean time until target blood 
glucose level was 5 hrs with both our and 
Preissigs’ approach. Concerning the issue 
on how successful our approach was to 
maintain the target glucose ranges of 4 – 8 
mmol/L (72–145 mg/dL), we found in 50% 
of the patients a rebound hyperglycemia 
with median blood glucose levels of 8.9 
mmol/L (162 mg/dL). However, duration 
of this rebound was relatively short with 
a median of 1 hr. Interestingly, there is a 
marked discrepancy between the dura-
tion of insulin treatment in our group in 
comparison with other studies. Although 
we only treated patients for a mean of 2.1 
days, Preissig et al treated patients for 6.3 
days and Vlasselaers et al treated patients 
with intensive insulin therapy throughout 
intensive care stay for 5.5 days. This might 
be due to the strict stopping criteria for 
insulin administration in our protocol.
In conclusion, we agree with Drs. Preissig and 
Rigby that it is important to describe e#  cient 
protocols for glycemic control in pediatric 
critically ill patients, which do not increase 
the occurrence of hypoglycemic events. 
Vlasselaers et al reported a bene! cial short-
term outcome in pediatric patients treated 
with intensive insulin therapy. However, the 
majority (75%) of their patients was admit-
ted after cardiac surgery, which means that 
further research is necessary to establish the 
bene! cial e" ects of insulin therapy in all dis-
ease categories a" ecting critically ill children.
The authors have not disclosed any poten-
tial con$ icts of interest.
Jennifer J. Verhoeven, MD, Koen F. M.
Joosten, PhD, Intensive Care, Erasmus
MC-Sophia Children’s Hospital, Rotterdam, 
The Netherlands
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To the Editor:
A major concern in the study by Dirk Vlasse-
laers and colleagues1 is the high incidence 
of hypoglycaemic events in the interven-
tion group (70 infants, 17 children [25%]). In 
a large Australian cohort,2 a U-shaped out-
come curve showed that both high and low 
glucose concentrations worsen outcome. 
There could be several reasons for the high 
incidence of hypoglycaemia in the study. 
First, the target ranges for plasma glucose 
concentrations were low (2·8–4·4 mmol/L 
for infants and 3·9–5·6 mmol/L for chil-
dren). Second, the infants’ glucose intake 
was lower than recommended (median 
3·5 mg/kg/min on day 1 compared with 
5·5 mg/kg/min according to guidelines 
from the European Society for Paediatric 
Gastroenterology, Hepatology and Nutri-
tion). Third, the treatment algorithm for 
insulin was adjusted by the nurses on the 
basis of their experience. In our institution, 
hyperglycaemia is treated (target glucose 
concentrations 4–8 mmol/L3) by use of 
a detailed stepwise algorithm to adjust 
insulin therapy.4 None of our patients has 
had a plasma glucose concentration of less 
than 2·2 mmol/L. Additionally, in adults in 
intensive care, use of a computer-assisted 
glucose control protocol was shown to 
maintain the incidence of hypoglycaemia 
(<2·2 mmol/L) at only 0·86%.5 Finally, the 
starting dose of insulin was high (0·1–0·2 
IU/kg/h), whereas a lower starting dose of 
0·02–0·05 IU/kg/h would seem to be safer.5 
An appropriate glucose intake, especially 
in infants, according to weight and age, in 
combination with a stepwise (computer-
assisted) insulin adjustment protocol and 
slightly higher glucose target concentra-
tions might decrease the incidence of hy-
poglycaemia without losing the bene! cial 
e" ects of insulin therapy in critically ill 
children. 
We declare that we have no con$ icts of 
interest. Koen Joosten, Sascha C Verbrug-
gen and Jennifer J Verhoeven Erasmus 
Medical Center/Sophia Children’s Hospital, 
Dr Molewaterplein 60, 3015 GJ Rotterdam, 
Netherlands
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Authors’reply:
Coert Zuurbier and colleagues argue 
that the glycaemic targets chosen for the 
control groups in randomised controlled 
trials investigating intensive insulin therapy 
in patients in intensive-care units (ICUs) 
should be more closely examined. We could 
not agree more. Variable control targets 
might indeed partly explain the variable 
results of studies in adults.1
Zuurbier and colleagues suggest that 
in the control group of our paediatric ICU 
study we should have targeted 7–8 mmol/L 
instead of 12 mmol/L, since this would bet-
ter re$ ect a “modern conventional” group. 
By contrast, Catherine Preissig and Mark 
Rigby make the opposite argument, claim-
ing we should have targeted 7–8 mmol/L in 
the intervention group. Both suggestions 
are worth investigating.
There is ample evidence for adverse 
outcomes associated with hyperglycaemia 
in adult and paediatric ICU patients. This 
association follows a J-shaped curve, the 
nadir being the “normal level” for age, and a 
linear rise in risk of death for levels exceed-
ing the upper normal range. Association 
does not necessarily mean causality, 
however.2 Indeed, hyperglycaemia could 
merely re$ ect severity of illness, a bene! -
cial adaptation to illness, or, as in diabetes 
mellitus, it can induce complications.
To di" erentiate between these three 
possibilities, a randomised controlled trial 
is the only option. In children, no such trials 
addressing this question had been done 
before ours, so there was no evidence for 
any glycaemia target in paediatric ICU pa-
tients. In any ! rst study, the control group 
should re$ ect this ignorance. This is exactly 
why we did the study, to investigate wheth-
er the “naturally” occurring hyperglycaemic 
response to illness is bene! cial or harmful. 
In the light of “primum non nocere”, the 
control group preferably gets no treatment. 
However, the only undisputable adverse 
e" ect of hyperglycaemia in any condition 
is glucosuria and concomitant hypovolae-
mia when blood glucose concentrations 
exceed the renal threshold of 12 mmol/L. 
Hence, a “don’t touch” approach unless this 
level is reached was chosen for the control 
group in our three randomised trials.[3], [4] and 
[5] This is the only correct choice for a ! rst 
study in a speci! c patient population. As a 
target for the intervention group, we chose 
“normal for age”. Whether another (higher 
than normal) target, as suggested by Preis-
sig and Rigby and by Koen Joosten and 
colleagues, is equally e" ective and avoids 
risk of hypoglycaemia should be studied 
by a randomised trial. Also the eventual 
bene! t of additional glucose infusion in 
infants, or a computerised closed-loop 
system, remains to be studied. The oppos-
ing viewpoints of these correspondents 
nicely illustrate how clinical practice often 
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evolves in opposite directions on the basis 
of expert opinions instead of evidence. We 
provided the ! rst bit of evidence. Clearly, 
this is only the beginning.
We declare that we have no con$ icts of 
interest.
G Van den Berghe, D Vlasselaers, L 
Desmet, I Vanhorebeek and D Mesotten 
Department of Intensive Care Medicine, 
Catholic University of Leuven, B-3000 Leu-
ven, Belgium
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In Chapter 1 we describe the background and initial goals of the studies presented in this 
thesis:
a) Energy requirements of critically ill children assessed by measurements of energy expendi-
ture and substrate utilization (chapters 2,3,4).
b) Pathophysiological aspects of stress hyperglycemia in two diagnostic groups (critically ill 
children with meningococcal sepsis and septic shock and critically ill children after cardiac 
surgery for congenital heart defects, chapters 5,6). 
c) Insulin/glucose ratio as a marker for insulin therapy in critically ill children with hypergly-
cemia (chapter 7).
d) Experiences with the development and implementation of a glucose control protocol in 
the pediatric intensive care unit (chapter 8). 
ENERGY REQUIREMENTS IN CRITICALLY ILL CHILDREN
During critical illness and recovery thereafter, adequate nutritional support is an important 
aspect of the clinical management of pediatric intensive care patients. Adequate nutrition 
in critically ill children is needed for survival, growth and development. Despite the growing 
attention for nutrition, many hospitalized children su" er from both acute and chronic malnu-
trition. Also, severe underfeeding and overfeeding may occur during hospital stay. 1-4 There is 
a high incidence of protein energy malnutrition in children with (congenital) heart disease, 
due to decreased intake, increased energy expenditure (attributable to cardiac failure or 
increased work of breathing), and malabsorption (attributable to altered gastrointestinal 
function by lower cardiac output).5 Another group at risk for malnutrition includes children 
with burn injuries. In these children a hypermetabolic stress response and poor intake result 
in energy de! cits, and the negative e" ects on nutritional status may persist for months after 
injury.6-7 An increased risk of malnutrition is also evident in preterm neonates and in children 
with chronic disease, major congenital anomalies, chronic lung disease (e.g. cystic ! brosis 
and broncho-pulmonary dysplasia), diseases of the gastro-intestinal tract (e.g. intestinal 
atresia, short bowel syndrome, in$ ammatory bowel disease), cancer, HIV-infection, renal 
disease, or cerebral palsy.8-11 Both underfeeding and overfeeding may lead to in-hospital 
complications and post discharge adverse e" ects, as described in the introduction to this 
thesis. Evaluation of nutritional support is best done by assessing of both energy intake and 
energy expenditure. 
In 1995, when we started to measure energy expenditure and substrate utilization in 
critically ill children by indirect calorimetry, research on this subject was still in its infancy. 
However, the importance of oxygen in metabolism and indeed life itself, was ! rst revealed by 
the work of the Anglo-Irish scientist Robert Boyle (1627-1691), who established the concept 
of the chemical elements. Crucially, Boyle demonstrated that when a lighted candle went out 
in a closed chamber, a mouse con! ned to the same chamber rapidly died. 
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In Chapter 2 we present the results of the ! rst energy expenditure measurements in 50 
mechanically ventilated children (median age 7 months (range 2 days to 13 years) with mixed 
diagnoses (median PRISM score 6 (range 0 to 13)). There was a close correlation between 
the measured resting energy expenditure (MREE) and predicted resting energy expenditure 
(PREE) by the Scho! eld formula for weight, age and sex, but Bland-Altman analysis showed 
lack of agreement between individual MREE and PREE. We therefore concluded that standard 
prediction equations are not appropriate to calculate energy needs and energy expenditure 
should be measured in the individual child. Since then, the relative di#  culty of indirect calo-
rimetry and the poor precision of standard predictive methods have inspired researchers to 
develop new prediction equations derived from energy expenditure measurements of venti-
lated, critically ill children. In chapter 4, energy expenditure was measured in 94 mechanically 
ventilated children (median age 6 months (range 2 days to 15 years) with mixed diagnoses 
(median PRISM score 9 (range 0 to 33)). Scho! eld’s equation for weight, height, age and sex 
showed the highest accuracy by predicting energy expenditure within 10% of the MREE in 
40% of the children. The lowest accuracies (16% and 19%) were found using the equations 
developed by White et al.12 for mechanically ventilated children. We have elaborated on the 
most plausible explanations for failure of the White equations to accurately predict REE. The 
! rst White equation includes 6 variables: age, weight, weight for age Z-score, body tempera-
ture, number of days after PICU, and primary reason for admission. An important caveat in 
the White equations is the use of estimated weights, which generally are known not to be 
reliable.13 White et al. reported the highest levels of energy expenditure in children after sur-
gery: the lowest in children with respiratory illness.12 However, others did not ! nd di" erences 
in MREE between children with sepsis, brain injury, respiratory failure, transplant and cardiac 
surgery.14 Moreover, we found, in accordance with others, a lack of agreement between MREE 
within diagnostic groups.15-18 Only after severe traumatic brain injury and after severe burn 
injury a hypermetabolic response is seen in the majority of children.18-21 Apparently, comor-
bidities and varying clinical conditions, such as catecholamine use, mechanical ventilation, 
sedation, neuromuscular blockade and a thermoneutral environment, are important factors 
signi! cantly in$ uencing MREE. Body temperature, too, greatly in$ uences energy expenditure 
in infants and children, as shown from a 6-12% increase in resting energy expenditure per 
degree increment in body temperature.22-23 Although this should be taken into account when 
calculating energy expenditure in the individual patient, it will not increase accuracy of a 
general prediction equation. In chapters 2,3 and 4 we reported a normo- or hypometabolic 
response in 70% of the children, which is in accordance with other reports in critically ill 
children.14, 16, 24 Serial energy expenditure measurements during PICU admission have shown 
a small coe#  cient of variation in measurements over one week.25 Therefore, the parameter 
“number of days after intensive care admission” is another questionable parameter in the ! rst 
White equation. 
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In Chapter 3 we determined the value of indirect calorimetry combined with nitrogen 
balance in 36 mechanically ventilated children (median age 10 months (range 1 week to 
13 years) with mixed diagnoses (median PRISM score 7 (range 0 to 17)). In only 47% of the 
patients measured RQ approximated the calculated RQ of the macronutrients administered 
(RQ macr), in 22% RQ was above RQmacr, suggesting overfeeding, and in 31% RQ was below 
RQmacr, suggesting underfeeding. The ratio of caloric intake/MEE was signi! cantly higher 
in children with a positive nitrogen balance compared to those with a negative nitrogen 
balance. Thus, feeding according to or in excess of MEE can be a guideline for providing 
adequate caloric intake. In the children with a positive nitrogen balance, the caloric intake 
exceeded MEE by 40%. The optimal caloric intake in critically ill children is still being debated. 
Obviously, caloric intake should equal measured energy expenditure in the acute phase of 
disease, clinically characterized by hemodynamic and respiratory instability. The acute meta-
bolic stress period, with its increased levels of stress (catabolic) hormones, such as cortisol, 
catecholamines and glucagon, usually lasts no longer than 1 or 2 days in the critically ill 
children.26-27 After the acute catabolic phase, caloric intake should be increased to account for 
tissue repair and growth. Previous studies in mechanically ventilated children showed that 
adequate energy intake was in the range of 1.2 to 1.5 times measured energy expenditure.14, 
28-31 We have previously shown that cumulative de! cits in energy and protein intake relative 
to recommended dietary reference intakes (DRI) for healthy children resulted in a decrease 
in body weight and upper arm circumference. One could speculate, therefore, that energy 
requirements for critically ill children in the recovery phase of disease should be close to or 
even above DRI levels.32-33 We recommend to tailor the daily increase in energy intake to pre-
vent excessive carbohydrate, protein and fat intake. Carbohydrate intake can be monitored 
by daily calculations of glucose intake, serial RQ measurements and blood glucose levels. 
Protein and fat intake can be monitored by urea and triglyceride levels. Moreover, C-reactive 
protein (CRP) can be used as an indicator for anabolic restoration. The in$ ammatory response 
to infection, accidental or surgical trauma, or burn injury plays a crucial role in the catabolic 
stress response. When the underlying disease is cured, in$ ammation goes down and the 
recovery phase ensues characterized by decreasing levels of cytokines, decreased CRP and 
increasing anabolic hormonal action. In this phase, energy and dietary proteins are necessary 
to restore the protein lost in the acute phase of the disease and for (catch) up growth.34 
Although the metabolic monitor is considered the best clinical (“golden”) standard for the 
assessment of energy expenditure, there are no randomized controlled clinical trials showing 
that indirect calorimetry improves outcomes. Indirect calorimetry still has probably a greater 
role in research than in guiding daily clinical patient care. Nevertheless, we have been using 
indirect calorimetry for 15 years on our PICU. On the basis of our experiences, a review of 
the literature, and the results of our data analysis, we propose an algorithm (Figure 1) for 
performing nutritional assessment and nutritional support in clinical daily practice based 
on previous work of our group35 and ESPGHAN guidelines on parenteral nutrition 2006.36-37 
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HYPERGLYCEMIA IN CRITICALLY ILL CHILDREN
Hyperglycemia occurring during critical illness results from a stress response modulated by 
the hypothalamic-pituitary-adrenal axis, the autonomic nervous system and cytokines. In 
critically ill children, the hyperglycemic response to stress is complex and not well clari! ed. 
Various factors play an important role in this process. For example, the presence of excessive 
counter-regulatory hormones (glucagon, growth hormone, catecholamines, cortisol) and cy-
tokines (IL-1, IL-6, and TNF-α); exogenous administration of catecholamines, glucocorticoids, 
dextrose; and the nature of nutritional support together with relative insulin de! ciency.38 In 
part II of this thesis we tried to obtain a better insight into pathophysiological mechanisms 
leading to hyperglycemia. 
Meningococcal sepsis and septic shock
The study presented in Chapter 5 describes pathophysiological aspects of the occurrence 
of hyperglycemia in 78 children with meningococcal sepsis and septic shock (median age 
3.5 years (range 0.1 to 16.1 years), median PRISM score 20 (range 4 to 43)). The objective of 
this study was to investigate the occurrence of hyperglycemia in relation with the insulin 
response and exogenous factors, such as glucose intake and drug use, in particular gluco-
corticoids, vasopressors and inotropes. Insulin sensitivity and β-cell function on admission 
were investigated by relating blood glucose levels to insulin levels and C-peptide levels and 
homeostasis model assessment (HOMA). One third of the children proved hyperglycemic 
(glucose level >8.3 mmol/L) on admission. For the majority of children spontaneous normal-
ization of blood glucose levels occurred within 48 hours, without insulin treatment. Insulin 
resistance was predominant in hyperglycemic children, although β-cell insu#  ciency or a 
combination of insulin resistance and β-cell insu#  ciency were also seen. Insulin resistance 
is the main pathophysiological mechanism of hyperglycemia in critically ill patients. It may 
be caused by high levels of counter-regulatory hormones and cytokines, and by therapeutic 
interventions. Regarding therapeutic interventions, we found a trend towards higher cortisol 
and glucose levels in the glucocorticoid treated children versus those without glucocorti-
coids. The administration of glucocorticoids is often indispensable in children with refractory 
shock and/or hypoglycemia. On the other hand, it may induce hyperglycemia, which will 
sustain with prolonged glucocorticoid use. The glucose administration rate did not have a 
signi! cant e" ect on the occurrence of hyperglycemia. Presumably glucose intake was too 
low (4 mg/kg/min in hyperglycemic children (range 0.2 to 10.4 mg/kg/min) to demonstrate 
the e" ect on glucose levels. In critically ill adults a glucose infusion rate >5mg/kg/min was 
associated with hyperglycemia and in critically ill children an association was seen between 
increased RQ (>1.0) and a glucose infusion rate of >8 mg/kg/min. Thus, although early admin-
istration of adequate amounts of carbohydrates in the acute phase of illness is necessary to 
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prevent hypoglycemia, excessive carbohydrate administration may result in hyperglycemia 
and concomitant adverse e" ects.
Other research groups have reported reported low insulin/glucose ratios in children with 
meningococcal septic shock,39 and low C-peptide levels in hyperglycemic critically ill children 
with respiratory and circulatory failure.40
In accordance with our ! ndings, they suggested that pancreatic β-cell dysfunction may be 
a cause of hyperglycemia. This complex phenomenon has been seldom evaluated in critical 
illness. Even in diabetes mellitus the pathophysiological mechanisms of the development of 
β-cell dysfunction are not fully understood. In vitro studies have shown that proin$ ammatory 
                                                 On admission (day 1)!
                                                  After admission 
* Glucose >8 mmol/l    !     glucose algorithm (go to Figure 3) 
Anthropometry 
! Weight (SDS) 
! Length (SDS) 
! MUAC/CC 
! Head circumference (SDS,<1yr)  
Laboratory parameters 
! Glucose* 
! CRP 
! Micronutrients (Mg, Ca, P) 
! Tg 
! (Insulin if BG>8 mmol/l (Future?)) 
Anthropometry 
! Weight -2x/ week 
! Length -1x/week (<1yr) 
! Head cf -1x/week (<1yr) 
! MUAC/CC -weekly 
 
 
Energy expenditure 
 
MREE: Indirect calorimetry  ASAP after admission and 2x/wk    
     (to adjust intake based on RQ)  
 
PREE: Schofield formula If indirect calorimetry not possible 
  
0-3 year 
0,2 x W + 1516,7 x L -  681,8 (!) 
16,3 x W + 1022,7 x L " 413,3 (#) 
3-10 year 
19,6 x W + 130,2 x L + 414,7 (!) 
17,0 x W + 161,7 x L + 371,0 (#) 
10-18 year 
16,2 x W + 137,1 x L + 515,3 (!) 
8,4 x W + 465,4 x L + 200,0 (#) 
Laboratory parameters 
! Glucose*   
! CRP 
! TG                          - daily  
! Urea  
! Micronutrients   
! N-balance  -on indication 
Figure 1a
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Energy requirements 
 
 Daily adjustment of intake  
Day 1  Glucose intake $%&'()%%*-6 mg/kg/min 
> 30kg  2-4 mg/kg/min 
Day 2-3 Start enteral feeding or                                                  
parenteral feeding if enteral feeding not possible 
Energy intake according to MREE or PREE 
Day 3-6 Increase energy intake to 2 x MREE or 2 x PREE         
or RDA (33) 
! Daily caloric intake calculations  
 
! Carbohydrate  
Enteral   60% of total energy intake 
Parenteral   10-18 g/kg/day  
 Indirect calorimetry 
 RQ >1.0   !    decrease carbohydrate or energy intake
 RQ <0.85 !    consider increasing energy intake 
 Blood glucose >8 mmol/l !  glucose algorithm (figure 2) 
 
! Protein  
 Enteral and parenteral 9-15% of total energy intake 
     1.5-4.0 g/kg/day 
 
! Fat  
Enteral   40% of total energy intake 
 
Parenteral 
 infants   3-4 g/kg/day                                   
older children  2-3 g/kg/day  
  
Weekly evaluation of growth  
 Minimal growth targets: 
 - 100-200 g/week for infants (keep up growth chart) 
 - no weight loss in older children 
Figure 1b
Figure 1. Proposed standard of nutritional assessment (1a) and nutritional support (1b) for critically ill children admitted to the PICU with an 
expected stay of more than24 hours.
ASAP, as soon as possible; BG, blood glucose level; CC, calf circumference; CRP, C-reactive protein; MREE, measured resting energy expenditure; 
MUAC, mid upper arm circumference; N-balance, nitrogen balance; PREE, predicted resting energy expenditure; RQ, respiratory quotient; SDS, 
standard deviation score; W, weight in kg; L, length in meters; RDA, recommended daily allowances (optimal requirement for healthy children 
allowing for energy needed for growth and recovery)
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cytokines (e.g. IL-1 and TNF-α) mediate inhibition of insulin secretion by pancreatic β-cells.41-42 
Furthermore, β-cells were found exquisitely sensitive to rapid physiological changes and may 
be at risk of becoming dysfunctional if these changes acutely occur above a certain thresh-
old, like in the ebb phase of the metabolic stress response.40 These changes may be induced 
by multiple factors like hypothermia, vasopressors, elevations of pro-in$ ammatory cytokines 
and use of glucocorticoids.40, 43 Also β-cell exhaustion is a reported phenomenon in critically 
ill adults with multi-organ dysfunction syndrome, characterized by increasing secretion up to 
a certain level and thereafter failing in response to further demand.44-45 
In general, we con! rmed the short duration of the acute metabolic stress response. 
Temporarily increased on admission, pro-in$ ammatory cytokines and cortisol levels, both 
decreased rapidly after the ! rst day of illness.26 This early resolution of the acute stress 
response, might also have in$ uenced the insulin resistant state and would explain the low 
indices hyperglycemia after 48 hours in the children studied. Hyperglycemia may persist for 
days or weeks in critically ill adults. 
Cardiac surgery for congenital heart disease
Since dysregulation of glucose homeostasis is common in children undergoing cardiac sur-
ger,46-50 we chose this patient group for further research on the pathophysiological aspects of 
hyperglycemia. In Chapter 6 we evaluated the time course of peri-operative blood glucose 
levels in 49 children undergoing cardiac surgery for congenital heart disease (median age 1.7 
years (range 2 months -18 years, median PRISM 13 score (range 5-31)). 
Hyperglycemia was present in 52% of the children at the end of surgery associated with 
normal or (relatively) decreased insulin/glucose ratio in almost all of them. In contrast, adults 
often show postoperative hyperglycemia due to an increase in insulin resistance induced by 
surgical trauma.51 
Moreover, spontaneous normalization of blood glucose occurred in almost all (94%) of 
children within 24 hours, without the use of insulin and without signi! cantly longer duration 
of ventilation, ICU or hospital stay. This was in line with one other study on glycemic pro! le 
in infants after the arterial switch operation.49 Others reported a more gradual decrease in 
blood glucose levels over 3-5 days following comparable cardiac surgery for congenital heart 
defects.46, 48, 50
We showed that the administration of glucocorticoids (in 65% of the children) during 
surgery was the main factor associated with hyperglycemia at the end of surgery. This was in 
accordance with ! ndings in adults after coronary bypass surgery,52 showing a considerable 
hyperglycemic e" ect associated with the administration of dexamethasone. Glucocorticoids 
inhibit the in$ ammatory response induced by cardiopulmonary bypass and may thus ame-
liorate its adverse e" ects. The use of glucocorticoids in cardiac surgery is controversial for its 
risk of important adverse e" ects that may occur.53 Since postoperative morbidity in our study 
was low, we concluded that the presumed positive e" ects of glucocorticoids seemed to have 
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outweighed the adverse e" ects of iatrogenic hyperglycemia. Future research should focus on 
the value of glucocorticoid therapy during pediatric cardiac surgery to weigh both the pros 
and cons of either hyperglycemia and glucocorticoid therapy, preferably in large randomized 
controlled trials .
In general, three major conclusions can be drawn from both studies on glucose homeostasis:
a) Hyperglycemia is a frequent, but spontaneously normalizes in the majority of children 
with meningococcal sepsis or septic shock and children after cardiac surgery for congeni-
tal heart defects. 
b) Both insulin resistance and (relative) β-cell dysfunction play a role in the occurrence of 
hyperglycemia in critically ill children.
c) Exogenous factors such as glucose intake and glucocorticoid administration signi! cantly 
in$ uence blood glucose levels. 
These conclusions raise some important questions: 
• Does insulin therapy have an additional positive e" ect on outcome in these diagnostic 
categories, considering that hyperglycemia normalizes spontaneously within 24-48 
hours? 
• Is the presence of a hypo-or hyperinsulinemic response helpful in assessing dose or dura-
tion of insulin therapy? 
• Is it possible to predict which children or patient groups with hyperglycemia could bene! t 
from insulin therapy or not?
To answer these questions, we performed a study to explore the relationship between insulin 
response to hyperglycemia and clinical outcome in critically ill hyperglycemic children. This 
study is presented in Part III, chapter 7. 
Methodological considerations 
A limitation of the studies presented in chapter 5 and 6 was the inability to assess the exact 
insulin sensitivity, because it was measured indirectly by insulin/glucose ratio and HOMA. 
The hyperinsulinemic euglycemic clamp technique is the “golden standard” for quantify-
ing insulin sensitivity in vivo because it directly measures the e" ects of insulin to promote 
glucose utilization under steady state conditions. We resorted to indirect methods, because 
the clamp technique is not very practical in clinical settings and not easily and safely imple-
mented in large studies with critically ill children. Therefore, as also previously described by 
others, we used levels of insulin and/or C-peptide and HOMA in relation with blood glucose 
levels and glucose intake rates to determine insulin sensitivity and β-cell function.39-40 54-56 
There is a good correlation between estimates of insulin resistance derived from HOMA and 
from the hyperinsulinemic clamp.57 β-cell function assessment is more di#  cult because the 
β-cell response to the secretory stimuli is complex and there is no gold standard.57 Fasting 
levels of insulin or C-peptide are the most reliable parameters (both for HOMA and insulin/
glucose or C-peptide/glucose ratios) for comparison between individuals and between 
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study populations. However, in critically ill patients it is rather di#  cult to achieve a fasting 
state. For one, gastric emptying is delayed, and glucose absorption will therefore continue 
for several hours after last feed.58 Second, as glucose is necessary to cover energy require-
ments of organs and tissues, exclusively dependent on glucose, such as the brain, glucose 
administration should not be stopped. Another justi! cation for the use of non-fasting insulin, 
C-peptide and glucose levels is based on the ! nding that exogenous glucose administration 
diminishes endogenous glucose production. The endogenous glucose production declines 
with increasing rate of intravenous glucose until it is almost completely suppressed.59 This 
was also seen in children after craniofacial surgery (unpublished data of our own). Assuming 
that the endogenous insulin secretion response is similar to endogenous and exogenous 
glucose, this suggests that the insulin/glucose ratio and HOMA are independent of glucose 
infusion rate. However, these issues seem to be more complicated, as others have shown 
that administration of glucose, even in larger amounts, to critically ill adults, failed to sup-
press endogenous glucose production.60 There are no data concerning endogenous glucose 
production in relation with the amount of administered glucose in critically ill children. 
In conclusion, HOMA, insulin/glucose ratio and C-peptide/glucose are useful markers of 
insulin sensitivity and/or β-cell function, also in critical illness, 54-55, 57, 61 but taking into account 
the following limitations:
• Reaching a fasting state is often not possible in clinical practice; in this case a continuous 
IV or enteral glucose infusion should be given to reach steady state glucose and insulin 
levels.
• Results need to be interpreted in relation with glucose intake and paired blood glucose 
level.
• Normal fasting values have not been validated for critically ill children. Quantifying the 
precise level of insulin sensitivity in individual critically ill patients is advised against, 
therefore. Only the presence or absence of insulin resistance should be established. 
GLYCEMIC CONTROL IN CRITICALLY ILL CHILDREN
As stated in the introduction to this thesis, treatment of hyperglycemia in critically ill adults 
has become standard of care.62 Nevertheless, strict glycemic control in PICUs remains con-
troversial because outcome data are lacking. Indeed, even in adult care it is not clear which 
patients should be treated with strict glycemic control. Furthermore, the major adverse e" ect 
of glucose control in adults and children is hypoglycemia, which may be more deleterious in 
the pediatric population, as sustained low blood glucose may impact brain development. 
In chapter 7 the relationship is presented between insulin response to hyperglycemia and 
clinical outcome in critically ill hyperglycemic children treated with insulin. We hypothesized 
that the presence of a hypo-or hyperinsulinemic response could be helpful in predicting 
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which children or patient groups with hyperglycemia could bene! t from insulin therapy. 
Sixty-four children with hyperglycemia meeting the criteria for insulin treatment (discussed 
in chapter 8) were included (median age 7.0 years (range 2 weeks to 17 years), median PRISM 
score 14 (range 0 to 36), mixed diagnoses). Blood samples for stress hormonal, metabolic and 
immunological parameters were drawn just before start of insulin infusion. We found that 
children with a hyperinsulinemic response were more often mechanically ventilated, had a 
longer duration of insulin therapy, mechanical ventilation and PICU stay than children with 
a hypoinsulinemic response. Duration of glucocorticoid use was strongly correlated with 
duration of insulin therapy, which might re$ ect the depressing e" ect of glucocorticoids on 
insulin sensitivity. 
On the other hand, a hypoinsulinemic response in combination with a short duration of 
insulin therapy was present in over three quarters (78%) of the children without respira-
tory failure. Therefore, the value of insulin therapy in these children is questionable. Their 
hyperglycemia would probably also have normalized within a day without insulin therapy 
and without negative e" ects on morbidity. This suggests that critically ill children without 
respiratory failure and without overt insulin “resistance” would not bene! t much from insulin 
therapy. Likely, these children might be at risk of hypoglycemia when treated with insulin. A 
randomized controlled trial in critically ill children with hyperglycemia should be performed 
to prove our hypothesis that the presence of a hypo- or hyperinsulinemic response can 
predict dose and duration of insulin therapy. With the rapid and highly sensitive immuno-
radiometric assay for insulin, the insulin/glucose ratio or HOMA could be suitable for use in 
clinical practice.63 
The glucose control protocol
Awaiting the results of randomized controlled trials to assess outcome in hyperglycemic 
children treated with insulin, we were one of the ! rst to develop a glucose control protocol 
for the treatment of hyperglycemia in critically ill children. In chapter 8 we describe our 
experiences with the implementation of this protocol on our PICU (! gure 2. Algorithm A). We 
included 50 critically ill hyperglycemic children (median age 3.5 years (range 1 month to 15 
years), median PRISM score 12 (range 8 to 22), mixed diagnoses). It appeared that the step-
wise nurse-driven protocol enabled to achieve normoglycemia (target glucose 4-8 mmol/L) 
within 12 hours after initiation of insulin therapy in 94% of the children. Although there were 
many protocol violations, these were mostly of minor importance and severe hypoglycemia 
<2.2 mmol/L did not occur. Three quarters of the children were treated with insulin for <3 
days. The question is whether these children will bene! t from insulin therapy, as the Leuven 
group reported a reduction in mortality only in a subgroup of medical adult patients who 
stayed and were treated with insulin in ICU for > 3days.64 
Since our publication, other authors have reported on their experiences with other proto-
cols for critically ill children.47, 65-69 The main features of the current protocols are summarized 
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in Table 1. There are some notable di" erences between the protocolized approaches to 
control hyperglycemia that need to be discussed (chapters 9 and 10). First, di" erent target 
ranges for plasma glucose levels are being used. Most obvious is the lowest minimal target 
level of 2.8 mmol/L accepted for children of 0-1 yr by Vlasselaers et al.65 Second, none of the 
authors de! ned glucose intake ranges, whereas we advocate to start with a standard glucose 
regimen: 4-6 mg/kg/min in children <30 kg; : 2-4 mg/kg/min in children >30 kg. Third, our 
protocol and the recently published Pediatric Yale Insulin Infusion Protocol (PYIIP)67 are the 
only ones to start with a moderate insulin infusion rate depending on the exact glucose 
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Figure 2. Algorithm A 
Glucose control protocol for infants and children (1 mo- 18 years) 
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level, whereas the other protocols use one or two starting doses, which are considerably 
higher than ours. Fourth, we have de! ned strict stopping criteria in contrast with the other 
protocols. It should be further investigated whether one or more of the above issues are 
associated with early achievement of normoglycemia, the presence of hypoglycemia and 
most importantly bene! cial outcome. Mean time until target blood glucose level was 5 hours 
with both our and Preissig’s approach47 and 10 hrs with PYIIP.67 
The high hypoglycemia rate ( blood glucose ≤ 2.2 mmol/L) of 25%, as described by Vlas-
selaers et al. and Jeschke et al. raises concerns.65, 69 Hypoglycemia rate in the PYIIP67 was 10%, 
which was still higher than with our approach. Analysis of 7195 blood samples of 323 children 
in our population showed hypoglycemia in only 0.3% of the samples, corresponding with 
4% of the children, as on Preissig’s approach.47 In randomized controlled trials investigating 
clinical e" ects of glycemic control in adults the occurrence of hypoglycemia varied between 
5 and 19%.70 Risk factors for hypoglycemia in critically ill patients include a previous diagnosis 
of diabetes mellitus, sepsis, shock, liver failure, the need for renal replacement therapy and 
decrease of nutrition without adjustment for insulin infusion.71-72 Hyperglycemic children 
with a hypoinsulinemic response are probably at increased risk of hypoglycemia during insu-
lin therapy compared to children with insulin resistance. Moreover, hypoglycemia symptoms 
in PICU patients may go unnoticed as they are nonspeci! c and may be obscured by sedation 
and neuromuscular blockade.
Concerning glycemic control with insulin therapy, two speci! c patient groups have to be 
taken into account: neonates below 28 days of age and children after traumatic brain injury. 
Since neonates and infants are at increased risk for hypoglycemia because of less mature 
regulatory capacities in glucose and insulin metabolism, we have evaluated our glucose 
protocol speci! cally in this young population. Although our protocol was equally e" ective 
in young infants and in older children, hypoglycemia occurred more frequently in infants 
(7%). Therefore we have adjusted some parts of the protocol for critically ill neonates (up to 
28 days of age), su ch that the initial insulin starting doses decreased by 10 mIU/kg/hour and 
the minimum insulin dose as stop criteria decreased to insulin rate <5 mIU/kg/kg/hour at any 
time, or <20 mIU/kg/hour during 24 hours (Figure 2. Algorithm B). 
The brain is an obligate glucose consumer that depends almost entirely on the availability 
of systemic glucose to maintain normal energy metabolism. Children with severe acute brain 
disease may have increased susceptibility to both hyper- and hypoglycemia. After acute 
brain injury, hyperglycemia (blood glucose >11 mmol/L) exacerbates secondary brain injury 
and independently predicts poor neurological outcome in adults and children.73-74 Control 
of blood glucose is therefore recommended for the treatment of brain-injured patients, al-
though its pathophysiology remains unclear. It is not known whether this association is due 
to direct detrimental e" ects of hyperglycemia or represents a marker of severe brain injury. 
On the other hand, brain metabolism is highly dependent on constant supply of glucose. As 
a consequence, the acutely injured brain is particularly sensitive to hypoglycemia, which can 
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induce a state of energy failure (metabolic crisis). Experimental studies (in cats) have shown 
that insulin-induced reduction of systemic glucose below 6-8 mmol/L closely correlated with 
a decrease in brain glucose levels and a concomitant increase of cerebral lactate, together 
with a signi! cant elevation of peri-ischemic cortical depolarizations. These ! ndings suggest 
that the use of intensive insulin therapy might carry a risk of relative “neuroglucopenia”, 
which in turn might lead to energy dysfunction and thus may further contribute to exacer-
bating secondary brain injury.75 There is clearly a lower limit of systemic glucose below which 
the availability of substrate might become harmful in the setting of severe brain injury. This 
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Figure 2. Algorithm B
Glucose control protocol for neonates (0-28 days) 
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was con! rmed in patients with TBI treated with intensive insulin therapy whose outcome 
tended to be worse than for those treated with conventional insulin therapy.76 The amount of 
cerebral damage due to hypoglycemia is likely to be both dose and time dependent, and hy-
poglycemia should, therefore, be treated promptly. Plasma glucose levels above 11 mmol/L 
are widely accepted to be harmful in patients with traumatic brain injury, but the optimal 
range for systemic glucose control has not yet been clearly established. Since the prevalence 
of severe traumatic brain injury has decreased, it is di#  cult to perform prospective trials with 
enough power to evaluate the precise impact of intensive insulin therapy on brain glucose 
metabolism and outcome. Awaiting the results of such trials, we recommend a cautious use 
of insulin therapy aiming at a more liberal target for systemic glucose control (6-10 mmol/L) 
in brain-injured children. 
In summary, although various experts and regulatory agencies have called for tight gly-
cemic control in critically ill adults. The supporting data remain somewhat incomplete and 
con$ icting, however. So far one randomized controlled trial of glycemic control in pediatric 
intensive care patients has shown improved short-term outcome, in terms of shorter PICU 
stay, and less mortality in infants and children treated with intensive insulin therapy targeting 
blood glucose levels to age-adjusted normal fasting concentrations.65 A second randomized 
controlled trial, in a selected group of severely burned children, showed lower incidences of 
infection and sepsis with the use of glycemic control.69
The survival bene! t of tight glycemic control in critically ill children is unknown, because 
of lack of large randomized controlled studies in critically ill children with various diagnoses. 
There are two multicenter trials currently addressing this issue. The CHiP (Control of Hyper-
glycemia in Pediatric Intensive Care) Trial66 in the United Kingdom is enrolling children on 
mechanical ventilation and vasoactive agent infusion (ISRCTN61735247, EudraCT 2006-
005715-10); the SPECS (Safe Pediatric Euglycemia in Cardiac Surgery) Trial in the United 
States is randomizing children undergoing cardiopulmonary bypass for cardiac surgery 
(ClinicalTrials.gov.Id:NCT00443599). Awaiting the results of these and hopefully other studies 
we recommend to apply the algorithm depicted in Figure 3.
RECOMMENDATIONS FOR FUTURE RESEARCH
Research on hyperglycemia in critically ill children should focus on pathophysiological 
mechanisms. By de! ning laboratory parameters (e.g. HOMA, insulin/glucose ratio, cytokine 
and/or CRP response) or clinical factors (e.g. diagnostic category, age and/or glucocorticoid 
or catecholamine use), that independently determine insulin requirements, it will be pos-
sible to develop equations that will predict which hyperglycemic children would bene! t from 
insulin therapy and which would not. 
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Future studies are needed to validate HOMA, insulin/glucose ratio and C-peptide/glucose 
ratio in comparison with the hyperinsulinemic euglycemic clamp technique in critically ill 
children. A simple manner would be to determine levels of insulin, C-peptide and glucose just 
before start of clamping. Moreover, serial measurements should be performed to evaluate re-
liability of paired blood samples at certain time points. Moreover, future studies may employ 
other methods or a combination of methods to more directly assess insulin sensitivity, such 
as hyperinsulinemic euglycemic clamping techniques. The ratio of insulin to glucagon may 
have additional value in studies on hormonal response to hyperglycemia. Glucagon is the 
primary hormonal stimulator of hepatic gluconeogenesis, which is resistant to the inhibitory 
e" ect of physiological concentrations of insulin during critical illness.77
To de! ne the optimal glucose intake in critically ill children of all ages and with various di-
agnoses, endogenous glucose kinetics should be quali! ed with stable isotope assays. In ad-
dition, energy expenditure and substrate use should be determined by indirect calorimetry. 
This will lead to a better understanding of the causes of hyperglycemia in critically ill children 
and will help to develop new guidelines on parenteral and enteral glucose intake. 
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Figure 3. Algorithm for hyperglycemia >8 mmol/L 
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Research on the e" ectiveness of insulin therapy for critically ill hyperglycemic children 
should focus on children receiving respiratory and/or cardiovascular support. Moreover, 
e" ectiveness and safety should be evaluated for surgical versus non-surgical children, 
speci! c diagnostic categories and for di" erent ages. Outcomes to be assessed are the inci-
dence of nosocomial infections, duration of PICU stay, duration of hospital stay, duration of 
endotracheal intubation, mortality, cardiac function, immune function, endocrine function, 
nutritional status, and neurodevelopmental evaluation with longitudinal follow-up. 
Study the usefulness of techniques for continuous glucose measurements. The currently 
available main techniques to measure subcutaneous glucose concentration are the micro-
dialysis technique and the platinum electrode. The advantage of a platinum electrode over 
a microdialysis system, is that it is much smaller and therefore more practical for use in neo-
nates and infants. Moreover, results are probably less in$ uenced by the local in$ ammatory 
reaction that is caused by the subcutaneous insertion of the probe.78 79-85
Hormonal treatment of hyperglycemia could be of interest. Glucagon-like peptide-1 (GLP-1) 
has recently been introduced in diabetic literature.86-87 In adults with type 1 and 2 diabetes, 
GLP-1 works as an adjunctive agent as a result of stimulation of insulin secretion, suppression 
of glucagon secretion and slowing of gastric emptying. Because the e" ects on insulin and 
glucagon are glucose-dependent, the use of GLP-1 does not appear to increase the risk of 
hypoglycemia. GLP-1 reduced the amount of exogenous insulin to control plasma glucose 
levels in 24 severely burned pediatric patients.88 Thus, GLP-1 potentially represents a novel 
agent to attenuate hyperglycemia in critically ill children. 
FINAL REMARKS
Nutritional support of critically ill children is of major importance. In this thesis energy re-
quirements of critically ill children in the acute phase of disease were assessed with resultant 
practical recommendations for clinical use. Furthermore we elaborated on the causes and 
consequences of hyperglycemia. Emphasis should be on measures preventing hyperglyce-
mia. A number of algorithms for daily clinical practice were developed (Figure 1,2,3), which 
should be implemented and can be considered as standard of care. In this way an optimal 
glucose supply (for important organs like the brain) can be guaranteed and the chances of 
complete recovery and normal functioning of the critically ill child can be increased. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
175
CH
AP
TE
R 1
0
Synthesis and Discussion
REFERENCES
 1. Chwals WJ. Overfeeding the critically ill child: fact or fantasy? New Horiz. 1994 May;2(2):147-55.
 2. Vo NM, Waycaster M, Acu"  RV, Lefemine AA. E" ects of postoperative carbohydrate overfeeding. 
Am Surg. 1987 Nov;53(11):632-5.
 3. Hulst JM, van Goudoever JB, Zimmermann LJ, Hop WC, Buller HA, Tibboel D, et al. Adequate 
feeding and the usefulness of the respiratory quotient in critically ill children. Nutrition. 2005 
Feb;21(2):192-8.
 4. Mehta NM, Duggan CP. Nutritional de! ciencies during critical illness. Pediatr Clin North Am. 2009 
Oct;56(5):1143-60.
 5. Cameron JW, Rosenthal A, Olson AD. Malnutrition in hospitalized children with congenital heart 
disease. Arch Pediatr Adolesc Med. 1995 Oct;149(10):1098-102.
 6. Hart DW, Wolf SE, Mlcak R, Chinkes DL, Ramzy PI, Obeng MK, et al. Persistence of muscle catabo-
lism after severe burn. Surgery. 2000 Aug;128(2):312-9.
 7. Suman OE, Mlcak RP, Chinkes DL, Herndon DN. Resting energy expenditure in severely burned 
children: analysis of agreement between indirect calorimetry and prediction equations using the 
Bland-Altman method. Burns. 2006 May;32(3):335-42.
 8. Hendricks KM, Duggan C, Gallagher L, Carlin AC, Richardson DS, Collier SB, et al. Malnutri-
tion in hospitalized pediatric patients. Current prevalence. Arch Pediatr Adolesc Med. 1995 
Oct;149(10):1118-22.
 9. Stallings VA, Charney EB, Davies JC, Cronk CE. Nutritional status and growth of children with 
diplegic or hemiplegic cerebral palsy. Dev Med Child Neurol. 1993 Nov;35(11):997-1006.
 10. Joosten KF, Zwart H, Hop WC, Hulst JM. National malnutrition screening days in hospitalised 
children in The Netherlands. Arch Dis Child. 2010 Feb;95(2):141-5.
 11. Joosten KF, Hulst JM. Malnutrition in pediatric hospital patients: Current issues. Nutrition. 2010 
Aug 12.
 12. White MS, Shepherd RW, McEniery JA. Energy expenditure in 100 ventilated, critically ill children: 
improving the accuracy of predictive equations. Crit Care Med. 2000 Jul;28(7):2307-12.
 13. Chwals WJ, Bistrian BR. Predicted energy expenditure in critically ill children: problems associated 
with increased variability. Crit Care Med. 2000 Jul;28(7):2655-6.
 14. Briassoulis G, Venkataraman S, Thompson AE. Energy expenditure in critically ill children. Crit Care 
Med. 2000 Apr;28(4):1166-72.
 15. Turi RA, Petros AJ, Eaton S, Fasoli L, Powis M, Basu R, et al. Energy metabolism of infants and chil-
dren with systemic in$ ammatory response syndrome and sepsis. Ann Surg. 2001 Apr;233(4):581-7.
 16. Vazquez Martinez JL, Martinez-Romillo PD, Diez Sebastian J, Ruza Tarrio F. Predicted versus mea-
sured energy expenditure by continuous, online indirect calorimetry in ventilated, critically ill 
children during the early postinjury period. Pediatr Crit Care Med. 2004 Jan;5(1):19-27.
 17. De Wit B, Meyer R, Desai A, Macrae D, Pathan N. Challenge of predicting resting energy expen-
diture in children undergoing surgery for congenital heart disease. Pediatr Crit Care Med. 2010 
Jul;11(4):496-501.
 18. Havalad S, Quaid MA, Sapiega V. Energy expenditure in children with severe head injury: lack 
of agreement between measured and estimated energy expenditure. Nutr Clin Pract. 2006 
Apr;21(2):175-81.
 19. Tilden SJ, Watkins S, Tong TK, Jeevanandam M. Measured energy expenditure in pediatric inten-
sive care patients. Am J Dis Child. 1989 Apr;143(4):490-2.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
CHAPTER 10
176
 20. Liusuwan RA, Palmieri TL, Kinoshita L, Greenhalgh DG. Comparison of measured resting energy 
expenditure versus predictive equations in pediatric burn patients. J Burn Care Rehabil. 2005 
Nov-Dec;26(6):464-70.
 21. Phillips R, Ott L, Young B, Walsh J. Nutritional support and measured energy expenditure of the 
child and adolescent with head injury. J Neurosurg. 1987 Dec;67(6):846-51.
 22. Taylor RM, Cheeseman P, Preedy V, Baker AJ, Grimble G. Can energy expenditure be predicted in 
critically ill children? Pediatr Crit Care Med. 2003 Apr;4(2):176-80.
 23. Joosten KF, Verhoeven JJ, Hop WC, Hazelzet JA. Indirect calorimetry in mechanically ventilated 
infants and children: accuracy of total daily energy expenditure with 2 hour measurements. Clin 
Nutr. 1999 Jun;18(3):149-52.
 24. Framson CM, LeLeiko NS, Dallal GE, Roubeno"  R, Snelling LK, Dwyer JT. Energy expenditure in 
critically ill children. Pediatr Crit Care Med. 2007 May;8(3):264-7.
 25. Oosterveld MJ, Van Der Kuip M, De Meer K, De Greef HJ, Gemke RJ. Energy expenditure and 
balance following pediatric intensive care unit admission: a longitudinal study of critically ill 
children. Pediatr Crit Care Med. 2006 Mar;7(2):147-53.
 26. Joosten KF, de Kleijn ED, Westerterp M, de Hoog M, Eijck FC, Hop WCJ, et al. Endocrine and meta-
bolic responses in children with meningococcal sepsis: striking di" erences between survivors 
and nonsurvivors. J Clin Endocrinol Metab. 2000 Oct;85(10):3746-53.
 27. de Groof F, Joosten KF, Janssen JA, de Kleijn ED, Hazelzet JA, Hop WC, et al. Acute stress response 
in children with meningococcal sepsis: important di" erences in the growth hormone/insulin-
like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab. 2002 
Jul;87(7):3118-24.
 28. de Klerk G, Hop WC, de Hoog M, Joosten KF. Serial measurements of energy expenditure in critically 
ill children: useful in optimizing nutritional therapy? Intensive Care Med. 2002 Dec;28(12):1781-5.
 29. Pollack MM, Cuerdon TC, Getson PR. Pediatric intensive care units: results of a national survey. Crit 
Care Med. 1993 Apr;21(4):607-14.
 30. Goran MI, Peters EJ, Herndon DN, Wolfe RR. Total energy expenditure in burned children using the 
doubly labeled water technique. Am J Physiol. 1990 Oct;259(4 Pt 1):E576-85.
 31. van der Kuip M, de Meer K, Westerterp KR, Gemke RJ. Physical activity as a determinant of total 
energy expenditure in critically ill children. Clin Nutr. 2007 Dec;26(6):744-51.
 32. Hulst JM, van Goudoever JB, Zimmermann LJ, Hop WC, Albers MJ, Tibboel D, et al. The e" ect 
of cumulative energy and protein de! ciency on anthropometric parameters in a pediatric ICU 
population. Clin Nutr. 2004 Dec;23(6):1381-9.
 33. Health Council of the Netherlands. Dietary Reference Intakes: energy, proteins, fats and digestible 
carbohydrates. The Hague: Health Council of the Netherlands, 2001; publication no. 2001/19.
 34. van Waardenburg DA, de Betue CT, Luiking YC, Engel M, Deutz NE. Plasma arginine and citrulline 
concentrations in critically ill children: strong relation with in$ ammation. Am J Clin Nutr. 2007 
Nov;86(5):1438-44.
 35. Ista E, Joosten K. Nutritional assessment and enteral support of critically ill children. Crit Care Nurs 
Clin North Am. 2005 Dec;17(4):385-93, x.
 36. Koletzko B, Goulet O, Hunt J, Krohn K, Shamir R. 1. Guidelines on Paediatric Parenteral Nutrition of 
the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and 
the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European 
Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr. 2005 Nov;41 Suppl 2:S1-87.
 37. Hulst JM. Nutritional assessment of critically ill children, the search for practical tools [disserta-
tion]. Rotterdam: Erasmus University Rotterdam; 2004.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
177
CH
AP
TE
R 1
0
Synthesis and Discussion
 38. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive 
Care Med. 2004 May;30(5):748-56.
 39. van Waardenburg DA, Jansen TC, Vos GD, Buurman WA. Hyperglycemia in children with menin-
gococcal sepsis and septic shock: the relation between plasma levels of insulin and in$ ammatory 
mediators. J Clin Endocrinol Metab. 2006 Oct;91(10):3916-21.
 40. Preissig CM, Rigby MR. Hyperglycaemia results from beta-cell dysfunction in critically ill chil-
dren with respiratory and cardiovascular failure: a prospective observational study. Crit Care. 
2009;13(1):R27.
 41. Mehta VK, Hao W, Brooks-Worrell BM, Palmer JP. Low-dose interleukin 1 and tumor necrosis factor 
individually stimulate insulin release but in combination cause suppression. Eur J Endocrinol. 
1994 Feb;130(2):208-14.
 42. Hughes JH, Colca JR, Easom RA, Turk J, McDaniel ML. Interleukin 1 inhibits insulin secretion from 
isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation. 
J Clin Invest. 1990 Sep;86(3):856-63.
 43. Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest. 2003 
Dec;112(12):1788-90.
 44. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and 
insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol 
Med. 2009 Aug;1(5):280-7.
 45. Steil GM, Agus MS. Critical illness hyperglycemia: is failure of the beta-cell to meet extreme insulin 
demand indicative of dysfunction? Crit Care. 2009;13(2):129.
 46. Falcao G, Ulate K, Kouzekanani K, Bielefeld MR, Morales JM, Rotta AT. Impact of postoperative 
hyperglycemia following surgical repair of congenital cardiac defects. Pediatr Cardiol. 2008 
May;29(3):628-36.
 47. Preissig CM, Rigby MR, Maher KO. Glycemic Control for Postoperative Pediatric Cardiac Patients. 
Pediatr Cardiol. 2009 Aug 25.
 48. Polito A, Thiagarajan RR, Laussen PC, Gauvreau K, Agus MS, Scheurer MA, et al. Association 
between intraoperative and early postoperative glucose levels and adverse outcomes after 
complex congenital heart surgery. Circulation. 2008 Nov 25;118(22):2235-42.
 49. Rossano JW, Taylor MD, Smith EO, Fraser CD, Jr., McKenzie ED, Price JF, et al. Glycemic pro! le in 
infants who have undergone the arterial switch operation: hyperglycemia is not associated with 
adverse events. J Thorac Cardiovasc Surg. 2008 Apr;135(4):739-45.
 50. Yates AR, Dyke PC, 2nd, Taeed R, Ho" man TM, Hayes J, Feltes TF, et al. Hyperglycemia is a marker 
for poor outcome in the postoperative pediatric cardiac patient. Pediatr Crit Care Med. 2006 
Jul;7(4):351-5.
 51. Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oeveren W, et al. Dexamethasone: 
bene! t and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study 
on myocardial, pulmonary, renal, intestinal, and hepatic injury. Chest. 2005 Oct;128(4):2677-87.
 52. van der Horst IC, Nijsten MW, Vogelzang M, Zijlstra F. Persistent hyperglycemia is an independent 
predictor of outcome in acute myocardial infarction. Cardiovasc Diabetol. 2007;6:2.
 53. Chaney MA. Corticosteroids and cardiopulmonary bypass : a review of clinical investigations. 
Chest. 2002 Mar;121(3):921-31.
 54. Basi S, Pupim LB, Simmons EM, Sezer MT, Shyr Y, Freedman S, et al. Insulin resistance in critically ill 
patients with acute renal failure. Am J Physiol Renal Physiol. 2005 Aug;289(2):F259-64.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
CHAPTER 10
178
 55. Saberi F, Heyland D, Lam M, Rapson D, Jeejeebhoy K. Prevalence, incidence, and clinical resolution 
of insulin resistance in critically ill patients: an observational study. JPEN J Parenter Enteral Nutr. 
2008 May-Jun;32(3):227-35.
 56. Legro RS, Castracane VD, Kau" man RP. Detecting insulin resistance in polycystic ovary syndrome: 
purposes and pitfalls. Obstet Gynecol Surv. 2004 Feb;59(2):141-54.
 57. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 
Jun;27(6):1487-95.
 58. Chapman MJ, Fraser RJ, Matthews G, Russo A, Bellon M, Besanko LK, et al. Glucose absorption and 
gastric emptying in critical illness. Crit Care. 2009;13(4):R140.
 59. Kalhan SC, Kilic I. Carbohydrate as nutrient in the infant and child: range of acceptable intake. Eur 
J Clin Nutr. 1999 Apr;53 Suppl 1:S94-100.
 60. Seematter G, Tappy L. E" ect of nutritional support on glucose control. Curr Opin Clin Nutr Metab 
Care. 2007 Mar;10(2):210-4.
 61. Das S, Misra B, Roul L, Minz NT, Pattnaik M, Baig MA. Insulin resistance and beta cell function 
as prognostic indicator in multi-organ dysfunction syndrome. Metab Syndr Relat Disord. 2009 
Feb;7(1):47-51.
 62. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: 
international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 
2008 Jan;36(1):296-327.
 63. Guest PC, Lowing C, Arden SD, Gray IP, Hutton JC. A rapid, sensitive and versatile two-site im-
munoradiometric assay for insulin. Mol Cell Endocrinol. 1989 Dec;67(2-3):173-8.
 64. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive 
insulin therapy in the medical ICU. N Engl J Med. 2006 Feb 2;354(5):449-61.
 65. Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den Heuvel I, et al. Intensive 
insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled 
study. Lancet. 2009 Feb 14;373(9663):547-56.
 66. Macrae D, Pappachan J, Grieve R, Parslow R, Nadel S, Schindler M, et al. Control of hyperglycaemia 
in paediatric intensive care (CHiP): study protocol. BMC Pediatr. 2010;10:5.
 67. Faraon-Pogaceanu C, Banasiak KJ, Hirshberg EL, Faustino EV. Comparison of the e" ectiveness 
and safety of two insulin infusion protocols in the management of hyperglycemia in critically ill 
children. Pediatr Crit Care Med. 2010 Jun 10.
 68. Fram RY, Cree MG, Wolfe RR, Mlcak RP, Qian T, Chinkes DL, et al. Intensive insulin therapy improves 
insulin sensitivity and mitochondrial function in severely burned children. Crit Care Med. 2010 
Jun;38(6):1475-83.
 69. Jeschke MG, Kulp GA, Kraft R, Finnerty CC, Mlcak R, Lee JO, et al. Intensive insulin therapy in 
severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med. 
2010 Aug 1;182(3):351-9.
 70. Vriesendorp TM, DeVries JH, Hoekstra JB. Hypoglycemia and strict glycemic control in critically ill 
patients. Curr Opin Crit Care. 2008 Aug;14(4):397-402.
 71. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit 
Care Med. 2007 Oct;35(10):2262-7.
 72. Vriesendorp TM, van Santen S, DeVries JH, de Jonge E, Rosendaal FR, Schultz MJ, et al. Predispos-
ing factors for hypoglycemia in the intensive care unit. Crit Care Med. 2006 Jan;34(1):96-101.
 73. Cochran A, Scaife ER, Hansen KW, Downey EC. Hyperglycemia and outcomes from pediatric 
traumatic brain injury. J Trauma. 2003 Dec;55(6):1035-8.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
179
CH
AP
TE
R 1
0
Synthesis and Discussion
 74. Melo JR, Di Rocco F, Blanot S, Laurent-Vannier A, Reis RC, Baugnon T, et al. Acute hyperglycemia 
is a reliable outcome predictor in children with severe traumatic brain injury. Acta Neurochir 
(Wien). 2010 Sep;152(9):1559-65.
 75. Oddo M, Schmidt JM, Mayer SA, Chiolero RL. Glucose control after severe brain injury. Curr Opin 
Clin Nutr Metab Care. 2008 Mar;11(2):134-9.
 76. Vespa P, Boonyaputthikul R, McArthur DL, Miller C, Etchepare M, Bergsneider M, et al. Intensive in-
sulin therapy reduces microdialysis glucose values without altering glucose utilization or improv-
ing the lactate/pyruvate ratio after traumatic brain injury. Crit Care Med. 2006 Mar;34(3):850-6.
 77. Mizock BA. Blood glucose management during critical illness. Rev Endocr Metab Disord. 2003 
May;4(2):187-94.
 78. Schoonen AJM. De draagbare pancreas. Op weg naar een biocompatibele glucose sensor. Con-
ceptuur. 2001(29):6-8.
 79. Beardsall K, Ogilvy-Stuart AL, Ahluwalia J, Thompson M, Dunger DB. The continuous glucose moni-
toring sensor in neonatal intensive care. Archives of disease in childhood. 2005 Jul;90(4):F307-10.
 80. Corstjens AM, Ligtenberg JJ, van der Horst IC, Spanjersberg R, Lind JS, Tulleken JE, et al. Accuracy 
and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients. 
Crit Care. 2006;10(5):R135.
 81. De Block C, Manuel-y-Keenoy B, Van Gaal L, Rogiers P. Intensive insulin therapy in the intensive 
care unit - Assessment by continuous glucose monitoring. Diabetes Care 2006 Aug;29(8):1750-6.
 82. Goldberg PA, Siegel MD, Russell RR, Sherwin RS, Halickman JI, Cooper DA, et al. Experience with 
the continuous glucose monitoring system in a medical intensive care unit. Diabetes Technol 
Ther. 2004 Jun;6(3):339-47.
 83. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabetic Medicine. 2006 
Jan;23(1):1-12.
 84. Piper HG, Alexander JL, Shukla A, Pigula F, Costello JM, Laussen PC, et al. Real-time continuous 
glucose monitoring in pediatric patients during and after cardiac surgery. Pediatrics. 2006 
Sep;118(3):1176-84.
 85. Vriesendorp TM, DeVries JH, Holleman F, Dzoljic M, Hoekstra JB. The use of two continuous glu-
cose sensors during and after surgery. Diabetes Technol Ther. 2005 Apr;7(2):315-22.
 86. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 
2010 Jul;25(7):1207-17.
 87. Raman VS, Heptulla RA. New potential adjuncts to treatment of children with type 1 diabetes 
mellitus. Pediatr Res. 2009 Apr;65(4):370-4.
 88. Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, et al. The use of exenatide 
in severely burned pediatric patients. Crit Care. 2010 Aug 11;14(4):R153.
 89. Verhoeven JJ, Brand JB, van de Polder MM, Joosten KF. Management of hyperglycemia in the 
pediatric intensive care unit; implementation of a glucose control protocol. Pediatr Crit Care Med. 
2009 Nov;10(6):648-52.

Cha pter 11
Summary
Samenvatting

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
183
Summary
Su
m
m
ar
y
SUMMARY
A variety of metabolic disturbances characterize the condition of critical illness, including 
hyperglycemia, dyslipidemia and increased protein turnover. This hypercatabolic state puts 
children at risk for protein-energy malnutrition. Malnourished children have a higher risk 
of complications, resulting in longer hospital stay and increased mortality. Furthermore, 
hyperglycemia has been identi! ed as an independent risk factor for adverse outcome. The 
e#  cacy of strict glycemic control with insulin therapy has been much debated. In Chapter 1 
we describe the background and initial goals of the studies presented in this thesis. The focus 
is on energy requirements in critically ill children in the acute phase of disease in relation 
with the hyperglycemic response to stress. Furthermore we elaborate on the causes and con-
sequences of hyperglycemia against the background of ! nding optimal strategies to control 
blood glucose levels.
This thesis is built up of three parts. Part I is dedicated to energy requirements of critically ill 
children. Energy expenditure of mechanically ventilated children was measured by indirect 
calorimetry. 
In Chapter 2 we present the results of energy expenditure measurements in 50 mechani-
cally ventilated children with mixed diagnoses. There was a close correlation between the 
measured resting energy expenditure (MREE) and predicted resting energy expenditure 
(PREE) as calculated with the Scho! eld formula for weight, age and sex, but Bland-Altman 
analysis showed lack of agreement between individual MREE and PREE. We concluded that 
standard prediction equations are not appropriate to calculate energy needs and that energy 
expenditure should be measured individually. 
In Chapter 3 we determined the value of indirect calorimetry combined with nitrogen bal-
ance in 36 mechanically ventilated children. The ratio of caloric intake/MREE in children with 
a positive nitrogen balance was signi! cantly higher than that in children with a negative 
nitrogen balance. In the children with a positive nitrogen balance, the caloric intake ex-
ceeded MREE by 40%. Obviously, caloric intake should equal measured energy expenditure 
in the acute phase of disease. Then, after the acute catabolic phase, caloric intake should be 
stepped up to account for tissue repair and growth. In the recovery phase of severe disease, 
the energy intake should be close to or even above recommended dietary reference intakes 
for healthy children. We recommend daily assessment of energy intake to tailor carbohy-
drate, protein and fat intake. Excessive carbohydrate intake should be monitored by serial RQ 
measurements and blood glucose levels. Protein and fat intake should be monitored by urea 
and triglyceride levels. 
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In chapter 4 energy expenditure was measured in 94 mechanically ventilated children with 
mixed diagnoses. The Scho! eld formula for weight, height, age and sex showed the highest 
accuracy by predicting energy expenditure within 10% of the MREE in 40% of the children. 
The equations developed by White et al. for mechanically ventilated children yielded the 
lowest accuracies (16% and 19%, respectively). We have elaborated on the most plausible 
reasons why the prediction equations fail to accurately predict REE.
Part II of this thesis covers pathophysiological mechanisms leading to hyperglycemia. 
The study presented in Chapter 5 describes pathophysiological aspects of the occurrence of 
hyperglycemia in 78 children, aged 1 month to 16 years, with meningococcal sepsis and sep-
tic shock. Insulin sensitivity and ß-cell function on admission were investigated by relating 
blood glucose levels to insulin levels and C-peptide levels and by using homeostasis model 
assessment (HOMA). One third of the children proved hyperglycemic on admission (glucose 
level >8.3 mmol/L). Blood glucose levels spontaneously normalized within 48 hours in most 
of the children, without insulin treatment. In general, the acute metabolic stress response 
lasted only shortly. After admission, pro-in$ ammatory cytokines and cortisol levels went up 
temporarily and both dropped rapidly after the ! rst day of illness. The hyperglycemic chil-
dren predominantly had insulin resistance, although ß-cell insu#  ciency or a combination of 
insulin resistance and ß-cell insu#  ciency was also seen. Insulin resistance may be caused by 
high levels of counter-regulatory hormones and cytokines, and by therapeutic interventions. 
Regarding therapeutic interventions, there was a trend towards higher cortisol and glucose 
levels in the children treated with glucocorticoids versus those without glucocorticoids. The 
administration of glucocorticoids is often indispensable in children with refractory shock 
and/or hypoglycemia. On the other hand, it may induce hyperglycemia, which will sustain 
with prolonged glucocorticoid use. 
In Chapter 6 we evaluated the time course of peri-operative blood glucose levels in 49 chil-
dren, aged 2 months to 18 years, undergoing cardiac surgery for congenital heart disease. 
Hyperglycemia was present in 52% of the children at the end of surgery and associated with 
normal or (relatively) decreased insulin/glucose ratio in almost all of them. In all but three 
of the children blood glucose levels spontaneously normalized within 24 hours, without the 
use of insulin and without signi! cantly longer duration of ventilation, ICU or hospital stay. 
The administration of glucocorticoids (in 65% of the children) during surgery was the main 
factor associated with hyperglycemia at the end of surgery. Since postoperative morbidity in 
our study was low, we concluded that the positive e" ects of glucocorticoids seemed to have 
outweighed the adverse e" ects of iatrogenic hyperglycemia.
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Part III addresses the clinical use of a glucose control protocol in critically ill children. The 
main questions to be answered were the following: Which children should be treated with 
insulin therapy and how should they be treated? 
Chapter 7 explores the relationship between insulin response to hyperglycemia and clinical 
outcome in critically ill hyperglycemic children treated with insulin. Sixty-four children with 
hyperglycemia, aged 2 weeks to 18 years with mixed diagnosis and meeting the criteria for 
insulin treatment (discussed in chapter 8) were included. Blood samples for stress hormonal, 
metabolic and immunological parameters were drawn just before start of insulin infusion. A 
hyperinsulinemic response was associated with a greater likelihood of mechanical ventila-
tion, and with longer duration of insulin therapy, mechanical ventilation and PICU stay as 
compared with a hypoinsulinemic response. Duration of glucocorticoid use was strongly 
correlated with duration of insulin therapy, which might re$ ect the depressing e" ect of 
glucocorticoids on insulin sensitivity. 
On the other hand, over three quarters (78%) of the children without respiratory failure 
showed a hypoinsulinemic response in combination with a short duration of insulin therapy. 
Therefore, the value of insulin therapy in these children is questionable. Their hyperglycemia 
would probably also have normalized within a day without insulin therapy and without nega-
tive e" ects on morbidity. This suggests that critically ill children without respiratory failure 
and without overt insulin “resistance” would not bene! t much from insulin therapy. 
In chapter 8 we describe our experiences with the implementation of a glucose control 
protocol for the treatment of hyperglycemia in critically ill children on our PICU. This study 
included 50 critically ill hyperglycemic children, aged 1 month to 15 years with mixed di-
agnoses. The stepwise, nurse-driven protocol enabled to achieve normoglycemia (target 
glucose 4-8 mmol/L) within 12 hours after initiation of insulin therapy in 94% of the children. 
There were many protocol violations, but these were mostly of minor importance and severe 
hypoglycemia <2.2 mmol/L did not occur. Three quarters of the children were treated with 
insulin for shorter than 3 days. The question is whether these children will bene! t from insulin 
therapy. In chapter 9 suggestions how to minimize the risk of hypoglycemia are postulated. 
Main measures include the determination of safe target ranges for plasma glucose concen-
trations, provide adequate continuous glucose intake and the use of a detailed algorithm to 
adjust insulin therapy.   
In chapter 10 we discuss our ! ndings in the context of the literature.  
On the basis of our experiences, a review of the literature, and the results of our data 
analysis, we propose a guideline for nutritional assessment and nutritional support in clinical 
daily practice. Additionally, we designed a decision tree for the treatment of hyperglycemia 
with insulin. In general, a target range for blood glucose levels of 4 to 8 mmol/L is proposed. 
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We recommend a cautious use of insulin therapy aiming at a more liberal target for systemic 
glucose control (6-10 mmol/L) in brain-injured children. 
The main conclusions obtained from the studies described in this thesis are the following:
• Prediction equations are not appropriate to determine energy requirements for 
ventilated, critically ill children.
• Indirect calorimetry should be used to measure energy expenditure and RQ to ac-
curately assess energy needs of the individual child and to guide nutritional therapy.
• Hyperglycemia is frequent, but spontaneously normalizes within 24 hours in the 
majority of critically ill children with or without insulin therapy. 
• Exogenous factors such as glucose intake and glucocorticoid administration signi! -
cantly in$ uence blood glucose levels. 
• Both insulin resistance and (relative) !-cell dysfunction play a role in the occurrence 
of hyperglycemia in critically ill children.
• Children with a hyperinsulinemic response have a longer duration of insulin therapy, 
mechanical ventilation and PICU length of stay compared to those with a hypoinsu-
linemic response.
• The use of a nurse-driven glucose control protocol is safe and e" ective in treating 
hyperglycemia in critically ill children.
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In Nederland worden elk jaar zo’n 5000 kinderen met verschillende medische en chirurgische 
aandoeningen opgenomen op de 8 Kinder Intensive Care afdelingen. Een gedeelte van deze 
kinderen is ernstig ziek, wat betekent dat ze kunstmatig beademd worden of medicatie 
nodig hebben om vitale organen te ondersteunen. Deze kinderen hebben een verhoogde 
kans op ondervoeding. Ernstige ziekte gaat gepaard met metabole ontregelingen van de 
koolhydraat-, vet- en eiwitstofwisseling. Er ontstaat een toestand waarbij het lichaam zichzelf 
afbreekt, ook wel katabole toestand genoemd. Deze katabole toestand, samen met vermin-
derde voedselinname, -opname, -benutting of toegenomen verliezen aan voedingssto" en, 
zorgen ervoor dat deze kinderen een verhoogd risico hebben op ondervoeding. Kinderen 
zijn in vergelijking met volwassenen extra gevoelig voor het ontstaan van ondervoeding 
tijdens ziekte doordat hun reserves aan voedingssto" en in het lichaam relatief kleiner zijn. 
Ondervoede kinderen hebben meer kans op complicaties die kunnen leiden tot langere op-
name duur en verhoogde mortaliteit. Daarnaast is een te hoog glucosegehalte in het bloed 
(hyperglycemie) tijdens PICU opname, geassocieerd met een slechtere prognose. Er is veel 
discussie over het feit of deze hyperglycemie behandeld moet worden en indien er behan-
deld wordt hoe strikt dit moet gebeuren met behulp van continue intraveneuze toediening 
van insuline. In hoofdstuk 1 worden de achtergronden en doelstellingen van de studies 
in dit proefschrift beschreven. Dit proefschrift richt zich met name op het bepalen van de 
energie behoefte van ernstig zieke kinderen in de acute fase van hun ziekte, alsmede op de 
oorzaken en gevolgen van het optreden van hyperglycemie. De resultaten kunnen gebruikt 
worden om het voedingsbeleid en maatregelen voor glucose controle te optimaliseren.
In Deel I wordt de energie behoefte van ernstig zieke kinderen geëvalueerd. Het energie 
verbruik van beademde kinderen wordt gemeten met behulp van een apparaat, ook wel 
indirecte calorimetrie genaamd.
In hoofdstuk 2 worden de resultaten beschreven van de metingen van het energie verbruik 
van 50 beademde kinderen met verschillende diagnoses. Er was een sterke correlatie tussen 
het gemeten rustmetabolisme (MREE) en het voorspelde rustmetabolisme (PREE) berekend 
met behulp van de Scho! eld formule voor gewicht, leeftijd en geslacht. Bland-Altman ana-
lyse toonde echter weinig overeenstemming tussen het individueel gemeten MREE en PREE. 
Wij concludeerden daarom dat standaard formules voor het berekenen van rustmetabolisme 
niet geschikt zijn om energie behoefte van ernstig zieke kinderen te bepalen. Het energie 
verbruik van deze kinderen moet dus worden gemeten met behulp van indirecte calorimetrie.
De waarde van indirecte calorimetrie in combinatie met stikstof balans wordt beschreven 
in hoofdstuk 3. Zesendertig kinderen werden geïncludeerd. Kinderen met een positieve 
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stikstof balans hadden een signi! cant hogere ratio van calorie inname/gemeten rustmeta-
bolisme ten opzichte van diegenen met een negatieve stikstof balans. De calorie inname 
van de kinderen met een positieve stikstofbalans was 40% hoger dan het gemeten rustme-
tabolisme. Het is duidelijk dat de calorie inname minstens gelijk moet zijn aan het gemeten 
rustmetabolisme in de acute fase van ziekte. Na de acute, katabole fase moet de energie 
inname worden verhoogd zodat weefsel herstel en groei kunnen plaatsvinden. De energie 
behoefte van ernstig zieke kinderen tijdens de herstel fase van hun ziekte ligt dichtbij of 
zelfs boven de aanbevolen “Dietary Reference Intakes” voor gezonde kinderen. Het voedings-
beleid moet dagelijks geëvalueerd worden zodat koolhydraat-, eiwit- en vetinname kunnen 
worden geoptimaliseerd. Overmatige koolhydraat toediening kan voorkomen worden door 
dagelijkse berekening van daadwerkelijke glucose intake, seriële meting van het respiratoire 
quotiënt (RQ) en bloed glucose waarden. Eiwit- en vetinname kunnen aangepast worden op 
basis van ureum en triglyceride bepalingen.
In hoofdstuk 4 worden de resultaten beschreven van de metingen van het energie ver-
bruik van 94 beademde kinderen met verschillende diagnoses. De Scho! eld formule voor 
gewicht, lengte, leeftijd en geslacht was het meest nauwkeurig in het voorspellen van het 
gemeten rustmetabolisme; 40% van de kinderen had een voorspelde waarde binnen een 
range van plus of min 10% van het gemeten rustmetabolisme. Hoewel de White formules 
speciaal ontwikkeld werden voor beademde kinderen, waren deze het minst nauwkeurig. 
Mogelijke oorzaken hiervoor staan in dit hoofdstuk beschreven.
Deel II van dit proefschrift beschrijft pathofysiologische mechanismen die hyperglycemie 
kunnen veroorzaken of onderhouden.
De studie beschreven in hoofdstuk 5 kijkt naar oorzaken van hyperglycemie bij 78 kinderen 
(leeftijd van 1 maand tot 16 jaar) met meningococcensepsis of septische shock. Bloed glu-
cose waarden werden gerelateerd aan insuline en C-peptide metingen middels “homeostasis 
model assessment  (HOMA). Hiermee werd inzicht verkregen in de  insuline gevoeligheid en 
ß-cel functie van de pancreas. Een derde van de kinderen was hyperglycemisch (gede! nieerd 
als bloed glucose >8.3 mmol/L) bij opname op de Kinder Intensive Care. Voor verreweg de 
meeste kinderen gold dat bloed glucose waarden spontaan normaliseerden binnen 48 uur 
na opname zonder insuline toediening. Ook de pro-in$ ammatoire cytokines en cortisol 
concentraties waren slechts tijdelijk verhoogd en daalden snel na de eerste ziektedag. De 
meeste kinderen met hyperglycemie waren insuline resistent, maar ook verminderde ß-cel 
functie of een combinatie van insuline resistentie en verminderde ß-cel functie werden 
gezien. Insuline resistentie kan veroorzaakt worden door contraregulerende hormonen en 
cytokines en door therapeutische interventies. Zo zagen we dat kinderen die werden behan-
deld met glucocorticoïden hogere cortisol en glucose concentraties hadden ten opzichte 
van kinderen die geen glucocorticoïden kregen. De toediening van glucocorticoïden aan 
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kinderen met persisterende shock en/of hypoglycemie op basis van bijnierinsu#  ciëntie lijkt 
vaak onvermijdelijk. Het is van belang om toediening van glucocorticoïden af te wegen te-
gen de potentieel nadelige e" ecten zoals het induceren en onderhouden van hyperglycemie 
wanneer glucocorticoïden meerdere dagen achter elkaar gebruikt worden.  
In hoofdstuk 6 wordt het peri-operatieve beloop van bloed glucose concentraties geëva-
lueerd van 49 kinderen (leeftijd van 2 maanden tot 18 jaar) die een hart operatie onder-
gingen in verband met een aangeboren hartafwijking. Ruim de helft van de kinderen was 
hyperglycemisch aan het eind van de operatie. Bijna al deze kinderen hadden een normale of 
(relatief ) lage insuline/glucose ratio. Bloed glucose concentraties normaliseerden spontaan, 
zonder insuline toediening, binnen 24 uur bij bijna alle kinderen (94%). Er was geen verschil 
in beademingsduur en IC- en/of ziekenhuis opnameduur in vergelijking met de kinderen die 
geen hyperglycemie hadden. De toediening van glucocorticoïden tijdens de operatie (aan 
65% van de kinderen) was de belangrijkste factor voor het optreden van hyperglycemie aan 
het eind van de operatie. Aangezien de postoperatieve morbiditeit in onze studie populatie 
laag was, kunnen we concluderen dat de beschreven positieve e" ecten van glucocorticoïd 
toediening groter waren dan de potentieel nadelige e" ecten van glucocorticoïd geïndu-
ceerde hyperglycemie.
In Deel III wordt ingegaan op de klinische aspecten ten aanzien van het gebruik van een pro-
tocol voor glucose controle. De belangrijkste vragen die aan bod komen zijn welke kinderen 
behandeld zouden moeten worden met insuline en hoe zij behandeld moeten worden.
In hoofdstuk 7 wordt gekeken naar de relatie tussen insuline respons op hyperglycemie en 
klinische uitkomst van ernstig zieke kinderen die behandeld werden met insuline. Vieren-
zestig kinderen (leeftijd van 2 weken tot 18 jaar) met hyperglycemie met verschillende diag-
noses, die in aanmerking kwamen voor insuline therapie (zoals beschreven in hoofdstuk 8) 
werden geïncludeerd. Net voor start van insuline toediening werd bloed afgenomen voor de 
bepaling van hormonale, metabole en immunologische parameters. Het bleek dat kinderen 
met een hyperinsulinemische respons vaker en langduriger beademd werden, langduriger 
behandeld werden met insuline, en langduriger opgenomen bleven op de PICU ten opzichte 
van kinderen met een hypoinsulinemische respons. De duur van glucocorticoïd gebruik was 
sterk gecorreleerd met duur van insuline behandeling en is een aanwijzing voor het nega-
tieve e" ect van glucocorticoïden op de insuline gevoeligheid.    
Aan de andere kant hadden de niet beademde kinderen meestal een hypoinsulinemische 
respons (in 78% van de gevallen) en werden zij slechts kortdurend behandeld met insuline. 
Het is de vraag wat de waarde is van insuline behandeling bij deze kinderen zonder aantoon-
bare insuline resistentie. Het is zeer aannemelijk dat de hoge bloed glucose waarden van 
deze kinderen ook spontaan zouden zijn genormaliseerd zonder toename van de morbiditeit. 
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In hoofdstuk 8 worden ervaringen met de implementatie van een glucose controle protocol 
voor de behandeling van hyperglycemie bij ernstig zieke kinderen opgenomen op de PICU 
beschreven. Vijftig ernstig zieke kinderen (leeftijd van 1 maand tot 15 jaar) met verschillende 
diagnoses werden geïncludeerd. Met het door verpleegkundigen uitgevoerde protocol bleek 
het mogelijk om in 94% van de kinderen normoglycemie (gede! nieerd als bloed glucose 
waarden tussen de 4 en 8 mmol/L) te bereiken binnen 12 uur na start van insuline infusie. Ern-
stige hypoglycemie (glucose <2.2 mmol/L) trad niet op tijdens de behandeling met insuline. 
Drie kwart van de kinderen werd minder dan 3 dagen behandeld met insuline. Het is maar 
zeer de vraag of je de prognose van deze kinderen kunt verbeteren met insuline therapie. In 
hoofdstuk 9 worden voorwaarden beschreven waaraan een glucose protocol zou moeten 
voldoen om de kans op het optreden van hypoglycemieën zo klein mogelijk te maken.
In hoofdstuk 10 worden de voornaamste bevindingen van onze studies besproken in relatie 
met eerdere publicaties. Op basis van onze ervaringen, literatuur gegevens en data analyses, 
doen we een voorstel voor routinematige “nutritional assessment” en “nutritional support” 
op de Kinder Intensive Care. Hierop aansluitend hebben we twee algoritmes gemaakt voor 
glucose controle met insuline; een voor neonaten jonger dan 28 dagen oud en een voor ou-
dere kinderen van 1 maand tot 18 jaar. In het algemeen wordt gestreefd naar bloed glucose 
waarden tussen de 4 en 8 mmol/L, echter voor kinderen met ernstig traumatisch hersenletsel 
adviseren we bloed glucose waarden tussen de 6 en 10 mmol/L aan te houden.
De belangrijkste conclusies resulterend uit dit proefschrift zijn de volgende:
• De energie behoefte van ernstig zieke kinderen kan niet nauwkeurig voorspeld wor-
den met predictie formules.
• Indirecte calorimetrie moet gebruikt worden om het energie verbruik en respiratoir 
quotiënt te meten zodat de energie behoefte en het voedingsbeleid per kind kan 
worden vastgesteld.
• Hyperglycemie komt vaak voor bij ernstig zieke kinderen  en herstelt meestal met of 
zonder behandeling met insuline binnen 24 uur.
• Exogene factoren zoals toediening van glucose en glucocorticoïden hebben een 
belangrijke invloed op bloed glucose waarden.
• Zowel insuline resistentie als relatieve !-cel dysfunctie spelen een rol bij het optreden 
van hyperglycemie bij ernstig zieke kinderen. 
• Kinderen met een hyperinsulinemische respons worden langer behandeld met insu-
line, langer beademd en hebben een langere verblijfsduur op de PICU in vergelijking 
met kinderen met een hypoinsulinemische respons. 
• De behandeling van hyperglycemie met insuline volgens een strict glucose protocol 
uitgevoerd door verpleegkundigen is veilig en e" ectief.
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ACTH, adenocorticotrope hormone
ALT, alanine aminotransferase
APC, activated protein C concentrate
AST, aspartate aminotransferase
CC, calf circumference
CHO, carbohydrate
CPB, cardiopulmonary bypass
CRP, C-reactive protein
DM, diabetes mellitus
DRI, dietary reference intakes
ECLS, extracorporeal life support
EN, enteral nutrition
ESPGHAN, European society for paediatric gastroenterology, hepatology and nutrition
FFA, Free Fatty Acids
GLP-1, glucagon-like-peptide-1
GLUT, glucose transporter
HOMA, homeostasis model assessment
HOMA-%B, ß-cell function
HOMA-%S, insulin sensitivity
ICU, intensive care unit
IL, interleukin 
LOS, length of stay
MREE, measured energy expenditure
mTEE, measured total energy expenditure
MUAC, mid upper arm circumference
N-balance, nitrogen balance
pBMR, predicted basal metabolic rate
PELOD-score, pediatric logistic organ dysfunction score
PEPCK, phosphoenolpyruvate carboxy kinase
PICU, pediatric intensive care unit
PREE, predicted resting energy expenditure
PRISM, pediatric risk of mortality 
PT, prothrombin time
RACHS, risk adjustment for congenital heart surgery
RDA, recommended daily allowences
REE, resting energy expenditure
RQ, respiratory quotient
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RQmacr, RQ of macronutrients administered
TDEE, total daily energy expenditure
TG, triglycerides
TISS, Therapeutic Intervention Scoring System
TMEE, total measured energy expenditure
TNF-", tumor necrosis factor-"
TPN, total parenteral nutrition
TUN, total urinary nitrogen excretion 
VAS, vasopressor score
WI-score, weighted inotropic score
WHO, world health organization
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DANK WOORD
Graag wil ik alle personen die hebben bijgedragen aan het tot stand komen van dit proef-
schrift bedanken. 
In de eerste plaats zijn dat alle kinderen en hun ouders die aan de verschillende onderzoeken 
hebben deelgenomen. Mijn dank voor hun medewerking is zeer groot. Ik besef dat wanneer 
je kind op de intensive care terecht komt de wereld om je heen stil staat. Ik hoop met dit 
proefschrift een bijdrage te hebben geleverd aan het verbeteren van de intensieve zorg voor 
ernstig zieke kinderen, zodat de kans op een volledig herstel voor deze kinderen toeneemt.    
Toen ik 15 jaar geleden als geneeskunde student voor het eerst de IC op kwam om te vragen 
of ik een keuzeonderzoek mocht doen, had ik nog geen idee waar dit uiteindelijk toe zou 
gaan leiden. Het was een mooie tijd, ik heb ervan genoten! 
Dr. K.F.M. Joosten, mijn copromotor; Koen, zonder jouw hulp was het never nooit zover geko-
men. Jij hebt je vanaf die eerste dag over me ontfermd en gesteund ook wanneer dingen net 
even iets anders liepen dan gepland. Bedankt voor alle energie die je in mij en dit proefschrift 
hebt gestoken. De cirkel is nu rond, op naar een volgende uitdaging!
Prof. dr. D. Tibboel, mijn promotor; Dick, jij raakte in een latere fase betrokken bij mijn onder-
zoek, toen ik inmiddels fellow intensive care was. De opleiding tot kinderarts-intensivist was 
een zeer intensieve periode, waarin ik ontzettend veel geleerd heb. Bedankt voor de kans die 
je me gegeven hebt om dit proefschrift af te ronden.  
Prof. dr. J. Bakker, Prof. dr. J.B. van Goudoever en Prof. dr. H.N. Lafeber wil ik bedanken voor de 
snelle beoordeling van mijn manuscript. 
Prof. dr. A.C.S. Hokken-Koelega, beste Anita, hartelijk dank voor het meedenken en je com-
mentaren. Fijn dat je plaatsneemt in de grote commissie. 
Dr. D.A. van Waardenburg, beste Dick, jij vertrok net naar Maastricht toen ik als student begon 
op de ICP, nu toch in de grote commissie, dank daarvoor.
Graag bedank ik alle co-auteurs van de verschillende manuscripten:
De onmisbare studentes, Marianne, Henrike en Carolien, bedankt voor jullie hulp bij het 
verzamelen en analyseren van de gegevens. Veel succes met jullie eigen carrières in de 
geneeskunde en in de farmacie.
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Dr. J.A. Hazelzet, beste Jan, zelfs ik ben inmiddels gaan hardlopen (en ik vind het nog leuk 
ook)! Bedankt voor je support, ook bij mijn opleiding tot kinderarts-intensivist.
E. van der Voort, beste Edwin, dank voor je vertrouwen! Tot binnenkort bij Leonidas!
Dr. M. Den Brinker en Dr. J.M. Hulst, beste Marieke en Jessie, ! jn dat jullie je data met mij 
wilden delen en bedankt voor alle adviezen.
S.C. Verbruggen, beste Sascha, succes met jouw eigen promotie volgende week.
Dr. W.C.J. Hop, beste Wim, ontzettend bedankt voor je geduld bij het uitleggen van de multi-
pele regressie analyse, de Blant-Altman en al die  andere ingewikkelde statistische analyses. 
Hoop dat je binnenkort een mooi huisje vindt in Frankrijk zodat je die kleine, veel te volle 
kamer in de hoogbouw even kunt ontvluchten.
Prof. dr. A.J.J.C. Bogers, Prof. dr. W. Helbing en Dr. R.J. van Thiel, beste Ad, Wim en Robert, 
hartelijk dank voor jullie bijdrage aan het onderzoek op de Thorax Intensive Care.
De verpleegkundigen van de ICP, ICC en later de ICK, bedankt voor jullie hulp bij het verzame-
len van de data. Jeannette en Mirjam, jullie hebben veel werk verricht bij de implementatie 
van het glucose protocol op de afdelingen, bedankt! Mirjam, wil je nu ik het boekje af heb 
ook een keer met mij op de foto? Marjolein, dank voor je hulp bij het verkrijgen van de PDMS 
gegevens.
Researchverpleegkundige, Marianne, ontzettend bedankt voor je hulp bij het opzetten van de 
isotopenstudie. Ik was onder de indruk van je zorgvuldige archivering van de bloed samples; na 
ruim 10 jaar wist je ze feilloos in die grote vrieskist terug te vinden, daar kan ik nog veel van leren.
Annet, zonder jou zouden veel studenten volledig de weg kwijtraken op die grote ICK. Be-
dankt voor je betrokkenheid en hulp, ook met het “PICEN”!
Ko Hagoort, dear Ko, enorm bedankt voor de snelle correcties, op het laatst zelfs vanuit Lombok!
Mijn kamergenoten van sk3280, Anke en Kim. We waren een goed trio, ik ben trots op ons 
alle drie. Anke, wat een eer dat ik binnenkort je paranimf mag zijn en Kim wat een eer dat je 
mijn paranimf wilt zijn.
Al mijn oude en nieuwe collega’s uit het Sophia Kinderziekenhuis, Sint Franciscus Gasthuis 
en het Maasstad Ziekenhuis, bedankt voor jullie collegialiteit en interesse in mijn onderzoek 
gedurende al die jaren.
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Annelies, Annemie, Carsten, Desiree, Frank, Jan, Helène, Marieke, Martin, Michael, Riwka en 
Rob, jullie vormen een bijzondere en hechte groep kinderartsen en ik ben blij dat ik bij jullie 
mag komen werken.
Lieve hockeymeiden, wat kennen we elkaar al weer vele jaren! Ik verheug me altijd enorm op 
de etentjes en uitjes met het “oude” clubje. Dat we op zondag met onze OV-kaart in de bus 
en trein naar de wedstrijden gingen lijkt al weer een eeuwigheid geleden! Inmiddels zit er al 
een heel nieuw jong dames- en herenteam op de bank te kijken naar hun geweldige mama's. 
Heerlijk!
Zuni, sinds jij er bent is ons leven een stuk relaxter geworden. Bedankt voor alles wat je voor 
ons en onze meiden doet, muchísimas gracias!
Lieve M&M&M, Madelon, Mariska en Marjolein, vanaf het 1e jaar geneeskunde zijn we beste 
vriendinnen en hebben we veel samen beleefd. Als er moeilijke vragen komen over de labo-
ratoriumbepalingen schuif ik ze graag door naar jou Madelon; super dat je nu ook mijn para-
nimf wilt zijn. Mariska en Marjolein, mijn coparanimfen! Dank voor jullie hechte vriendschap. 
Joos, Kim, Madelon en Marjolein, bedankt voor jullie zorgvuldige correcties in de laatste fase.
Lieve Andor, Brigitte, Micky, Sting & Vinz; Joos, Ton, Odile & Aurelie; Jon, Steven, Koen, Onno & 
...; Jasper-Hugo, bedankt voor jullie interesse, support en alle gezellige “Family Things”.
Koos en Sonja, jullie hebben enorm geholpen. Sonja, bedankt dat ik in de vakanties en 
weekenden bij jullie mocht komen werken terwijl jij op de meiden lette. Het was heerlijk om 
tussen het schrijven door even te schaatsen of te varen door het prachtige Friese land. Prof. 
dr. J.R.B.J. Brouwers, beste Koos, bedankt voor je kritische commentaren op de stukken. Ik 
vind het heel bijzonder dat je in mijn promotiecommissie zit.
Papa en mama, dAdEnny, mijn brabantse nuchterheid heb ik van jullie; doe maar gewoon... 
Bedankt voor jullie onvoorwaardelijke liefde en steun bij alles wat ik doe. Het verplaatsen van 
jullie kampeervakantie naar de Zuid-Hollandse polder, gaf mij de ruimte voor het afronden 
van de laatste manuscripten.  Ontzettend bedankt voor alles, ik hou van jullie!
Ik kon het toch niet laten, dus bij deze: “hedde ge da gezeed gehad ja minde da werklijk woar,
hoe dude ge da, hoe dude ge da, hoe hedde ge da gedoan?”
Lieve Anniek en Juliet, onze prachtige meiden, elke dag met jullie is een feestje. Ik hou zo 
ontzettend veel van jullie! D
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Arjen, love of my life, wat is het leven geweldig met jou! Promoveren en een huis bouwen 
gaan toch prima samen! Wat wordt ons volgende avontuur?
Jennifer
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